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Loss of mature pancreatic beta cell identity and reversion to a progenitor endocrine 
state has been defined as beta cell dedifferentiation. Research has shown this to 
occur in beta cell lines to rodent and non-human primate models of diabetes and 
pancreatic islets of humans with diabetes. A concurrent increase in alpha cell mass 
alongside this beta cell dedifferentiation suggests that beta-to-alpha cell 
transdifferentiation also occurs in diabetes. This thesis examines beta-to-alpha cell 
transdifferentiation using beta cell lines and mouse models of diabetes. In INS-1 and 
MIN6 cells cultured under lipotoxic and cytokine conditions displayed reductions in 
insulin expression in conjunction with increased glucagon expression and a rise of 
cells co-expressing both hormones. INS-1 cells in particular also exhibited changes in 
gene expression with reduced beta cell markers and increased alpha cell and 
progenitor markers consistent with the beta-to-alpha cell transdifferentiation. 
Histological analysis of islets from mice treated with streptozotocin, hydrocortisone 
or high fat fed diet revealed morphological changes consistent with impaired beta 
cell identity. To truly ascertain beta cell transdifferentiation in animal models, lineage 
tracing studies were carried out using Ins1cre/+;Rosa26-eYFP C57Bl/6 mice with 
specifically labelled beta cells. Studies in these mice confirmed previously suspected 
beta-to-alpha cell transdifferentiation in multiple low-dose streptozotocin, high fat 
fed and hydrocortisone models of diabetes. Taking this further, the incretin 
therapies, liraglutide and sitagliptin, and novel peptide agents, apelin and xenin, 
were able to prevent this transdifferentiation in these mice. SGLT2 inhibition had no 
effect on beta cell transdifferentiation. These results suggest the potential benefit of 
beta cell restoration therapy of transdifferentiated beta cells for the treatment of 
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1.1 Endocrine Pancreas  
The exocrine portion of the pancreas constitutes 98% of its mass and is accountable 
for the production of digestive enzymes delivered to the small intestine via the 
pancreatic duct. However the pancreas has come to be known as the essential organ 
involved in regulation of blood glucose despite only 2% of its mass being involved in 
this function. This endocrine portion of the pancreas consists of spherical islets of 
Langerhans, on average 100µm in size, scattered throughout the organ. Each islet 
consists of several thousand cells which are categorised depending on the 
polypeptide hormone they secrete surrounded by a capsule of connective tissue 
(Bosco et al, 2010). Islets have a rich blood supply and are innervated by the 
autonomic nervous system enabling them to finely regulate hormone secretion in 
response to nutrients, hormones and regulatory peptides. In both humans and mice 
insulin secreting beta cells comprise the bulk of each islet making up 50-70% and 60-
80% of the islet mass respectively. Glucagon producing alpha cells are the next major 
cell type making up 20-40% and 10-20% of human and mouse islets respectively. 
Somatostatin secreting delta cells and pancreatic polypeptide secreting PP cells make 
up a further 10% and 5% of human and mouse islets respectively. Finally less than 1% 
of islet cells are ghrelin containing epsilon cells (Saito et al, 1979; Kim et al, 2009; 
Steiner et al, 2010; Cabrera et al, 2006; Brissova et al, 2005). Although islet size 
distribution is similar between humans and mice, the spatial distributions of the cell 
types comprising the islets differ. Mouse islet architecture consists of a central core 
of beta cells surrounded by a mantle of predominantly alpha cells with some delta 
cells (Cabrera et al, 2006). Humans however, display a disorganised cellular 
composition with alpha cells dispersed throughout the islet (Wieczorek et al, 1998). 
3 
  
Paracrine interactions between these endocrine cell types can influence secretory 
activity of constituent cell types (Bosco et al, 1989). 
 
1.2 Diabetes prevalence 
Diabetes mellitus is a chronic metabolic disorder of impaired blood glucose control 
and is characterised by hyperglycaemia. The worldwide prevalence of diabetes has 
increased rapidly over recent decades. This is largely attributed to increased 
urbanisation and adoption of sedentary lifestyles. In 1980 there was an estimated 
108 million people living with diabetes (NCD Risk Factor Collaboration, 2016). 20 
years later, at the turn of the millennium, this estimated prevalence increased to 151 
million people (IDF, 2014). The most recent report based on 2017 data estimates that 
there are 451 million people living with diabetes, with this number expected to 
increase to 693 million by 2045 (Cho et al, 2018). To put these numbers into 
perspective, based on the 2017 global population of 7.6 billion people (UN, 2017), 
diabetes affects 6% of the world’s population. The impact of treating diabetes comes 
at a high economic burden. In the UK, the NHS spends 10% of its budget (£10 billion 
a year) on treating diabetes and associated complications with this cost expected to 
increase over the next 20 years (Hex et al, 2012). Similarly, in the US the cost of 
treating diabetes, based on 2017 figures, was $327 billion, with medical bills for 
diabetics being on average 2.3 times higher than for individuals without diabetes 




1.3 Diabetes: type-1 & type-2  
Diabetes is classified into two main types. Type-1 diabetes is due to autoimmune 
destruction of insulin secreting beta cells and accounts for ~10% of diabetic cases. 
What triggers this predominantly T cell mediated autoimmune attack, whether 
environmental or genetic, is poorly understood (Lehuen et al, 2010). Typically, this 
type of diabetes is diagnosed in children and young adults (<30 years) which usually 
present to clinicians with severe hyperglycaemia. At this point of symptomatic 
diagnosis, 60-80% of pancreatic beta cells have already been lost (Nokines and 
Lernmark, 2001). Given that type-1 diabetes can be partly inheritable, many genes 
have now been implicated to giving a predisposition towards developing type-1 
diabetes such as alleles of major histocompatibility locus (HLA). Although thought of 
as disease of insulin-deficiency, insulin resistance is becoming recognised as 
increasingly common in type-1 patients, likely a result of the high doses of exogenous 
insulin administered (Fourlanos et al, 2004).    
The remaining 90% of cases are made up of type-2 diabetes which is characterised 
by impaired insulin secretion, initially elevated before declining due to worsening 
insulin resistance in peripheral tissues (muscle, liver and adipose), culminating in 
poor glycaemic control and hyperglycaemia (Lin and Sun, 2010). Endoplasmic 
reticulum (ER) stress, hypoxic stress, oxidative stress, cytotoxicity, glucotoxicity, 
lipotoxicity and beta cell dedifferentiation are thought to be the major causes of this 
beta cell dysfunction (Accili et al, 2010; Kitamura, 2013). This form of diabetes is 
largely attributed to hedonistic and physically inactive Western lifestyles (Leahy, 
2005). Obesity is the biggest risk factor for type-2 diabetes with an estimated 80% of 
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type-2 diabetes being overweight or obese (Bloomgarden, 2000). Coincident with 
global rates of obesity rising, there has been a large increase in the number of people 
diagnosed with diabetes. Children are not spared from this fate with increases in 
childhood obesity resulting in more and more young people presenting with type-2 
diabetes. As developing countries follow the trend of urbanisation and adoption of 
Western diets the prevalence of type-2 diabetes is set to dramatically increase. That 
said the risk is not entirely environmental with genetic factors and ageing also 
influencing the risk. 
 
1.4 Diabetic Complications  
Acute, life-threatening complications of diabetes can occur if left entirely untreated 
as a result of severe fluctuations in blood glucose such as ketoacidosis from excessive 
hyperglycaemia and hypoglycaemic comas (Forbes and Cooper, 2013). Long-term 
vascular complications of diabetes are equally devastating and fall under two groups, 
microvascular and macrovascular, both partly due to damage caused by chronic 
hyperglycaemia. Microvascular complications refer to those affecting small blood 
vessels including retinopathy, nephropathy and neuropathy. Macrovascular 
complications however relate to large artery damage such as accelerated 
cardiovascular and cerebrovascular disease resulting in myocardial infarction and 
strokes respectively. Dementia (Cukierman et al, 2005), depression (Nouwen et al, 
2011), and sexual dysfunction (Adeniyi et al, 2011; Thorve et al, 2011) are other less 




1.4.1 Diabetic Nephropathy 
Diabetic nephropathy is characterised by proteinuria and progressive decline in 
glomerular filtration rate. Left untreated, nephropathy is a major cause of end-stage 
renal failure and can be fatal (Gilbertson et al, 2005; Mogensen et al, 1983). 
Development of nephropathy is complicated, and the diabetic kidney presents with 
hyperplasia and hypertrophy of glomeruli (Seyer-Hansen et al, 1980). As kidney 
tubules grow, the kidney filters increasing amounts of glucose, fatty acids, amino 
acids, growth factors and cytokines which set off pathological pathways such as 
energy imbalances, redox complications, inflammation and fibrosis (Mauer et al, 
1984; Vallon et al, 2003). Furthermore, kidney disease presents as a risk factor for 
macrovascular complications (Lancet, 2010), hypertension and impaired glycaemic 
control (UKPDS, 1998). 
 
1.4.2 Diabetic Retinopathy  
Diabetic retinopathy is the major cause of blindness in adults characterised by retinal 
lesions and changes in vascular permeability, capillary degeneration and excessive 
neovascularisation (Frank, 2004; Hirai et al, 2011). Retinopathy is defined by non-
proliferative and proliferative disease stages. The non-proliferative stage involves 
hyperglycaemia induced intramural pericyte death and thickening of the basement 
membrane altering the blood-retinal barrier and vascular permeability but produces 
no visual impairment (Frank et al, 2004). Ischaemia and release of angiogenic factors 
can lead to degeneration and occlusion of retinal capillaries and progression into the 
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proliferative stage where neovascularisation and macular oedema impair vision 
(Bresnick et al, 1976). 
 
1.4.3 Diabetic Neuropathy 
Diabetic neuropathy is estimated to affect more than half of diabetic individuals and 
brings with it a 15% risk of lower limb amputation (Abbott et al, 2011). Neuropathy 
is characterised by nerve fiber deterioration leading to loss of sensory perception due 
to alterations in sensitivity to vibrations and thermal thresholds. Up to 50% of 
patients with neuropathy experience pain along with hyperalgesia, paraesthesia and 
allodynia, which collectively impede quality of life (Obrosova et al, 2009). Longer 
neurons are first to lose conduction velocity hence why loss of sensation is first 
observed in the feet and later the hands, termed “glove and stocking” distribution. 
This loss of sensation can allow for injury and infection to go unnoticed leading to the 
need for amputations (Forbes and Cooper, 2013). There are currently no approved 
therapies for neuropathy which makes optimised glycaemic control ever more 
important.  
 
1.4.4 Macrovascular complications  
Diabetes increases the risk of cardiovascular disease, raising the risk of myocardial 
infarction threefold, and accounts for more than half the mortality in diabetes 
(Haffner et al, 1998; Laing et al, 2003; Domanski et al, 2002). Diabetic individuals 
exhibit premature atherosclerosis and diastolic dysfunction. The former can give rise 
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to atherosclerotic plaques that occlude vessels giving rise to cardiovascular events 
(Okon et al 2005), whilst the latter cardiomyopathy can lead to exertional dyspnoea 
and heart failure (Boudina et al, 2007). Glycaemic control, assessed using HbA1c, is 
used to predict cardiovascular risk in diabetes (Borg et al, 2010; Cederberg et al, 
2010). Control of glycaemia can limit oxidative stress and chronic inflammation, both 
of which influence the development of pathogenic thrombogenic plaques (Feng et 
al, 2005).  
 
1.5 Diabetes therapies 
1.5.1 Insulin replacement therapy  
For type-1 diabetes insulin replacement therapy is the safest and most widely used 
treatment. However insulin replacement therapy is increasingly used in type-2 
diabetes when oral and peptide derived drugs fail to provide adequate blood glucose 
control. Correct timing/dosing of insulin to prevent hypoglycaemia is however a risk 
of this therapy. Advances in chemical modifications to produce insulin formulations 
with varied half-lives enable patients to achieve both long and short term glycaemic 
control. Technological advancement has allowed for the development of closed-loop 
insulin pump systems that act dynamically to release insulin in response to sensing a 
rise in blood glucose levels (Tasuchmann and Hovorka, 2014). Beta cell replacement 
therapy either by whole pancreas or islet transplantation has the potential to cure 
type-1 diabetes (Shapiro et al, 2000) but is limited due to the scarcity of donor islets 
and adverse effects of long term immunosuppressant drug use. Furthermore, this 
expensive surgery is not long lasting, with patients showing a decline in islet graft 
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function over time warranting further transplants. Currently, this therapy is limited 
to diabetics with intractable hypoglycaemia and brittle diabetes. 
 
For most cases of type-2 diabetes there are a number of different agents available to 
regulate blood glucose when healthy lifestyle changes fail to keep hyperglycaemia in 
check. Current anti-diabetic pharmacotherapies improve insulin sensitivity, stimulate 
glucose-induced insulin secretion and increase excretion / decrease absorption of 
glucose and carbohydrates respectively.  
 
1.5.2 Biguanides  
Metformin is a biguanide drug and is a first line treatment prescribed for type-2 
diabetes for almost 4 decades (Pappachan et al, 2018). The anti-diabetic effect of 
metformin stems from its ability to inhibit hepatic gluconeogenesis and improve 
insulin sensitivity in peripheral tissues. The mechanism of action is poorly 
understood, however it is suggested to involve inhibition of mitochondrial 
respiratory chain. Metformin is generally well tolerated with gastrointestinal side 
effects (nausea, vomiting and diarrhoea) only being transient. However, a firm 
contra-indication for metformin use is kidney failure due to increased risk of lactic 
acidosis (Bailey, 1993). Some studies have found metformin to also reduce body 
weight and reduce HbA1c particularly when coupled with healthy lifestyle changes 
(Meneghini et al, 2011; Domecq et al, 2015). Metformin has also been found 
beneficial for gestational diabetes (Jiang et al, 2015), polycystic ovary syndrome 
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(Naderpoor et al, 2015) and non-alcoholic fatty liver disease (Chalasani et al, 2012), 
all of which are conditions that feature insulin resistance. 
 
1.5.3 Sulfonylureas 
When metformin is unable to manage type-2 diabetes, clinicians regularly move on 
to second-line agents such as sulfonylureas (tolbutamide, glicazide) as an additional 
therapy. These drugs stimulate beta cell insulin release by binding to the ATP-
dependant K+ (KATP) channel, thus closing the channel leading to cell membrane 
depolarisation causing voltage gated calcium channels to open and Ca2+ influx to the 
beta cell culminating in exocytosis of insulin containing vesicles (Lebovitz et al 1978; 
Burke et al, 2008). Given that this mechanism works irrespective of the prevailing 
glucose level, improper use of sulfonylureas can cause hypoglycaemia. The increase 
in insulin secretion can also lead to weight gain, with average weight gain reported 
as 1.8-2.6kg (Domecq et al, 2015), making this anti-diabetic agent less favourable for 
patients given that obesity is a common co-morbidity.  
 
1.5.4 Meglitinides 
Meglitinides, such as regagliinide and nateglinide, have a similar mechanism of action 
as sulfonylureas albeit with a weaker affinity to the KATP channel (Malaisse, 2003). 
These drugs show similar risk of hypoglycaemia however weight gain was found to 





Thiazolidinediones, such as pioglitazone, act as insulin sensitizers. They bind to and 
activate the peroxisome-proliferator-activated receptor gamma (PPARγ), expressed 
on liver, muscle and adipose tissues (Yki-Jarvinen, 2004), to stimulate glucose and fat 
metabolism, ultimately reducing glucose levels without affecting insulin release 
(Grossman et al, 1997). These drugs are used with caution, as rosiglitazone was 
withdrawn due to cardiovascular concerns, whilst pioglitazone use has been 
associated with heart failure (Liao et al, 2017), secondary osteoporosis (Billington et 
al, 2015), fractures (Liao et al, 2017) and urinary bladder cancer (Yan et al, 2018). 
Furthermore patients can be reluctant to opt for this agent given the mean weight 
gain of 2.6kg associated with its use (Domecq et al, 2015).  
 
1.5.6 Alpha-glucosidase inhibitors  
As the name suggests alpha-glucosidase inhibitors (e.g. acarbose and voglibose) 
inhibit this brush border enzyme found in the small intestine responsible for cleaving 
monosaccharides from complex carbohydrates. These drugs act to retard 
carbohydrate absorption in the intestine which in turn slows glucose release 
(Lebovitz, 1997). Meta-analysis of α-glucosidase inhibitor use, revealed favourable 
anti-diabetic outcomes such as a 0.55% reduction in HbA1c, a 3mmol/L reduction in 
2 hour postprandial glucose and average 0.63kg body weight reduction (Gao et al, 
2018). Many patients discontinue use due to unfavourable side effects of flatulence 
and diarrhoea.  
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1.5.7 Dipeptidyl peptidase-4 inhibitors  
Dipeptidyl peptidase-4 (DPPIV) inhibitors, such as sitagliptin and vidagliptin, act as 
incretin enhancers by inhibiting enzymatic breakdown of GLP-1 and GIP. Maintaining 
active levels of GLP-1 and GIP helps stimulate glucose-dependent insulin release with 
these two hormones accounting for 50-70% of total insulin secreted in response to 
oral glucose (Baggio and Drucker, 2007). Furthermore, their actions suppress 
glucagon release, delay gastric emptying and promote both satiety and weight loss 
(Mest et al, 2005; Arthen and Schmidtz, 2004; Song et al, 2017; Nauck et al, 1997; 
Flint et al, 1998). Studies using DPPIV inhibitors in Zucker rats (Pospisilik et al, 2002) 
showed improved beta cell function, whilst type-2 diabetic patients (Herman et al, 
2006) displayed improved glycaemic control and insulin secretion. Additionally, a 
meta-analysis of DPPIV inhibitor use confirmed reduced postprandial glucose 
elevation, fasting plasma glucose and HbA1c levels (average 0.5-1% reduction) with 
little risk of hypoglycaemia or effect on body weight (Lyu et al, 2017; Pappachan et 
al, 2015). Some murine studies have observed an increase in pancreatic ductal 
metaplasia, although no such effects have been found in humans (Engel et al, 2013). 
 
1.5.8 GLP-1 receptor agonists 
Injectable GLP-1 receptor agonists such as exenatide and liraglutide are DPPIV 
resistant forms of GLP-1 given to overcome the short half-life of endogenous GLP-1 
(Drucker and Nauck, 2006). By exogenous administration they produce the anti-
diabetic effects of GLP-1 previously outlined. GLP-1 receptor agonists have been 
found to benefit other systems, having cardiovascular protective effects (Marso et al, 
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2016), reducing dyslipidaemia, non-alcoholic fatty liver disease, diabetic kidney 
disease, blood pressure and affording neuronal protection (Pappachan et al, 2015; 
Tuduri et al, 2016; Nauck et al, 2017). Given that diabetes and obesity increases the 
risk of many of these disorders, GLP-1 receptor agonists may provide a useful tool in 
the arsenal against them. In particular, liraglutide has also been shown to be effective 
against obesity. When given at a 1.2mg daily dose a 1.7kg body weight loss was 
reported (Domecq et al, 2015) whilst a supramaximal 3mg daily dose reported a 
mean weight loss of 8.4kg (Pi-Sunyer et al, 2015). FDA (US Food and Drug 
Administration) concerns regarding pancreatitis and pancreatic cancer associated 
with GLP-1 receptor agonist use have been refuted by long-term studies in non-
human primates and randomised controlled trials. However, a risk of cholelithiasis 
was noted (Nybord et al, 2012; Monami et al, 2017).   
 
1.5.9 Sodium glucose cotransporter-2 inhibitors  
Sodium glucose cotransporters (SGLT) expressed on kidney tubules are responsible 
for glucose reabsorption. 90% of glucose filtered through renal glomeruli is 
reabsorbed by SGLT2 whilst the remaining 10% is reabsorbed by SGLT1 (Gallo et al, 
2015). Evidence that SGLT can be pharmacologically inhibited to increase renal 
glucose excretion has been in the literature since the 1930s (Chasis et al, 1933). 
Despite this, SGLT2 inhibitor drugs have only been trialled in the past decade. 
Inhibitors such as dapagliflozin and empagliflozin prevent glucose reabsorption 
within the proximal renal tubules to increase urinary glucose excretion, ultimately 
lowering blood glucose in an insulin independent mechanism. SGLT2 inhibitor use 
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has been shown to reduce HbA1c by 0.66%, body weight by 1.8kg, reduce systolic 
blood pressure by 4.45 mm of Hg and improve cardiovascular and kidney disease 
(Vasilakou et al, 2013; Zinman et al, 2015; Wanner et al, 2016). Common side effects 
and causes for discontinuation are urinary tract infections and genital fungal 
infections due to high urinary glucose levels (Abdelgadir et al, 2018). The EMPA-REG 
trial noted prolonged use of empagliflozin resulted in gradual loss of hypoglycaemic 
effect (Zinman et al, 2015). Reasons for this are not fully understood but many 
suspect an increase in pancreatic alpha cell mass and increased glucagon release 




Amylin is a polypeptide co-secreted with insulin from beta cells and is involved in 
regulation of insulin and glucagon secretion (Mieticki-Baase, 2016). Pramlinitide is a 
synthetic analogue prescribed in the USA for both type-1 and 2 diabetes to suppress 
glucagon secretion and improve metabolic control (Qiao et al, 2017). Major side 
effects include nausea, vomiting and risk of hypoglycaemia especially when used in 
conjunction with insulin (Fineman et al, 2002; Qiao et al, 2017). 
 
1.5.11 Bariatric surgery  
Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB), gastric banding and 
vertical sleeve gastrectomy, are currently used for the treatment of gross obesity. 
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These procedures also induce improvements of blood glucose control and, in some 
cases, remission of type-2 diabetes (Maleckas et al, 2015). Indeed weight loss by 
pharmacotherapies has been shown to improve type-2 diabetes by restoring insulin 
sensitivity, however eventual weight regain leads to worsening diabetes (Johansson 
et al, 2014; Franz et al, 2007). A meta-analysis concluded that bariatric surgery 
achieved notably greater weight loss and reductions in HbA1c and fasting plasma 
glucose compared to medical treatment (Ribaric et al, 2014). Improvements in 
diabetes are usually observed before substantial weight loss occurs following surgery 
with the exact reasons for this still not fully understood. The incretin theory suggests 
that following RYGB there is rapid nutrient delivery to the distal small intestine where 
L cells are located resulting in increased GLP-1 and peptide YY (PYY) secretion (Strader 
et al, 2005). Alternative theories to explain the anti-diabetic effect of bariatric surgery 
include suppression of hepatic glucose production (Mithieux, 2009), increased bile 
acid production reducing insulin resistance and altering gut microbiota (Watanabe et 
al 2006; Pournaras et al, 2012; Liou et al, 2013).  
 
These current anti-diabetic agents have undoubtedly improved quality of life for 
diabetic patients, however they are not without their own adverse effects. Despite 
their use, secondary diabetic complications still develop and persist. Only through 
strict blood glucose control have these complications been shown to be slowed 
(UKPDS 1998; Heller, 2009). As a result, new anti-diabetic therapies that impact 
development of complications are much sought after. New peptides and hybrid 
formulations are currently being explored. Novel approaches to restore functional 
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beta cell mass are being researched including transdifferentiation from other islet 
cell types to insulin secreting cells, stimulating beta cell proliferation and promoting 
islet neogenesis from pancreatic progenitor cells (Márquez-Aguirre et al, 2015).  
 
1.6 Islet endocrine plasticity – transdifferentiation 
The pathogenesis of beta cell dysfunction in type-2 diabetes has not been fully 
elucidated. Advancement in lineage tracing technology has brought to light evidence 
of mature pancreatic beta cells changing from their differentiated state to become 
dedifferentiated or transdifferentiated into another cell type in models of type-2 
diabetes. Beta cell dedifferentiation is classed as a loss of mature beta cell 
components, usually associated with an increase in the expression of progenitor 
markers, resulting in reduced insulin secretion (Weir et al, 2013). Transdifferentiation 
is classified as a differentiated islet cell losing its mature phenotype to produce a 
different hormone entirely. This process can be direct, in which an islet cell starts to 
express a second hormone before losing expression of its initial hormone or indirect 
whereby an intermediate dedifferentiation stage occurs prior to reactivation of 
transcription factors that lead to differentiation into a different islet cell type (van 
der Meulen and Huising, 2015). 
Murine beta cells have been shown to be capable of dedifferentiating and 
transdifferentiating into both alpha cells and delta cells. So far extreme experimental 
conditions have been utilised to cause transdifferentiation of islet endocrine cells, 
including but not limited to extreme beta cell ablation (Thorel et al, 2010), genetically 
altering expression of specific transcription factors such as Arx (Courtney et al, 2013), 
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Pax4 (Collombat et al, 2007), PDX-1 and FOXO1 (Talchai et al, 2012). These 
transcription factors are clearly vital for both inducing islet endocrine cell 
differentiation and maintaining this differentiated phenotype. When expression of 
these transcription factors are lost so too is the mature islet endocrine cell 
phenotype. This has been shown by Talchai et al, (2012) where natural loss in FOXO1 
expression caused by aging results in susceptibility to developing diabetes due to 
dedifferentiation of beta cells. This process is not restricted to mice with human beta 
cells both in vitro (Weinberg et al, 2007), ex vivo (Spikjer et al, 2013; Gershengorn, et 
al, 2014; Diedisheim et al, 2018) and from type-2 diabetic donors (Cinti et al, 2015) 
displaying dedifferentiation. This implicates dedifferentiation as a mechanism in the 
development of type-2 diabetes. Table 1.1 highlights the breadth of studies that have 
observed changes in beta cell differentiation.  
Further studies in both animal models and type-2 diabetic patients (Butler et al, 2007) 
show low levels of beta cell apoptosis suggesting that these beta cells could be 
dedifferentiating or transdifferentiating. The latter beta to alpha cell 
transdifferentiation would also help to explain the increase in alpha cell number and 
alpha cell infiltration into the core of the islets. However, examination of islets from 
type-2 diabetics has also suggested that the relative expansion in alpha cell number 
is partly due to the reduction in beta cell number (Henquin and Rahier, 2011).   
A number of specific transcription factors vital for promoting and maintaining mature 
beta and alpha cells (Figure 1.1) have been outlined by Huising et al, (2015). Beta cell 
maturity and dedifferentiation and transdifferentiation processes can be monitored 
using these transcription factors. For beta cells, these transcription factors include 
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Pdx-1, Foxo1, Nkx6.1 and the secretory hormone insulin. For alpha cells the secretory 
product glucagon as well as transcription factors Arx and Brn4 can be assessed. Arx 
is essential for alpha cell development and maturity (Bramswig and Kaestner, 2011) 
whilst Brn4 is considered to be an alpha cell specific transcription factor (Heller et al, 
2004). The progenitor marker Ngn3 can be monitored for identifying dedifferentiated 
endocrine cells (Talchai et al, 2012). 
 
1.7 Animal models of diabetes 
Animal models have played an essential role in the understanding of disease 
pathology and in identifying novel therapeutic targets (Al-awar et al, 2016). Given the 
complexity of diabetes and with variations in pathogenesis between type-1 (insulin 
deficiency) and type-2 (beta cell dysfunction/insulin resistance) a number of different 
animal models can be employed. For type-1 models, insulin deficiency is commonly 
attained by chemical ablation of pancreatic beta cells (streptozotocin and alloxan) or 
through inbreeding of mice strains that spontaneously develop autoimmune 
diabetes (BB rats, NOD mice and Akita mice) (King, 2012). For type-2 models, 
recreating insulin resistance and beta cell failure is key. Given that human diabetes 
is closely related to obesity it is no surprise that diet-induced (high fat fed) and 
genetic obesity (Lepob/ob and Lepdb/db mice) animal models display type-2 diabetes 
development. 
Streptozotocin is a nitrosurea analogue which shares a similar structure to glucose 
and is taken up by the pancreatic bet cells via the GLUT2 transporter (Lenzen, 2008; 
Wang and Gleichmann, 1998). Within the beta cell, streptozotocin alkylates DNA 
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leading to DNA fragmentation and cell death. A single high dose of streptozotocin 
(100-200mg/kg in mice) induces rapid destruction of beta cells ensuring 
hyperglycaemia (Srinivasan and Ramaro, 2007; Dekel et al, 2009). Alternatively 
multiple low-doses (20-50mg/kg in mice) of streptozotocin administered over 5 days 
induces insulitis leading to a reduction in islet number and insulin secretory capacity 
(Gleichman, 1998; Bonnevie-Nielsen et al, 1981; Like and Rossini, 1976). These mice 
exhibit severe hyperglycaemia with reduced levels of plasma and pancreatic insulin. 
Reciprocal increases in plasma and pancreatic glucagon are also noted with plasma 
GLP-1 also raised (Vasu et al, 2015). Islet morphology is markedly altered with severe 
loss of beta cell mass, largely due to beta cell apoptosis, and expansion of alpha cell 
mass (Vasu et al, 2015; O’Brien et al, 1996).  
Diet induced high fat feeding of C57Bl/6 mice was first used in 1988 to induce type-
2 diabetes (Surwit et al, 1988). Several weeks of high fat feeding (approximately 50% 
fat content) results in obesity and impaired glucose homeostasis attributed to 
inadequate compensation by islet beta cells. (Winzell and Ahren, 2004). Strain 
specific variations have been noted with NIH Swiss mice exhibiting hyperglycaemia 
whilst this isn’t present in high fat fed C57Bl/6 mice (Gault et al, 2007; Moffett et al, 
2015). C57Bl/6 mice kept on high fat diet for 45 weeks show increased pancreatic 
insulin content, reduced pancreatic glucagon content with no significant changes in 
pancreatic GLP-1 and GIP contents (Moffett et al, 2015). Histologically, high fat fed 
mice exhibit larger islets due to increases in both beta and alpha cell mass, apoptosis 
and proliferation with altered size distribution favouring larger islets (<25,000µm2) 
over smaller islets (<10,000µm2) (Moffett et al, 2015).  
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The corticosteroid hydrocortisone can be administered to mice to induce insulin 
resistance (Bailey and Flatt, 1982; Swali et al, 2008). Despite having no impact on 
non-fasting glycaemia, hydrocortisone, induces peripheral insulin resistance and 
causes an increase in plasma and pancreatic insulin levels (Vasu et al, 2015). 
Histologically, hydrocortisone dosed mice display larger islets associated with 
increased beta and alpha cell areas with size distribution favouring larger islets. Beta 
cell proliferation was found markedly increased in these mice with beta cell apoptosis 
raised but to a much lesser extent (Vasu et al, 2015; Khan et al, 2016; Khan et al, 
2017).   
21 
  
1.8 Aims of thesis 
The studies presented in this thesis explore beta cell transdifferentiation using in 
vitro and in vivo models of diabetes. This is further expanded on to investigate the 
impact of current antidiabetic therapies on beta-to-alpha transdifferentiation. The 
aim of each chapter is outlined below:  
1. To identify beta-to-alpha cell transdifferentiation by protein and gene 
expression using established pancreatic beta cell lines. Preliminary 
investigations into beta cell transdifferentiation in streptozotocin, 
hydrocortisone, high-fat fed and db/db models of diabetes.  
2. To investigate the role of incretin therapies (liraglutide and sitagliptin) on 
beta-to-alpha cell transdifferentiation in a multiple low-dose streptozotocin, 
high-fat fed and hydrocortisone models of diabetes. 
3. To explore the effect SGLT2 inhibition and insulin on beta cell 
transdifferentiation in multiple low-dose streptozotocin, high-fat fed and 
hydrocortisone models of diabetes. 
4. To investigate the role of emerging peptide therapies (apelin and xenin) on 
beta-to-alpha cell transdifferentiation in a multiple low-dose streptozotocin, 
high-fat fed and hydrocortisone of diabetes.  
These studies will attempt to elucidate if beta cell transdifferentiation plays a role in 
islet adaptation and glucose regulation during diabetes and high fat feeding. 
Furthermore these studies hope to identify a possible mechanism in which both 




Table 1.1: Transdifferentiation of pancreatic endocrine cells 
Beta cell dedifferentiation Reference 
Human diabetic donor islets  Cinti et al, 2015 
Human islets  Gershengorn et al, 2014 
Human islets / EndoC-βH1 cell line, FGF2 exposure Diedisheim et al, 2018 
Non-human primate, diet induced diabetes/obesity Fiori et al, 2013  
Neonatal diabetes Wang et al, 2014  
Db/db mice  Sheng et al, 2015; Ishida et 
al, 2017 
KATP-GOF mice  Wang et al, 2014 
miR-7 overexpressing mice  Latreille et al, 2014 
Nkx2.2 knock out  Sussel et al, 1998 
Ex vivo mouse islets  Weinberg et al, 2007 
Rat 85-95% pancreatectomy  Jonas et al, 1999 
β-to-α cell transdifferentiation Reference 
Human islets  Spijker et al, 2013 
Beta cell specific FOXO1 knock out  Talchai et al, 2012 
Misexpression of Arx in beta cells  Collombat et al, 2007 
Beta cell specific Pdx-1 knock out  Gao et al, 2014  
Nkx2.2 knock out  Papizan et al, 2011 
Beta cell specific DNA methyltransferase knock out  Dhawan, 2011 
α-to-β cell transdifferentiation Reference 
Diphtheria toxin-induced beta cell ablation Chera et al, 2014  
Diphtheria toxin-induced beta cell ablation  Thorel et al, 2010  
Metronidazole-induced beta cell ablation Ye et al, 2015  
Alpha cell specific Arx knock out  Courtney et al, 2010 





Figure 1.1: Transcription factors involved in the development and maintenance of 
alpha, beta and delta cells 
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Development of pancreatic endocrine alpha, beta and delta cells derive from a common 
precursor. The expression and maintenance of specific transcription factors drives 


































2.1 Materials  
Distilled water was produced by a Milli-Q water purification system (Millipore, 
Millford, MA, USA). Chemicals and reagents were sourced as follows:  
Abcam (Cambridge, UK): mouse monoclonal antibody to insulin, goat polyclonal 
antibody to GFP, rabbit polyclonal antibody to ki-67, rabbit polyclonal antibody to 
Pdx-1, rabbit polyclonal antibody to GLUT2, rabbit polyclonal antibody to Foxo-1, 
rabbit polyclonal antibody to Ngn-3 and rabbit polyclonal antibody to Arx.  
BDH Chemicals Ltd. (Poole, UK): Acetic acid (glacial), calcium chloride (CaCl2.6H2O), 
dichloromethane (CH2Cl2), di-sodium hydrogen orthophosphate (Na2HPO4), ethanol, 
D-glucose, hydrochloric acid (HCl), magnesium sulphate (MgSO4.7H2O), 
paraformaldehyde (PFA), potassium dihydrogen orthophosphate (KH2PO4), sodium 
bicarbonate (NaHCO3), sodium chloride (NaCl), tri-sodium citrate (C6H5Na3O7.2H2O) 
and sodium dihydrogen orthophosphate (NaH2PO4).  
Gibco Life Technologies Ltd. (Paisley, UK): Antibiotics (100U/ml penicillin and 0.1g/L 
streptomycin), Dulbecco’s Modified Eagle Medium (DMEM) (25mM glucose) 
supplemented with 4500mg/L glucose, L-glutamine and without pyruvate, DMEM 
(11.1mM glucose) supplemented with L-glutamine and 15mM HEPES, foetal bovine 
serum (FBS), Hanks buffered saline solution (HBSS 10x stock) and trypsin/EDTA (10x 
stock).  
Invitrogen (Paisley, UK): Alexa Fluor 594 goat anti-mouse IgG (H+L), Alexa Fluor 488 
goat anti-mouse IgG (H+L), Alexa Fluor 350 goat anti-mouse IgG (H+L), Alexa Fluor 
594 goat anti-guinea-pig IgG (H+L), Alexa Fluor 488 goat anti-guinea-pig IgG (H+L), 
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Alexa Fluor 594 goat ant-rabbit IgG (H+L), Alexa Fluor 488 goat anti-rabbit IgG (H+L), 
Alexa Fluor 488 donkey anti-goat IgG (H+L), 100bp DNA ladder, SYBR® Safe DNA gel 
stain and xylene.  
Oxoid (Basingstoke, UK): Phosphate buffered saline (PBS) tablets  
Perkin Elmer (Cambridge, UK): Sodium iodide – 125I (74Mbq/20µl stock) 
Sigma-Aldrich Chemical Company Ltd. (Poole, UK): Acetonitrile, bovine insulin 
(crystalline), bovine serum albumin (essentially fatty acid free, endotoxin free), 
charcoal (activated/untreated), dextran T-70, 4’,6-diamidino-2-phenylindole (DAPI), 
diethyl pyrocarbonate (DEPC), dimethyl sulphoxide (DMSO), C,N-diphenyl-N’-4,5-
dimethyl thiazol 2 yl tetrazolium bromide (MTT), ethylene diaminetetraacetic acid 
(EDTA), glycerol, hydrogen peroxide (H2O2; 30% w/w), N-2-hydroxyethylpeprazine-
N’-2-ethane=sulphonic acid (HEPES), isopropanol, 2-mercaptoethanol, palmitic acid 
sodium salt, potassium chloride (KCl), sodium hydroxide (NaOH), standard agarose, 
streptozotocin, 1,3,4,6-tetrachloro-3α,6α-diphenylglycouril (iodogen), thimerosol, 
Triton X-100, trizma base, trizma hydrochloride, trypan blue solution (0.4%), tunel 
reaction mixture and tween-20.  
VWR International (Lutterworth, UK): PolysineTM coated slides  
 
2.2 Tissue Culture 
All cell lines used were cryopreserved at Ulster University, Coleraine in liquid 
nitrogen. Cells were cultured in aseptic conditions as described. Thawed cells were 
suspended in 10ml of warmed tissue culture media and centrifuged at 900rpm for 5 
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minutes. The resulting pellet was resuspended in a tissue culture flask and stored in 
an LEEC incubator (Laboratory Technical Engineering, Nottingham, UK) at 37°C 
supplied with 5% CO2 and 95% air.  
All cell lines were sourced from the Ulster University’s cell technology unit. The rat-
derived INS-1 clonal cell line was cultured in RPMI-1640 (11.1mM glucose) 
supplemented with 10% FBS, 1% penicillin-streptomycin (5000IU/l), 200µM 2-
mercaptoethanol and  1mM sodium pyruvate (Shi et al, 2011). INS-1 cells contain a 
high insulin content, are glucose responsive and maintain these beta cell 
characteristics over 116 passages (Asfari et al, 1992; Merglen et al, 2004). The mouse 
insulinoma, MIN6 cell line was cultured in high glucose DMEM (22.2mM glucose), 
10% FBS, 1% penicillin-streptomycin (5000IU/L) and 200µM 2-mercaptoethanol 
(Vasu et al, 2015). These cells respond appropriately to glucose within the 
physiological range however this response has been noted to decline through 
successive passages (Miyazaki et al, 1990). The rat insulinoma, RINm5F cell line was 
cultured in RPMI-1640 (11.1mM glucose), 10% FBS and 1% penicillin-streptomycin 
(5000IU/L) (Flatt et al, 1988; Gazdar et al, 1980). These cell consist of and mainly 
secrete insulin but have been shown to also produce glucagon and somatostatin 
(Skelin et al, 2009). Additionally, these cells differ from primary beta cells by their 
abnormal glucose transport and sensitivity to glucose (Halban et al, 1983).  
Cells were routinely passaged in the following manner. Confluent flasks of cells were 
aspirated of media and washed with hanks buffered saline solution (HBSS) to remove 
the FBS coating. 5ml of warmed trypsin (50ml 10X trypsin-EDTA with 450ml HBSS) 
was added to culture flasks and kept at 37°C for 5 minutes to allow cellular 
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detachment from the flask surface. After confirmation of detachment under the 
microscope, trypsin action was neutralised by the addition of 7ml trypsin and 
transferred to a sterlin tube (Sterlin Ltd, Hounslow, UK) and cells were pelleted by 
centrifugation at 900rpm for 5 minutes. The supernatant was discarded and a single 
cell suspension was created by addition of fresh media. 100µl of this suspension was 
counted using a Neubauer haemocytometer (Scientific Supplies Co., UK). Once 
counted cells were seeded at a specified density for experiments or returned to the 
culture flasks.  
 
2.3 Determination of cell viability by MTT  
The MTT is a colorimetric assay to indirectly assess mitochondrial oxidative processes 
to determine cell viability. This assay was conducted on cell monolayers (INS-1, MIN6 
& RINm5F) cultured in 24 well plates for 24 or 48 hours in the following test 
conditions: normal media, glucotoxic (25mM glucose), lipotoxic (0.25mM palmitate), 
cytokine cocktail (300U/ml IL-1β, IFN-γ and 40U/ml TNF-α) and hydrogen peroxide 
(1mM). 5mg/ml stock MTT was made by dissolving MTT (C,N-diphenyl-N’-4, 5-
dimethyl thiazol-2-yl tetrazolium bromide) (Sigma-Aldrich,) powder in KRB buffer 
which was then wrapped in foil to protect from light. Working MTT was prepared by 
a 1:10 dilution of this stock with KRB buffer with 5.6mM glucose. 1ml of this working 
solution was pipetted to each well and allowed to incubate at 37°C for 60 minutes. 
This incubation time allows metabolically active and thus viable cells to reduce this 
tetrazole to form a precipitate. Following aspiration of the MTT solution 250µl of 
DMSO was added to each well to solubilise the precipitate. 100µl aliquot of each 
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sample was transferred to a 96 well plate and read using a Flexstation 
spectrophotometer measuring absorbance at 570nm.  
 
2.4 Immunocytochemistry  
Fluorescent immunocytochemistry was carried out on cell monolayers to assess 
protein expression. Cell lines were cultured on sterilised 16mm circular glass cover 
slips in the previously stated test conditions for 24 and 48 hours. Following culture, 
media was aspirated from the wells and cells were washed with PBS before fixation 
by immersion in 4% paraformaldehyde for 30 minutes. Heat mediated antigen 
retrieval was carried by addition of 1ml sodium citrate buffer and incubation for 20 
minutes at 95°C followed by a further 20 minutes at room temperature to cool. BSA 
blocking was then carried out by addition of 1ml 3% BSA solution and incubation at 
room temperature for 45 minutes. Primary antibodies were then made up to the 
manufacturer’s guidelines (Table 2.1) and 200µl added per well and allowed to 
incubate overnight at 4°C. The next day, cells were washed twice with PBS to remove 
excess antibody. Fluorescently labelled secondary antibody (Table 2.1) was diluted 
1/300 and added, 200µl/well, and allowed to incubate at 37°C for 45 minutes. After 
this period cells were washed twice with PBS before addition and incubation with 
DAPI for a further 15 minutes at 37°C. A final two washes with PBS was then carried 
out before careful removal of the cover slips onto polysine coated slides. Cells could 
then be imaged and photographed using a fluorescent microscope (Olympus system 
microscope, model BX51) fitted with FITC (488nm) and TRITC (594nm) filters with 
Cell^F software.  Immunocytochemistry was quantified by counting expression of 
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proteins of interest within the cells from >5 frames, with each frame containing >150 
cells using ImageJ software. 
 
2.5 mRNA extraction and conversion to cDNA  
mRNA was extracted from cultured cells using the trizol method as follows. Cultured 
cells were first washed in HBSS before 10 minutes incubation with 1ml TRI reagent 
(Sigma-Aldrich,). After mixing, the lysed cell solution was transferred to a 1.5ml 
Eppendorf and centrifuged at 12,000G for 10 minutes at 4°C. The resulting 
supernatant was transferred to a fresh Eppendorf, leaving behind the insoluble 
material. 200µl of chloroform was then added to the cell lysate and mixed thoroughly 
before centrifuging at 12,000G for 15 minutes at 4°C. Of the three distinct layers 
produced, the upper aqueous layer of RNA was extracted and mixed with 500µl 
isopropanol and centrifuged at 14,000G for 20 minutes at 4°C in order to precipitate 
the RNA. The RNA precipitate was washed thrice in 75% ethanol before finally being 
solubilised in 20µl RNA-free water. To determine the concentration and purity of RNA 
a 1µl sample was tested on a NanoDrop ND-1000 UV/Vis spectrophotometer. All 
mRNA samples were stored at -70°C, however only samples showing an 
OD260/OD280 ratio >1.8 were considered pure and used for cDNA conversion.  
1-3µg of cDNA was generated by reverse transcription of mRNA as follows. OligoDT 
was added to RNA samples and heated to 70°C within a thermocycler to denature 
the secondary structure of RNA and allow annealing. A mastermix of first strand 
buffer, dNTPs, DTT and superscript reverse transcriptase was then added and left to 
incubate in the thermocycler at 42°C for 1 hour. Following this time the mixture was 
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then heated to 70°C to inactivate the transcriptase enzyme. The concentration of 
cDNA was confirmed using a NanoDrop ND-1000 UV/Vis spectrophotometer. cDNA 
samples were stored at -20°C until required.  
 
2.6 Real time reverse transcription polymerase chain reaction (Real time RT-PCR) 
An 18µl PCR reaction mix was established comprised of 9µl SYBR green, 6µl RNA-free 
water, 1µl primers (forward and reverse) and 1µl previously generated cDNA. A 
negative template control for each primer and a housekeeping β-actin positive 
control was run with each PCR. Reactions were conducted in 8-well low tube strips 
with clear low flat caps (BioRad). Amplification was carried out using a Miniopticon 
two-colour real time PCR detection system under the following conditions: 1. Initial 
denaturation 95°C, 5 minutes, 2. Final denaturation 95°C, 30 seconds, 3. Annealing 
58°C, 30 seconds, 4. Extension 72°C, 30 seconds. The results were analysed using 
crossing points (Cp) from genes of interest normalised in respect the housekeeping 
β-actin control.  
 
2.7 Animals 
8 week old male C57Bl/6 mice were purchased from [Envigo, UK]. Breeding pairs of 
Ins1cre/+ and Rosa26-eYFP mice were purchased from the Jackson Laboratory, New 
York, USA (Thorens et al, 2015). In brief Ins1cre+/- mice were generated by homologous 
recombination of Cre within the second exon of the Ins1 gene. These Ins1Cre+/- mice 
were then crossed with established Rosa26-eYFP mice to generate Ins1cre/+;Rosa26-
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eYFP mice (Figure 2.1; Srinivas et al, 2001). Selective Cre recombination of floxed 
eYFP gene within beta cells tags them with a fluorescent marker from birth allowing 
for lineage tracing experiments (Figure 2.2). Identification of tagged cells is carried 
out by immunohistochemical staining for GFP which binds to the YFP expressed only 
within tagged cells (Thorens et al, 2015).  Generation of this double-transgenic colony 
was carried out in-house by crossbreeding both strains of mice and subsequent 
inbreeding of double knock-in transgenic mice. Genotyping was carried out, once 3-
4 weeks old, to confirm the genotype of the offspring. For 
streptozotocin/hydrocortisone studies, mice were used aged 12 weeks. For diet-
induced diabetic studies, mice were kept on a high fat diet for 11 weeks until obese. 
Animals were housed within the University Behavioural and Biomedical Research 
Unit kept in temperature-controlled rooms (22°C) under 12 hour light-dark cycle 
(0800-2000hr) with access to standard chow diet (60% carbohydrate, 30% protein 
and 10% fat) (Trouw Nutrition, Cheshire, UK) and drinking water ad libitum. To ensure 
welfare, the unit was maintained by fully trained staff. When conducting studies 
animals were single-housed with access to food and drinking water ad libitum, unless 
stated. All procedures were carried out with ethical approval and strict adherence to 
the UK Animals (Scientific Procedures) Act 1986.  
 
2.8 Genotyping 
To confirm genotype of transgenic mice genotyping was carried out. Mice were 
lightly anaesthetised under isoflurane before excision of 1mm section of ear tissue 
which was then kept in RNA-free water (39µl). To digest the tissue and extract DNA, 
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10µl 5X Bioline PCR buffer and 1.3µl Proteinase K (20mg/ml) were added to make a 
50µl reaction mix. Samples were run in the thermocycler to induce heat-activated 
proteinase K enzyme action first for 40 minutes at 60°C, followed by 10 minutes at 
95°C to terminate enzyme activity. PCR was then used to amplify the inserted genes 
of interest (Ins1Cre and eYFP). A 25µl reaction mix was concocted using 18µl RNA-free 
water, 2.5µl 5X Bioline PCR buffer, 0.2µl primer pair mix (50µM), 1.25µl DMSO, 0.1µl 
Bioline Taq Polymerase and 3µl of Proteinase K reaction mix. PCR amplification was 
carried out on the thermocycler under the following settings: 1. Initial denaturation 
94°C, 3 minutes, 2. Final denaturation 94°C 1 minute, 3. Annealing 58°C, 4. Extension 
72°C, 1 minutes, 5. Repeat steps for 35 cycles. The PCR product was then run on a 1% 
agarose gel to visualise expression of transgenes to determine mice genotype. 250ml 
50X Tris Acetate-EDTA (TAE) buffer for electrophoresis was made up consisting of 
60.5g TRIS base, 14.275ml glacial acetic acid, 4.65g disodium EDTA and 250ml water. 
Ultrapure agarose (Invitrogen, UK) was dissolved in 1X TAE buffer (1% w/v) by 
heating. Upon cooling SYBR Safe DNA dye (Invitrogen, UK) was added (1µl/10ml) 
before casting into moulds and combs added to create wells. Once solidified gel was 
placed in an electrophoresis tank and immersed in 1X TAE buffer. To identify loaded 
wells PCR reaction products were mixed with orange G dye (2mg/ml, dissolved in 
30% glycerol) (Sigma-Aldritch, UK) before loading into wells. To identify bands 5µl of 
100bp ladder (Invitrogen, UK) was all loaded into one well. The current was set to 
100V and the electrophoresis allowed to run for 25 minutes whereby DNA had 
separated by size and traversed the gel. Gels were then read on the G-box imaging 
machine where visualisation of Ins1Cre/+ (675bp) and eYFP (422bp) bands were a 
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positive confirmation of genotype (Figure 2.1). Amplification and visualisation of 
housekeeping β-catenin (220bp) was used as a positive control.  
 
2.9 Glucose tolerance test  
Intraperitoneal glucose tolerance tests were conducted on overnight fasted mice. A 
tail vein bleed from conscious mice was used to withdraw blood which was collected 
into heparin-coated microcentrifuge tubes (Sarstedt, Numbrecht, Germany) and kept 
on ice. Blood was collected by this method at time point 0 minute prior to dosing the 
glucose load (18mmol/kg body weight) and at 15 minute, 30 minute and 60 minute 
time points. Determination of blood glucose was also conducted at these time points 
using an Accu-Check® Aviva meter with their associated Aviva® sensor test strips. To 
separate plasma from blood cells, blood samples were centrifuged for 5 minutes at 
13000g at 4°C using a Beckman microcentrifuge (Beckman Instruments, Galway, 
Ireland). Separated plasma, needed for determining plasma insulin, was stored in 
1.5ml Eppendorf tubes at -20°C.  
 
2.10 Pancreatic insulin and protein content  
Upon completion of an in vivo study, the pancreas was harvested from each mouse 
and sectioned longitudinally, with half kept for histological analysis and half snap 
frozen in liquid nitrogen and kept for protein extraction. This latter half was weighed 
and homogenised in ice cold acid ethanol (75% (v/v) ethanol, 23.5% (v/v) distilled 
water and 1.5% (v/v) 12N HCl) within 8ml bijou tubes. Protein extract samples were 
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centrifuged at 3000RPM for 20 minutes at 4°C and the resulting supernatant 
transferred to a 15ml centrifuge tube. pH neutral TRIS buffer was added and samples 
dried out to a fine powder within the speedvac. Finally, protein samples were 
resuspended in 2ml TRIS buffer and stored at -20°C until needed. Insulin content was 
assessed using an insulin radioimmunoassay, whilst total protein content in extracts 
was assessed using a Bradford assay as described. BSA standards were prepared in 
triplicate ranging from 0 – 2 mg/ml (0, 0.13, 0.17, 0.23, 0.3, 0.4, 0.55, 0.75, 0.96, 1.31, 
1.75 & 2mg/ml) concentrations in distilled water whilst 5µl of diluted samples were 
added in duplicate to a 96 well plate. 250µl of 1:8 distilled water diluted Bradford 
reagent was then added to all wells and left to incubate at room temperature for 
thirty minutes. Following this incubation the plate was read using a Vmax plate reader 
to measure absorbance at 595nm wavelength. Sample protein content was then 
determined using the linear range of the generated standard curve (Figure 2.3). 
 
2.11 Plasma and pancreatic glucagon content  
Glucagon levels were assessed by glucagon ELISA (EZGLU-30K, Millipore, Millford, 
MA, USA) conducted under manufacturer’s guidelines. Plasma and pancreatic extract 
samples were first processed to extract protein. 50µl plasma or 150µl pancreatic 
extract was mixed with 75µl or 225µl acetonitrile respectively before centrifugation 
at 17,000G for 5 minutes. The resulting supernatant was transferred to a fresh 
Eppendorf and dried down to a fine powder using the speedvac. Samples were 
reconstituted in 30µl of assay buffer for ELISA. Glucagon standards were established 
in duplicate ranging from 0-2ng/ml (0, 0.02, 0.05, 0.1, 0.2, 0.5, 1 & 2ng/ml, Figure 2.4) 
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in assay buffer. The ELISA plate was rinsed in wash buffer prior to use and addition 
of 20µl assay buffer, 10µl standards/samples and 20µl antibody capture/detection 
mixture. The plate was sealed and left on a rocker at 4°C for 44 hours. Following this 
incubation period, the plate was rinsed three times in wash buffer before the 
addition of 100µl of enzyme solution and a further incubation at room temperature 
for 30 minutes. A further six washes were carried out after this incubation and 100µl 
working substrate solution added. The plate was left on a plate shaker for 1 minute 
and then relative light units were recorded on a luminometer plate reader at 425nm.  
 
2.12 Iodination of insulin   
To quantify insulin levels in cell and plasma samples an in-house radioimmunoassay 
was carried out using iodinated insulin. Our in-house protocol for iodinating insulin 
involves: overnight evaporation of 100µl iodogen (1,3,4,6-tetrachloro-3α, 6α-
diphenylcoluril) dichloromethane solution (100µl/ml) within a flow hood. The next 
day, bovine insulin was made up by dissolving 1mg in 10mM HCl before being diluted 
in sodium phosphate buffer to 125µg/ml. 20µl of this bovine insulin solution was 
transferred to the coated iodogen tubes before addition of 5µl Na125I (74MBq/20µl). 
This solution was allowed to mix on ice for 15 minutes. After this time, the solution 
was transferred to a fresh Eppendorf tube containing 500µl sodium phosphate buffer 
(50mM). Reverse phase high performance liquid chromatography (LKB, Bromma, 
Sweden) was carried out to separate the reaction mixture. Solvent A (0.12% (v/v) 
trifluoroacetic acid (TFA) in water) and solvent B (0.1% (v/v) TFA in 70% acetonitrile 
dissolved in 30% (v/v) water) made up the mobile phase of the reaction. The 4.6 
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x250mm Vydar C-8 analytical reverse HPLC column (Hesperia, Ca, USA) was first 
washed with solvent A. The reaction mixture was then added and the concentration 
of solvent B raised in the following stages: 0% - 40% duration 10 minutes, 40% - 80% 
duration 40 minutes, 80% - 100% duration 10 minutes. 1ml of eluent was collected 
each minute over the 60 minute period. From these 60 fractions, 5µl from each was 
analysed for radioactivity on the gamma counter (1261 Multigamma counter LKB 
Wallac, Finland) and those with a suitable binding affinity were kept at 4°C (Figure 
2.5).  
 
2.13 Insulin Radioimmunoassay (RIA)  
Insulin release was determined by dextran-coated charcoal radioimmunoassay 
characterised by Flatt and Bailey (1981). Stock RIA buffer was prepared consisting of 
40mM sodium phosphate buffer, 0.3% (w/v) sodium chloride, 0.02% (w/v) 
thimerosal. 40mM sodium dihydrogen orthophosphate base was then added to 
adjust the pH of the final stock to pH7. A working RIA buffer was then used by 
dissolving bovine serum albumin (BSA) (0.5g/100ml) in stock RIA buffer. Rat insulin 
standards were serial diluted in working RIA buffer from 20ng/ml to 0.039ng/ml in 
triplicate LP3 tubes. Unknown samples were used in duplicates and contained 200µl 
of sample, 100µl guinea pig anti-porcine insulin antiserum (IAS PID, 1:30,000-
1:45,0000 dilution) and 100µl of labelled I125 insulin (~10,000 counts per minute 
(CPM) per 100µl in working RIA buffer). To allow equilibrium, between labelled and 
unlabelled insulin, samples were kept at 4˚C for 48 hours. To prepare stock dextran 
coated charcoal (DCC) solution, 5g dextran T70 and 50g charcoal was dissolved in 1 
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litre stock RIA buffer and kept at 4°C until required. A 1:4 dilution of this stock DCC 
with stock RIA buffer was used to generate working DCC with 1ml added to every 
standard and sample tube except for total counts and allowed to incubate at 4°C for 
20 minutes. The tubes were then centrifuged for 20 minutes at 4°C at 2500rpm 
(Model J-6B centrifuge, Beckmann instruments Inc, UK). Following decantation of the 
resulting supernatant, the remaining charcoal pellet was assessed for radioactivity in 
the gamma counter (1261 Multigamma counter, LKB Wallac, Finland).  The spline 
curve-fitting algorithm was used to determine the concentration of insulin in 
unknown samples. 
 
2.14 Tissue processing for Immunohistochemistry  
Excised pancreatic tissues from mice were fixed in paraformaldehyde solution (4% 
w/v in phosphate buffered saline) for ~48 hours to cross-link proteins, thereby 
preserving cellular architecture. Tissue processing was then carried out using an 
automated tissue processor (Leica Biosystems, Nussloch, Germany). In brief, this 
involved dehydrating tissues in increasing concentrations of ethanol (70-100%) 
before immersion in xylene to clear the alcohol and allow for embedding in warm 
paraffin wax. Once embedded and cooled the tissues were then sectioned into 5µl 
slices using a microtome (Leica Biosystems, Nussloch, Germany) and placed onto 






2.15 Immunohistochemistry (fluorescence immunoreactivity) 
Immunoreactive staining for insulin, glucagon, GFP, Pdx-1, GLUT2 and ki-67 was 
assessed, first by dewaxing slides by immersion in xylene for 20 minutes. Following 
this, sections were rehydrated in decreasing concentrations of ethanol (100-50%) 
before carrying out heat-mediated antigen retrieval, to break down PFA cross-links 
so antibody can later bind, in sodium citrate buffer (10mM sodium citrate, pH6.0) for 
20 minutes at 95°C. Slides were then given 20 minutes to cool before addition of 3% 
bovine serum albumin (BSA) blocking solution (3% w/v in phosphate buffered saline), 
to block non-specific antibody binding, for 45 minutes at room temperature. Sections 
were then incubated overnight at 4°C with primary antibodies listed in Table 2.1. The 
next day, excess antibody was removed by rinsing slides three times in PBS for 5 
minutes each.  Slides were then incubated with the relevant fluorophore conjugated 
secondary antibodies (table 2.1) for 45 minutes at 37°C. Excess antibody was then 
removed by washing slides thrice in PBS for 5 minutes each. Slides were then 
incubated with nuclear stain DAPI dihydrochloride (300nM in PBS) for 15 minutes at 
37°C. A final set of rinsing in PBS was done to remove excess DAPI before mounting 
the slides using aqueous mounting medium (glycerol:PBS – 1:1) and cover slips. 
Resulting slides were viewed using a fluorescent microscope (Olympus system 
microscope, model BX51) fitted with the FITC, TRITC and DAPI filters. Islets were 
photographed under TRITC and FITC filters using the linked camera adapter system 
(DP70 digital camera system) on Cell^F software. To assess beta cell apoptosis a 
TUNEL assay was carried out following manufacturer’s guidelines (In situ cell death 
kit, Fluorescein, Roche Diagnostics, UK). In brief, following immunostaining for 
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insulin/glucagon, slides were incubated in TUNEL solution for 1 hour at 37°C before 
subsequent rinsing in PBS.  
 
2.16 Image Analysis 
Images were analysed using Cell^F imaging software to assess: islet area, beta cell 
area, alpha cell area (expressed at µm2), percentage beta cells and percentage alpha 
cells. For islet size distribution islets were defined as small, medium or large if they 
were <10,000µm2, 10,000-25,000µm2 or 25,000µm2 respectively. Islet architecture 
was defined by the proportion of islets displaying central alpha cells. To define beta 
cell transdifferentiation, insulin, GFP staining was assessed by quantifying the 
number of insulin negative, GFP positive staining cells, whilst glucagon, GFP staining 
was assessed by quantifying glucagon positive, GFP positive staining cells.  Beta cell 
and alpha cell apoptosis was quantified by counting the number of insulin positive or 
glucagon positive, TUNEL positive cells respectively. Similarly this was done to 
analyse proliferation in beta and alpha cells using ki-67 co-stained with insulin or 
glucagon respectively. ImageJ software was used to quantify beta cell Pdx1 
expression, expressed as a percentage of the number of insulin positive cells 
expressing Pdx1. All counts were determined in a blinded manner with >60 islets 
analysed per treatment group. 
 
2.17 Statistics  
Graphpad PRISM (version 5) software was used to analyse results with data 
presented as mean plus or minus standard error of the mean (SEM). Groups of data 
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were compared and statistical analysis carried out using two-tailed unpaired 
Student’s t-tests or one-way ANOVA, two-way ANOVA, with Bonferroni post-hoc test 








Primary Antibodies  
Target Host  Clonality  Dilution  Source  
Insulin Mouse Monoclonal  1:400 Abcam (ab6995) 
Glucagon  Guinea-pig  Polyclonal  1:400 Raised in-house (PCA2/4)  
GFP  Goat  Polyclonal 1:1000  Abcam (ab5450)  
Ki-67  Rabbit  Polyclonal 1:500 Abcam (ab15580) 
Pdx-1  Rabbit  Polyclonal  1:200  Abcam (ab47267) 
GLUT2  Rabbit  Polyclonal 1:200  Abcam (ab54460) 
Foxo-1  Rabbit  Polyclonal 1:200 Abcam (ab52857) 
Ngn-3 Rabbit  Polyclonal 1:200 Abcam (ab38548) 
Secondary Antibodies  
Target  Host  Reactivity  Dilution  Source  
IgG  Goat  Mouse  1:400  Alexa Fluor 594, Invitrogen 
IgG  Goat  Mouse  1:400  Alexa Fluor 488, Invitrogen 
IgG Goat  Mouse  1:400  Alexa Fluor 350, Invitrogen 
IgG Goat  Guinea-pig  1:400 Alexa Fluor 594, Invitrogen 
IgG Goat  Guinea-pig 1:400  Alexa Fluor 488, Invitrogen  
IgG Goat  Rabbit  1:400 Alexa Fluor 594, Invitrogen 
IgG Goat  Rabbit  1:400 Alexa Fluor 488, Invitrogen 
IgG Donkey  Goat  1:400  Alexa Fluor, 488, Invitrogen 
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Generation of double knock-in Ins1cre+/-;Rosa26-eYFP mice (Thorens et al, 2015). (A) 
Tissue specific cre-lox mediated expression of eYFP within beta cells due to selective 
knock in of Cre recombinase within Ins1 gene. (B) PCR analysis confirming expression 
of Ins1creand eYFP transgenes.  
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Representative images from Ins1cre+/-;Rosa26-eYFP mice showcasing expression of GFP exclusively within pancreatic beta cells. Confirmed by 
immunohistochemistry for (A) insulin (red) and GFP (green) and (B) glucagon (red) and GFP (green).  
DAPI Glucagon GFP Combined 




















Figure 2.1: Total protein quantification determined by Bradford assay using bovine 
serum albumin as standards from concentrations ranging from 0-2mg/ml. Values 
are mean±SEM, n=3  
 
Bradford quantification of total protein
using BSA standard
































Figure 2.2: Glucagon quantification determined by ELISA using standards from 
concentrations ranging from 0-2ng/ml. Values are mean±SEM, n=3.   
Glucagon ELISA standard curve











Figure 2.5 Iodination of insulin  








































Figure 2.3: Purification of iodinated insulin by RP-HPLC. I125 labelled insulin was 
prepared by solid-phase iodogen method and purified by HLPC. The peak fraction, 












Beta-to-alpha cell transdifferentiation was assessed using beta cell lines (INS-1, MIN6 
and RINm5F cells) following long-term exposure to known beta cell stressors (high 
glucose, lipid toxicity and cytokine toxicity). INS-1 cells proved to be most susceptible 
to changes in plasticity with lipotoxic and cytokine exposure resulting in an increase 
in cells co-expressing insulin and glucagon or purely expressing glucagon. Changes 
suggestive of beta cell transdifferentiation were observed at a gene expression level 
with downregulation of beta cell markers (insulin, GLUT2 and FOXO1), upregulation 
of alpha cell (glucagon and Arx) and progenitor markers (Ngn-3). Streptozotocin 
treated C57Bl/6 mice exhibited hyperglycaemia linked to a loss of beta cell mass. 
Alpha cell mass was greatly expanded and distributed within the core of the islet. 
Beta cell markers Pdx1 and GLUT2 were reduced which, considered in the context of 
alpha cell expansion, could suggest beta-to-alpha cell transdifferentiation.  
Hydrocortisone produced beta cell mass expansion to overcome steroid induced 
insulin resistance. Hydrocortisone did not impact alpha cell mass greatly so the 
potential for beta-to-alpha cell transdifferentiation was limited. However reductions 
in Pdx1 and GLUT2 observed suggest beta cell dedifferentiation. Similarly, there was 
little suggestion of beta cell transdifferentiation in db/db mouse islets as beta and 
alpha cell masses expanded proportionally to one another. High fat fed mouse islets 
displayed a disproportional increase in alpha cell mass compared to beta cell mass 
expansion suggestive of beta-to-alpha cell transdifferentiation. Exendin-4 limited this 
alpha cell expansion implicating the role of incretins in maintaining beta cell maturity. 
These studies emphasize the need for lineage tracing to reliable identify and quantify 
beta-to-alpha cell transdifferentiation.   
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3.2 Introduction  
Beta cell lines have been generated to mimic primary beta cell physiology in order to 
investigate beta cell function and dysfunction. Understanding this physiology may aid 
the development of novel therapies for diabetes. Given that primary beta cells poorly 
proliferate, much effort has been taken to generate immortalised beta cell lines that 
retain regulated insulin secretory activity. Ideally these cells lines should contain a 
high insulin content, express beta cell specific proteins (glucokinase and GLUT2) and 
exhibit glucose responsive insulin secretion (Skelin et al, 2010). 
The insulinoma cell line INS-1 is a rat derived X-ray radiation induced cell line (Asfari 
et al, 1992; Merglen et al, 2004). Despite only producing 20% of the total insulin 
content of primary beta cells the INS-1 cell line is glucose responsive due to 
expression of GLUT2 and glucokinase. MIN6 cells are derived from a transgenic 
mouse expressing the SV40 T-antigen within the insulin promoter leading to an 
insulinoma (Miyazaki et al, 1990; Vasu et al, 2015). The rat insulinoma cell line 
(RINm5F) were one of the first beta cell lines generated from the X-ray radiation 
induced insulinoma in NEDH rats (Gazdar et al, 1980; Skelin et al, 2009). These cells 
contain small amounts of insulin however they also contain glucagon and 
somatatosatin. Other abnormalities in glucose responsiveness and transport have 
also been noted. (Gazdar et al, 1980; Praz et al, 1983; Halban et al, 1983). 
A number of stressors have been found to impact on the viability and function of 
pancreatic beta cell lines. These effects translate to both rodent and human islets, 
emphasising the benefits of cell models in understanding diabetes aetiology (Vasu et 
al, 2014). Pancreatic beta cell lines show reduced insulin content and gene expression 
51 
  
when exposed to a cytokine cocktail of IFNγ, IL-1β and TNFα or lipotoxic conditions 
(Vasu et al, 2013; Vasu et al, 2014). Similarly, INS-1 and MIN6 cells have been found 
to be susceptible to lipotoxic palmitate which induces ER stress leading to beta cell 
apoptosis (Sargysan et al, 2011; Lee et al, 2011; Karaskov et al, 2006). Long term 
culture in these stress conditions may have the potential to cause beta cell 
transdifferentiation within cell lines. 
The leptin receptor deficient db/db mice are widely used as a monogenic model of 
obesity and type-2 diabetes. This spontaneous mutation originated within the 
Jackson Laboratory and was found to be caused by an autosomal recessive mutation 
in the leptin receptor (Hummel et al, 1966; Chen et al, 1996; Lee et al, 1996). Leptin, 
an adipokine, is involved in satiety with its loss of function resulting in hyperphagia, 
obesity, hyperinsulinaemia and hyperglycaemia (Srinivasan and Ramarao, 2007; 
Pathak et al 2015). Islets from these mice show irregular morphology displaying islet 
hypertrophy with the ordered architecture of beta and alpha cells becoming mixed 
(Kawasaki et al, 2005).  These mice can also be used as a model of beta cell 
dedifferentiation given their reduction in several beta cell markers (insulin, Foxo1, 
MafA and NeuroD1) and upregulation of progenitor marker Aldh1a3 (Ishida et al, 
2017; Kjørholt et al, 2005).  
The present studies will utilise the three described cell lines (INS-1, MIN6 and 
RINm5F) hoping to identify beta cell transdifferentiation in response to known beta 
cell stressors. Preliminary in vivo studies involving C57Bl/6 mice will look to identify 
signs of beta cell transdifferentiation in multiple low dose streptozotocin and 
hydrocortisone models of diabetes. Finally analysis of islet morphology using samples 
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from high fat fed mice (Vasu et al, 2017) and leptin receptor deficient mice (Pathak 
et al, 2015) will be examined for signs of beta cell transdifferentiation.  
 
3.3 Methods  
Materials and methods have been briefly summarised below. Full explanations of 
each method can be found within Chapter 2.  
 
3.3.1 Cell Culture and stressor conditions  
All cell lines were cultured under aseptic conditions as described. INS-1 cells were 
cultured within RPMI-1640 (11.1mM glucose) supplemented with 10% FBS, 1% 
penicillin-streptomycin antibiotics, 200µM 2-mercaptoethanol and 1mM sodium 
pyruvate. MIN6 cells were maintained in DMEM (4.5g/L glucose), 10% FBS, 1% 
penicillin-streptomycin antibiotics and 2-mercaptoethanol. RINm5F cells were 
cultured in RPMI-1640 (11.1mM glucose), 10% FBS and penicillin-streptomycin. For 
high glucose culture media RPMI-1640 was supplemented with glucose to generate 
a 25mM solution (INS-1 and RINm5F) and sterile filtered before use. For MIN6 high 
glucose DMEM (22mM) was used. For lipotoxic media RPMI-1640 (INS-1 and RINm5F) 
and low glucose DMEM (2mM) was supplemented with sodium palmitate, dissolved 
in 50% ethanol. An intermediate stock was made up in fatty acid free BSA before 
being diluted in media to 0.25mM. For glucolipotoxic media sodium palmitate was 
similarly diluted in high glucose media counterparts. For cytokine treatments a 
cocktail was made up consisting of IL-1β (150U/ml and 300U/ml), IFN-γ (150U/ml and 
300U/ml) and TNF-α (20U/ml and 40U/ml) at low and high concentrations 
respectively. All cell lines were cultured in these stress conditions (high glucose, 
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lipotoxic, glucolipotoxic, low and high cytokines) for 24 and 48 hours. Following this 
culture, cells underwent MTT assay to assess viability and immunocytochemistry for 
insulin/glucagon. Cells were only used for RNA extraction and qPCR following 48 hour 
culture within stressor conditions.  
 
3.3.2 MTT  
MTT powder was dissolved into a stock solution of 5mg/ml in working KRBB without 
glucose. Working MTT was made up by a 1/10 dilution of stock MTT with 5.6mM 
glucose KRBB. Cultured cells were incubated with working MTT for one hour at 37°C. 
After this period a precipitate had formed which was solubilised by addition of 
DMSO. The plate was then read on a Flexstation at wavelength 570nm.  
 
3.3.3 Immunocytochemistry 
For immunocytochemistry, cells were cultured on sterilised 16mm round glass cover 
slips within 12 well plates. Following 24 or 48 hour incubation, the cells were rinsed 
in PBS before being fixed in 4% PFA. After this time antigen retrieval was carried out 
by incubation in citrate buffer heated to 90°C. Cells were then blocked in BSA before 
incubation with primary antibodies (mouse anti-insulin and guinea pig anti-glucagon) 
for 2 hours at 37°C. Unbound antibody was then removed by two washes in PBS 
before incubation with secondary antibodies (goat anti-mouse 594 and goat anti-
guinea pig 488) for 45 minutes at 37°C. Excess antibody was removed by PBS washes 
and cells were incubated for a final time with DAPI to stain nuclei. After a final wash 
in PBS, the cover slips were carefully removed from each well and mounted onto 
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polysine histology slides ready for imaging. Images were taken using an Olympus 
fluorescent microscope fitted with DAPI (350nm) FITC (488nm) and TRITC (594nm) 
filters and a DP70 camera adapter system 
 
3.3.4 RNA extraction, cDNA conversion and qPCR 
For RNA isolation cells were seeded in 6 well plates at a density of 500,000 cells and 
cultured for 48 hours in different stress conditions. Following the culture period cells 
were washed in HBSS before addition of ice cold Trizol to lyse the cells. The 
homogenous lysate was transferred to an Eppendorf and centrifuged at 12,000G for 
10 minutes at 4°C and the supernatant removed to a fresh Eppendorf. Phase 
separation was then carried out using chloroform and centrifugation at 12,000G for 
15 minutes at 4°C. Of the resulting 3 layers, the upper transparent aqueous layer of 
RNA was extracted into a fresh Eppendorf. RNA precipitation was then carried out 
using isopropanol and centrifuged at 14,000G for 20 minutes at 4°C. The resulting 
RNA pellet was then washed three times in 75% ethanol before being air-dried. The 
RNA pellet was then solubilised by the addition of RNA-free water. A NanoDrop ND-
1000 UV/Vis spectrophotometer was used to determine RNA quantity and quality. 
Quality was assessed by 260/280 OD ratios >1.8. RNA was stored at -70°C.  
 
cDNA (1µg) was produced by reverse transcription of isolated RNA. In short, oligoDT 
was mixed with RNA samples and heated to 70°C using a thermocycler. A mastermix 
of dNTPs, DTT, first strand buffer and superscript reverse transcriptase was added to 
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the samples and heated to 42°C for 1 hour. To terminate the reaction after this time 
the mixture was heated to 70°C.  
 
qPCR was carried out using a Miniopticon two-colour real time PCR detection system. 
Using an 18µl reaction mix consisting of SYBR green, RNA-free water, primers and 
cDNA. A negative template control was added for each primer and β-actin used as a 
housekeeping control. qPCR was run under the following conditions: 1. Initial 
denaturation 95°C, 5 minutes, 2. Final denaturation 95°C, 30 seconds, 3. Annealing 
58°C, 30 seconds, 4. Extension 72°C, 30 seconds. Results were analysed using Cp 
values normalised in respect to β-actin. 
 
3.3.5 Animals  
8 week old male C57Bl/6 mice were purchased and single housed within the BBRU. 
Mice had free access to standard chow diet and drinking water and kept in 
temperature controlled rooms on a 12 hour light-dark cycle. Mice were divided into 
three treatment groups: 1. Saline control, 2. Streptozotocin-treated and 3. 
Hydrocortisone-treated. The first group received daily ip injections of saline (0.9% 
NaCl) for the ten day duration of the study. The second group received five 
consecutive daily injections of streptozotocin (50mg/kg) freshly dissolved in 0.5M 
citrate buffer, pH4.5. The third group received ten daily doses of hydrocortisone 
(70mg/kg). Mice were allocated 8 per treatment group with body weight, blood 
glucose, calorie and fluid consumption monitored regularly. 
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Pancreas blocks were obtained from previously carried out study using high fat fed 
NIH Swiss mice treated with saline or exendin-4 (Vasu et al, 2017). In this study 8 
week old male mice (8 mice/group) were kept on high fat diet (45% fat, 20% protein 
and 35% carbohydrate) for 20 weeks, with exendin-4 (25nmol/kg, ip) dosed twice 
daily for 28 days.   Additional pancreas samples were obtained from a db/db leptin 
receptor deficient mice study treated with saline, GIP(6-30)Cex-K40[Pal], a GIP 
antagonist,  or liraglutide (Pathak et al, 2015). In this study 13 week old male db/db 
mice were allocated 8 per treatment group and dosed twice daily with liraglutide 
(0.25nmol/kg, ip) or GIP(6-30)Cex-K40[Pal] (2.5nmol/kg, ip) for 28 days. 
 
3.3.6 Immunohistochemistry  
Pancreatic tissue was excised from C57Bl/6 mice at the end of the study and fixed in 
4% PFA for 48 hours. Tissues were then put through a Leica automated tissue 
processor to dehydrate the tissue ready for embedding into wax blocks. 5µm sections 
were cut and collected on to polysine coated slides. Immunohistochemistry was 
carried out starting with immersion in xylene to clear wax followed by rehydration in 
an ethanol gradient (100-50%). Heat mediated antigen retrieval was carried out using 
citrate buffer heated to 90°C, followed by blocking in 4% BSA solution. Primary 
antibody was then added to the slides and allowed to incubate overnight at 4°C. The 
following antibodies were used: mouse monoclonal anti-insulin antibody (ab6995, 
1:1000; Abcam), guinea-pig anti-glucagon antibody (PCA2/4, 1:200; raised in-house), 
guinea pig anti-Pdx1 antibody (ab47267, 1:200; Abcam) and rabbit anti-GLUT2 
(1:200; Abcam). Unbound antibody was cleared the next day by washing in PBS 
before incubation with secondary antibodies. The following secondary antibodies 
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were used as appropriate: Alexa Fluor488 goat anti-guinea pig IgG — 1:400, Alexa 
Fluor 594 goat anti-mouse IgG — 1:400, Alexa Fluor 488, goat anti-rabbit IgG — 
1:400, Alexa Fluor 594 goat anti-rabbit IgG — 1:400. Excess secondary antibody was 
washed away by two rinses with PBS. Slides were then incubated with DAPI to stain 
nuclei. Upon completing a final PBS wash slides were mounted with glass cover slips, 
ready for imaging on an Olympus fluorescent microscope fitted with DAPI (350nm) 
FITC (488nm) and TRITC (594nm) filters and a DP70 camera adapter system. 
 
3.3.7 Image Analysis  
Cell^F imaging software was used to assess islet area, beta cell area, alpha cell area 
(expressed as µm2. Islets were quantified at small (<10,000 µm2), medium (10,000-
25,000 µm2) or large (>25,000 µm2) to assess islet size distribution. Islet architecture 
was deemed irregular by the abnormal presence of centrally located alpha cells. 
GLUT2 expression was assessed by fluorescence intensity. Beta cell Pdx1 expression 
was assessed using Image J software and expressed as a percentage of the number 
of insulin positive cells co-expressing Pdx1. >60 islets were analysed per treatment 
group. Additionally Image J was used to assess insulin and glucagon expression from 
stained cell lines. 6 frames were analysed per treatment group, with each frame 
consisting of ~150 cells.  
 
3.3.8 Statistics 
All graphs and Figures were produced using GraphPad PRISM v.5 software with data 
presented as mean ± SEM. For comparisons between two groups the Student’s t-test 
was implemented. For comparisons between more than two groups, one-way 
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ANOVA tests utilising Bonferroni post-hoc tests were carried out. For animal data 
where multiple groups were compared with each other over various time points two-
way RM ANOVA tests were conducted using Bonferroni post-hoc tests. A p-value 
<0.05 was deemed a significant result.   
 
3.4 Results  
3.4.1 Viability of INS-1 cells exposed to beta cell stressors  
After 24 hours in culture with beta cell stressors INS-1 cells exposed to lipotoxic (58.0 
± 1.5 vs 92.2 ± 4.1%, p<0.001, Figure 3.1A) and both low (54.4 ± 8.3%, p<0.001) and 
high cytokine (44.3 ± 1.2%, p<0.001) conditions displayed a significant reduction in 
cell viability. Cell viability remained reduced even after 48 hours culture in lipotoxic 
(66.8 ± 09 vs 96.9 ± 1.2%, p<0.001, Figure 3.1B) or low cytokine (53.5 ± 0.9%, p<0.001) 
conditions. Culture in a higher dose of cytokines exacerbated the reduction in cell 
viability after 48 hours (34.4 ± 0.5%, p<0.001). Hydrogen peroxide was used as a 
positive control to determine maximal cell death.  
 
3.4.2 Insulin and glucagon expression from INS-1 cells exposed to beta cell stressors 
Expression of insulin and glucagon from INS-1 cells was determined by 
immunocytochemistry. After 24 hours culture in high glucose media INS-1 cells 
displayed an increase in cells solely expressing insulin (68.8 ± 2.3 vs 61.3 ± 0.4%, 
p<0.05, Figure 3.2A) whilst lipotoxic culture showed an reduction (54.6 ± 2.4%, 
p<0.05). The number of INS-1 cells solely expressing glucagon was unchanged during 
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24 hours culture in these conditions (Figure 3.2B). Of interest INS-1 cells began to 
show dual expression of insulin and glucagon following 24 hours culture in lipotoxic 
(13.2 ± 0.5 vs 7.6 ± 0.6%, p<0.001, Figure 3.2C), high cytokine (12.6 ± 1.1%, p<0.01) 
and glucolipotoxic (12.6 ± 1.4%, p<0.05) conditions. Following 48 hours culture there 
was a notable reduction in INS-1 cells exclusively expressing insulin from lipotoxic 
(46.6 ± 3.9 vs 65.3 ± 2.9%, p<0.01, Figure 3.2D), high cytokine (57.2 ± 0.6%, p<0.01) 
and glucolipotoxic (52.2 ± 4.2%, p<0.05) conditions. The proportion of INS-1 cells 
solely expressing glucagon was markedly increased after 48 hours culture in high 
glucose 23.8 ± 1.1 vs 13.1 ± 1.0%, p<0.001, Figure 3.2E), lipotoxic (23.6 ± 2.0%, 
p<0.01), high cytokine (20.3 ± 1.7%, p<0.05) and glucolipotoxic (19.1 ± 0.5%, p<0.01) 
conditions. All tested conditions caused an increase in INS-1 cells dual expressing 
insulin and glucagon after 48 hours culture: high glucose (7.0 ± 0.5 vs 3.7 ± 0.4%, 
p<0.01, Figure 3.2F), lipotoxic (14.5 ± 1.4%, p<0.001), low cytokine (11.6 ± 0.7%, 
p<0.001), high cytokine (13.5 ± 0.7%, p<0.001) and glucolipotoxic (8.3 ± 1.8%, 
p<0.05). 
 
3.4.3 INS-1 cells gene expression of beta, alpha and progenitor markers  
Gene expression was assessed from INS-1 cells cultured for 48 hours in high glucose, 
low cytokine and high cytokine conditions. Quality RNA from lipotoxic conditions 
could not be obtained. High glucose culture resulted in increased expression of 
insulin (1.7 ± 0.06 vs 1.0 ± 0.2AU, p<0.05, Figure 3.3A), urocortin-3 (2.1 ± 0.06 vs 10 
± 0.3AU, p<0.05, Figure 3.3D), Pdx-1, (3.2 ± 0.1 vs 1.0 ± 0.1 AU, p<0.001, Figure 3.3E), 
neurogenin-3 (1.9 ± 0.2 vs 1.0 ± 0.2 AU, p<0.05, Figure 3.3F), glucagon (2.6 ± 0.1 vs 
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1.0 ± 0.2 AU, p<0.01, Figure 3.3G), Arx (7.8 ± 0.08 vs 1.0 ± 0.2 AU, p<0.001, Figure 
3.3H) and PC1 (21.2 ± 0.08 vs 1.0 ± 0.2 AU, p<0.001) whilst reducing PC2 expression 
(0.6 ± 0.1 vs 1.0 ± 0.02 AU, p<0.05, Figure 3.3J). Low cytokine culture notably reduced 
Foxo1 (0.2 ± 0.1 AU, p<0.05) and PC2 (18.4 ± 0.4 AU, p<0.001) gene expression whilst 
upregulating expression of urocortin-3 (15.1 ± 1.2 AU, p<0.001), neurogenin-3 (7.0 ± 
1.0 AU, p<0.01), Arx (3.0 ± 0.3 vs 1.0 ± 0.2 AU, p<0.01) and PC1 (18.4 ± 0.4 vs 1.0 ± 
0.2 AU, p<0.001).  Culturing INS-1 with high cytokine supplemented media caused 
similar changes in gene expression with the addition of reducing insulin (0.2 ± 0.2 AU, 
p<0.05) and GLUT2 (0.03 ± 0.2 AU, p<0.05) gene expression.  
 
3.4.4 Viability of MIN6 cells exposed to beta cell stressors 
MIN6 cells incubated for 24 hours displayed reduced cell viability when cultured in 
high glucose (88.4 ± 2.5 vs 97.4 ± 1.7%, p0.01, Figure 3.4A) , lipotoxic (40.4 ± 0.9%, 
p<0.001), low and high cytokine (92.2 ± 1.1%, p<0.05 and 88.8 ± 1.5%, p<0.01 
respectively) and glucolipotoxic (45.3 ± 1.0%, p<0.001) conditions. A similar 
reduction in cell viability was found when incubation time was extended to 48 hours. 
In particular lipotoxic (15.8 ± 0.4 vs 97.6 ± 1.0%, p<0.001, Figure 3.4B) and 
glucolipotoxic (25.4 ± 0.8%, p<0.001) conditions showed worsening cell viability. 
 
3.4.5 Insulin and glucagon expression from MIN6 cells exposed to beta cell stressors 
Following 24 hours culture immunocytochemistry for insulin and glucagon displayed 
a reduction in MIN6 cells solely expressing insulin in lipotoxic (74.3 ± 0.6 vs 89.6 ± 
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1.6%, p<0.001, Figure 3.5A) and low cytokine conditions (78.8 ± 1.1%, p<0.001). 
Lipotoxic culture increased the number of MIN6 cells solely expressing glucagon (9.8 
± 0.6 vs 4.1 ± 0.7%, p<0.001, Figure 3.5B) and cells dual expressing insulin and 
glucagon (16.0 ± 0.7 vs 3.7 ± 0.4%, p<0.001, Figure 3.5C).  Similarly low cytokine (8.9 
± 0.7%, p<0.001) and glucolipotoxic (7.7 ± 0.8%, p<0.01) conditions increased the 
number of MIN6 cells co-expressing insulin and glucagon. After 48 hours culture 
further reductions in MIN6 insulin expression were found in lipotoxic (59.4 ± 4.1 vs 
81.2 ± 0.6%, p<0.01, Figure 3.5D) and cytokine conditions with the former still 
exhibiting an increase in cells co-expressing insulin and glucagon (16.6 ± 1.8 vs 3.9 ± 
0.2%, p<0.01, Figure 3.5F). 
 
3.4.6 MIN6 cells gene expression of beta and alpha cell markers 
Gene expression was assessed from MIN6 cells cultured for 48 hours in high glucose, 
low cytokine and high cytokine conditions. Lipotoxic conditions failed to produce 
quality RNA. In MIN6 cells high glucose culture resulted in a reduction in insulin (0.4 
± 0.03 vs 1.0 ± 0.1 AU, p<0.01, Figure 3.6A) and Pdx-1 (0.4 ± 0.08 vs 1.0 ± 0.08 AU, 
p<0.01, Figure 3.6B) expression whilst glucagon gene expression was elevated (2.1 ± 
0.2 vs 1.0 ± 0.2 AU, p<0.05, Figure 3.6C). Low cytokine treatment elicited an increase 
in insulin (1.6 ± 0.1 AU, p<0.05) gene expression despite Pdx-1 expression diminishing 
(0.4 ± 0.8 AU, p<0.01), whist glucagon expression increased (1.9 ± 0.07 AU, p<0.01). 
High cytokine treatment displayed similar changes in gene expression albeit without 




3.4.7 Viability of RINm5F cells exposed to beta cell stressors 
Rat derived RINm5F showed reduced viability when cultured with high glucose (71.6 
± 0.7 vs 98.8 ± 0.6%, p<0.001, Figure 3.7A), lipotoxic (24.3 ± 0.6%, p<0.001), high 
cytokine (80.7 ± 1.6%, p<0.001) and glucolipotoxic (28.3 ± 2.9%, p<0.001) conditions 
for 24 hours. Extending culture time to 48 hours exacerbated the reduction in 
viability observed in high glucose (37.2 ± 0.7 vs 96.4 ± 1.3%, p<0.001, Figure 3.7B), 
lipotoxic (13.1 ± 0.4%, p<0.001) and glucolipotoxic (8.9 ± 0.2%, p<0.001) conditions. 
 
3.4.8 Insulin and glucagon expression from RINm5F cells exposed to beta cell 
stressors 
Immunocytochemistry was used to assess protein expression of insulin and glucagon. 
After 24 hours culture all tested conditions exhibited a reduction in RINm5F cells 
solely expressing insulin: high glucose (83.0 ± 1.1 vs 91.6 ± 1.3%, p<0.001, Figure 
3.8A), lipotoxic (77.0 ± 0.5%, p<0.001), low cytokine (84.9 ± 1.4%, p<0.01), high 
cytokine (83.2 ± 2.1%, p<0.05) and glucolipotoxic (67.8 ± 2.3%, p<0.001). During this 
time cells starting to exclusively express glucagon appeared in high glucose (12.0 ± 
0.7 vs 7.0 ± 1.0%, p<0.01, Figure 3.8B), lipotoxic (13.6 ± 0.7%, p<0.01) and 
glucolipotoxic (16.6 ± 2.3%, p<0.05) conditions. The number of cells co-expressing 
insulin and glucagon was increased by all culture conditions after 24 hours: high 
glucose (5.0 ± 0.6 vs 1.4 ± 0.2, p<0.05, Figure 3.8C), lipotoxic (9.4 ± 0.6%, p<0.001), 
low cytokine (7.9 ± 0.7%, p<0.001), high cytokine (7.9 ± 1.1%, p<0.01) and 
glucolipotoxic (15.5 ± 2.4%, p<0.01). After 48 hours cells cultured in normal RPMI 
media started to reduce insulin (Figure 3.8D) and increase glucagon (Figure 3.8E) 
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expression and as a result many of the stressor conditions failed to significantly affect 
expression. Cells dual expressing insulin and glucagon continued to be raised after 48 
hour culture. Of note 48 hours with lipotoxic culture elicited the greatest reduction 
in insulin (51.5 ± 2.7 vs 81.3 ± 3.3%, p<0.001, Figure 3.8D) expression alongside the 
greatest increase in glucagon (18.7 ± 1.7 vs 11.9 ± 1.2%, p<0.05, Figure 3.8E) and dual 
expressing cells (31.7 ± 1.8 vs 5.2 ± 0.9%, p<<0.001, Figure 3.8F). 
 
3.4.9 Effects of streptozotocin or hydrocortisone on body weight, cumulative 
energy intake, cumulative fluid intake and blood glucose in C57Bl/6 mice 
C57Bl/6 mice showed a decline in body weight (Figure 3.9A) and percentage body 
weight change when treated with streptozotocin (-6.0 ± 0.4 vs 1.2 ± 0.8% p<0.001, 
Figure 3.9B) or hydrocortisone (-3.1 ± 1.4%, p<0.05). Cumulative energy intake was 
only reduced by streptozotocin (496.7 ± 10.3 vs 550.1 ± 14.1kJ, p<0.05, Figure 3.9C) 
whilst no effect on fluid intake (Figure 3.9D) was found. Non-fasting blood glucose 
was progressively elevated by streptozotocin (19.5 ± 1.8 vs 8.1 ± 0.6mM, p<0.001, 
Figure 3.9E-F) whereas hydrocortisone had no sustained effect on blood glucose 






3.4.10 Effects of streptozotocin or hydrocortisone on pancreatic islet area, beta cell 
area, alpha cell area, islet size distribution, percentage beta cells and percentage 
alpha cells and islet architecture 
Representative images of islets stained for insulin (red) and glucagon (green) are 
presented in Figure 3.10A. Streptotozocin resulted in a massive reduction in islet area 
(2748 ± 165.3 vs 10140 ± 1016µm2, p<0.001, Figure 3.10B) due to a loss of beta cell 
area (3112 ± 249.2 vs 7446 ± 542.9µm2, p<0.001, Figure 3.10C) despite alpha cell area 
increasing (2341 ± 246.2 vs 1547 ± 207.6µm2, p<0.05, Figure 3.10D). Hydrocortisone 
elicited an increase in islet area (16400 ± 1262µm2, p<0.001) due to an increase in 
beta cell area (10370 ± 1019µm2, p0.05). Islet size distribution was markedly altered 
by streptozotocin with complete ablation of large and medium sized islets (Figure 
3.10E) whilst hydrocortisone reduced the proportion of small sized islets (38.0 ± 1.3 
vs 65.3 ± 5.0%, p<0.001, Figure 3.10E) and increased medium sized islets (49.0 ± 1.0% 
vs 23.6 ± 5.7%, p<0.001, Figure 3.10E). Percentage beta cells was reduced (59.7 ± 1.6 
vs 85.7 ± 1.0%, p<0.001, Figure 3.10F) by streptozotocin with reciprocal increase in 
percentage alpha cells (38.3 ± 1.6 vs 13.6 ± 0.9%, p<0.001, Figure 3.10G). 
Hydrocortisone elicited the opposite change with increased percentage beta cells 
(89.9 ± 0.6%, p<0.001) and reduced percentage alpha cells (10.0 ± 0.6%, p<0.01). The 
number of islets with irregularly located central alpha cells was increased by 
streptozotocin (59.4 ± 2.6 vs 21.3 ± 3.5%, p<0.001, Figure 3.10H) and to a lesser 





3.4.11 Effects of streptozotocin or hydrocortisone on pancreatic beta cell markers 
Representative images of islets stained for insulin (red) alongside either Pdx-1 (green) 
or GLUT2 (green) are displayed in Figure 3.11A and B respectively. The percentage of 
beta cells expressing Pdx-1 was equally reduced by streptozotocin (59.6 ± 1.8 vs 72.0 
± 1.9%, p<0.001, Figure 3.11C) and hydrocortisone (60.7 ± 2.1%, p<0.001). GLUT2 
expression, determined by fluorescence intensity (MFI), was similarly reduced by 
streptozotocin (60.4 ± 4.1 vs 93.3 ± 3.4MFI, p<0.001, Figure 3.11D) and 
hydrocortisone (62.6 ± 5.0MFI, p<0.001). 
 
3.4.12 Effects of high fat feeding alone or in combination with exendin-4 on 
pancreatic islet area, beta cell area, alpha cell area, islet size distribution, 
percentage beta cells, percentage alpha cells and islet architecture 
Characteristic images of islets from exendin-4 treated high fat fed mice are presented 
in Figure 3.12A showing insulin (red) and glucagon (green). High fat feeding resulted 
in an increase in islet area (27130 ± 3552 vs 10240 ± 1027µm2, p<0.001, Figure 3.12B) 
with similar elevations in beta cell area (21450 ± 3081 vs 7401 ± 992.2µm2, p<0.01, 
Figure 3.12C) and alpha cell area (3239 ± 347.8 vs 1755 ± 241.4µm2, p<0.01, Figure 
3.12D). Exendin-4 treatment exacerbated these elevations in islet area (48320 ± 
7072µm2, p<0.05) and beta cell area (43120 ± 6625µm2, p<0.01) whilst having no 
discernible effect on alpha cell area. High fat feeding altered islet size distribution 
with increases in the number of large sized islets (41.7 ± 3.1% vs 27.5 ± 4.8%, p<0.05, 
Figure 3.12E) at the expense of medium sized islets (18.3 ± 1.7 vs 30.0 ± 4.1%, p<0.05, 
Figure 3.12E). Treatment with exendin-4 had no additional effect on islet size 
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distribution. Percentage beta cells was reduced (82.8 ± 1.1 vs 89.0 ± 0.9%, p<0.001, 
Figure 3.12F) by high fat feeding with a mutual increase in percentage alpha cells 
(17.5 ± 1.1 vs 12.9 ± 1.1%, p<0.01, Figure 3.12G). Exendin-4 therapy was able to 
reduce percentage alpha cells (12.6 ± 1.0% p<0.001) back to levels similar to lean 
mice. The number of islets showcasing central alpha cells was increased in high fat 
fed mice (78.8 ± 8.3 vs 32.1 ± 6.0%, p<0.01, Figure 3.12H) with exendin-4 treatment 
having no significant effect on this.   
 
3.4.13 Effects of GIP antagonist or liraglutide treatment on pancreatic islet area, 
beta cell area, alpha cell area, islet size distribution, percentage beta cells, 
percentage alpha cells and islet architecture in leptin receptor deficient (db/db) 
mice 
Representative images of db/db mice treated twice daily with GIP(6-30)Cex-K40[Pal] 
(2.5nmol/kg) or liraglutide (0.25nmol/kg) for 28 days are presented in Figure 3.13A 
showing insulin (red) and glucagon (green).  Compared to WT C57Bl/6 mice, leptin 
receptor deficient db/db mice exhibit larger islets (16920 ± 1245 vs 9776 ± 827.2µm2, 
p<0.001, Figure 3.13B), with increased beta cell area (13910 ± 1045 vs 8725 ± 
730.9µm2, p<0.001, Figure 3.13C) and alpha cell area (2984 ± 245.6 vs 1501 ± 
111.7µm2, p<0.001, Figure 3.13D). Islet size distribution is similarly altered with an 
increase in medium (35.8 ± 4.4 vs 20.0 ± 4.4%, p<0.05, Figure 3.13E) and large (21.8 
± 4.0 vs 8.3 ± 1.9%, p<0.05, Figure 3.13E) sized islets at the expense of smaller ones 
(43.1 ± 5.4 vs 70.6 ± 5.5%, p<0.01, Figure 3.13E). Islet architecture was found 
dysregulated with a significant number of islets found with central alpha cells (69.2 ± 
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4.3 vs 21.3 ± 3.5%, p<0.001, Figure 3.13H). Treatment with GIP antagonist had no 
additional change on islet morphology or size distribution in these mice. Liraglutide 
however impacted islet morphology reducing islet area (12620 ± 964.4µm2, p<0.05), 
beta cell area (10430 ± 802.9µm2, p<0.05) and alpha cell area (2207 ± 208.2µm2, 
p<0.05) but had no impact on islet size distribution.  
 
3.5 Discussion  
Beta cell lines offer great insight into the pathophysiology of diabetes and the 
identification of novel therapeutics. The present work utilises three widely used beta 
cell lines (INS-1, MIN6 and RINm5F) to try and identify beta cell plasticity. 
INS-1 cells offered the best opportunity to investigate beta cell transdifferentiation 
with these cells showing substantial responses to beta cell stressors. In particular 
lipotoxic and cytokine culture resulted in a consistent increase in cells co-expressing 
insulin and glucagon and cells purely expressing glucagon, suggestive of a beta-to-
alpha transdifferentiation. The latter cytokine cocktail in particular altered INS-1 
gene expression with reduction in mature beta cell proteins insulin, GLUT2 and 
FOXO1 linked with increases in progenitor marker Ngn3 and alpha cell marker Arx. 
Loss of FOXO1 has been shown to lead to beta cell dedifferentiation (Talchai et al, 
2012) with the increase in Arx indicative of beta-to-alpha cell transdifferentiation 
(Collombat et al, 2007). 
MIN6 cells proved more robust against cytokine-induced changes in viability however 
they showed similar increases in cells co-expressing insulin and glucagon. Preliminary 
gene expression studies revealed reductions in beta cell marker Pdx1 and increases 
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in glucagon. Loss of Pdx1 (Gao et al, 2014) and activation of Arx (Collombat et al, 
2007) expression has been shown to trigger beta-to-alpha cell transdifferentiation 
making it plausible that MIN6 exposed to cytokines undergo this process. RINm5F 
cells were highly susceptible to glucotoxic and lipotoxic stress but cells that tolerated 
these insults showed co-expression of insulin and glucagon. However given how toxic 
these conditions were on the cells gene expression analysis could not be reliably 
conducted.  
Most beta cell lines are not purely insulin producing with many of them producing 
additional islet hormones such as glucagon and somatostatin to some degree (Skelin 
et al, 2009). This is quite unlike primary beta cells that are defined by the hormone 
they secrete thus making the use of these cell lines a limitation when investigating 
beta cell transdifferentiation. With two of these cell lines being derived from a 
radiation induced NEDH rat insulinoma it is questionable whether they resemble true 
beta cells. As a result beta cell plasticity is best studied using in vivo models of 
diabetes.  
C57Bl/6 mice became characteristically hyperglycaemic following 5 doses of 
streptozotocin (Vasu et al, 2015). Islet area was markedly reduced due to loss of beta 
cell mass despite substantial increases in alpha cell mass. Islet morphology was 
altered with alpha cells now making up 40% of the islet following streptozotocin 
treatment. Mature beta cell proteins GLUT2 and Pdx1 were also reduced by 
streptozotocin supporting the notion that beta-to-alpha cell transdifferentiation 
could account for these changes (Talchai et al, 2012). This is of particular interest in 
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light of human data in type-2 diabetics showing similar expansions in alpha cell mass 
and loss of beta cell mass and insulin content (Yoon et al, 2003).  
Hydrocortisone had little impact on metabolic parameters of C57Bl/6 mice despite 
substantially increasing islet area and beta cell mass (Vasu et al, 2015). This strongly 
implies that these mice were insulin resistant given how much beta cell mass 
expanded in order to maintain normoglycaemia. These mice showed reductions in 
Pdx1 and GLUT2 a sign that these beta cells may be dedifferentiating (Talchai et al, 
2012). 
Pancreatic tissues from past high fat fed NIH Swiss mouse studies were examined by 
immunohistochemistry (Vasu et al, 2017). Metabolically these mice displayed severe 
obesity and hyperglycaemia, associated with hyperinsulinemia, hyperglucagonemia 
and impaired insulin sensitivity (Vasu et al, 2017). Histological analysis of high fat fed 
mice islets revealed increases in beta cell and alpha cells masses resulting in overall 
islet mass expansion. Alpha cell mass increased disproportionately to beta cell mass, 
which didn’t increase to the same extent. This could suggest that some beta cells may 
be transdifferentiating towards alpha cells, especially given the rise of cells co-
expressing insulin and glucagon. Diet induced diabetes has already been shown to 
cause beta cell dedifferentiation in non-human primates therefore may have the 
potential to lead towards alpha cell transdifferentiation (Fiori et al, 2013). Treatment 
with exendin-4 appeared to exacerbate islet hypertrophy however it limited this 
alpha cell mass expansion. This could implicate GLP-1 has an effect on maintaining 
beta cell maturity in addition to its known metabolic benefits of reduced calorie 
consumption, blood glucose and HbA1c (Vasu et al, 2017).  
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Histology samples were obtained from previous C57Bl/KsJ db/db mice study and 
examined for signs of beta cell transdifferentiation (Pathak et al, 2015). 
Metabolically, these mice displayed hyperglycaemia and hyperinsulinemia 
associated with impaired glucose tolerance. Leptin receptor deficient mice showed 
characteristic changes in islet morphology becoming hypertrophied with disordered 
distribution of beta and alpha cells (Kawasaki et al, 2005). Given that beta cell mass 
and alpha cell mass expand to similar extents it may be unlikely that a 
transdifferentiation is occurring in these mice. However this may be a reflection on 
the severity of diabetes in these mice.  Severely diabetic db/db mice have been 
shown to have reduced proportion of insulin expressing cells with increases in 
glucagon and somatostatin expressing cells. The inverse change was found in db/db 
mice with only mild diabetes including: islet hypertrophy with an increase in insulin 
expressing cells and reduction in glucagon and somatostatin expressing cells 
(Baetens et al, 1978).  Nonetheless, treatment of these mice with the GLP-1 receptor 
agonist liraglutide was sufficient to limit islet hypertrophy. GIP antagonism had no 
discernible impact on islet morphology despite similar studies showing prevention of 
islet hypertrophy in leptin deficient ob/ob mice (Gault et al, 2005). In terms of glucose 
homeostasis however, both GLP-1 activation and GIP antagonism reduced plasma 
insulin and glucose levels (Pathak et al, 2015). Although not presently examined, 
others have identified beta cell dedifferentiation in db/db mice shown through loss 
of beta cell markers (insulin, Foxo1, MafA and NeuroD1) and upregulation of 
progenitor marker, Aldh1a3 (Ishida et al, 2017). This dedifferentiation can be 
potentiated by treatment with angiotensin-2 quantified by further reductions in Pdx1 
and Foxo1 and elevations in Ngn3 (Chen et al, 2018). These authors speculate that 
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activation of the renin-angiotensin system (RAS) increases oxidative stress and 
contributes to beta cell dedifferentiation.  
The major limitation of these in vivo studies is that beta cells cannot be tracked in 
order to reliably conclude that beta-to-alpha cell transdifferentiation is occurring. 
Alternative causes of these changes in islet morphology could be apoptosis of beta 
cells or proliferation or reduced apoptosis of alpha cells. Lineage tracing studies 
whereby pancreatic beta cells are tagged with a protein marker enable them to be 
identified when they lose insulin expression and potentially start to express glucagon.  
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Viability of INS-1 cells exposed to beta cell stressors for (A) 24 and (B) 48 hours determined by MTT. INS-1 cells were cultured in the following 
conditions: low glucose  (11.1mM), lipid control (50µl 50% ethanol), high glucose (25mM), lipotoxic  (0.25mM palmitate), low cytotoxic (100U 
IFNy, IL-1B, 20U TNFa), high cytotoxic (300U IFNy,  IL-1B, 40U TNFa) and glucolipotoxic (25mM glucose, 0.25mM palmitate). Values are mean ± 
SEM, n=8/treatment. Comparisons are versus low glucose (*) or versus lipid control (Δ), significant when ***/ΔΔΔ p<0.001. 














































































Percentage of INS-1 cells expressing insulin, glucagon or dual expression of both proteins following (A-C) 24 hour and (D-F) 48 hour culture with 
beta cell stressors: low glucose  (11.1mM), high glucose (25mM), lipotoxic (0.25mM palmitate), low cytotoxic (IFNy, IL-1B, TNFa), high cytotoxic 
(IFNy, IL-1B, TNFa) and glucolipotoxic  (25mM glucose, 0.25mM palmitate) prior to immunocytochemical staining for insulin and glucagon. Values 
are mean ± SEM, n=6 frames/treatment, each frame comprising >100 cells. Comparisons are versus low glucose (*) significant when * p<0.05, ** 
p<0.01 and ***p<0.001.

















































































































































































































































INS-1 gene expression of (A) insulin, (B) GLUT2, (C) Foxo1 (D) Ucn3, (E) Pdx1, (F) Ngn3, 
(G) Glucagon, (H) Arx (I) PC1 and (J) PC2 following 48 hour culture with low glucose, 
high glucose, low cytokine and high cytokine conditions. Gene expression was 
normalised to Actin gene expression. Values shown are mean ± SEM (n=3). *p<0.05, 

















































































































































































































































































































































































Viability of MIN6 cells exposed to beta cell stressors for (A) 24 and (B) 48 hours determined by MTT. MIN6 cells were cultured in the following 
conditions: low glucose  (2mM), lipid control (50% ethanol), high glucose (22mM), lipotoxic  (0.25mM palmitate), low cytotoxic (100U IFNy, IL-1B, 
20U TNFa), high cytotoxic (300U IFNy,  IL-1B, 40U TNFa) and glucolipotoxic (25mM glucose, 0.25mM palmitate). Values are mean ± SEM, 
n=8/treatment. Comparisons are versus low glucose (*) or versus lipid control (Δ), significant when ***/ΔΔΔ p<0.001. 














































































Percentage of MIN6 cells expressing insulin, glucagon or dual expression of both proteins following (A-C) 24 hour and (D-F) 48 hour culture with 
beta cell stressors: low glucose  (2mM), high glucose (22mM), lipotoxic (0.25mM palmitate), low cytotoxic (IFNy, IL-1B, TNFa), high cytotoxic 
(IFNy, IL-1B, TNFa) and glucolipotoxic  (22mM glucose, 0.25mM palmitate) prior to immunocytochemical staining for insulin and glucagon. Values 
are mean ± SEM, n=6 frames/treatment, each frame comprising >100 cells. Comparisons are versus low glucose (*) significant when * p<0.05, ** 
p<0.01 and ***p<0.001. 











































































































































































































































MIN6 gene expression of (A) insulin, (B) GLUT2 and (C) Pdx-1 following 48 hour culture with low glucose, high glucose, low cytokine and high 
cytokine conditions. Gene expression was normalised to Actin gene expression. Values shown are mean ± SEM (n=3). *p<0.05, **p<0.01, 
























































































































Viability of RINm5F cells exposed to beta cell stressors for (A) 24 and (B) 48 hours determined by MTT. RINm5F cells were cultured in the following 
conditions: low glucose  (11.1mM), lipid control (50µl 50% ethanol), high glucose (25mM), lipotoxic  (0.25mM palmitate), low cytotoxic (100U 
IFNy, IL-1B, 20U TNFa), high cytotoxic (300U IFNy,  IL-1B, 40U TNFa) and glucolipotoxic (25mM glucose, 0.25mM palmitate). Values are mean ± 
SEM, n=8/treatment. Comparisons are versus low glucose (*) or versus lipid control (Δ), significant when ***/ΔΔΔ p<0.001. 


















































































Percentage of RINm5f expressing insulin, glucagon or co-expression of both following (A-C) 24 hour and (D-F) 48 hour culture with beta cell 
stressors: low glucose  (11.1mM), high glucose (25mM), lipotoxic (0.25mM palmitate), low cytotoxic (IFNy, IL-1B, TNFa), high cytotoxic (IFNy, IL-
1B, TNFa) and glucolipotoxic  (25mM glucose, 0.25mM palmitate) prior to immunocytochemical staining. Values are mean ± SEM, n=6 
frames/treatment, each frame comprising >100 cells. Comparisons are versus low glucose (*) significant when * p<0.05, ** p<0.01 and 
***p<0.001.








































































































































































































































Figure 3.9: Effect of streptozotocin or hydrocortisone on body weight, cumulative 









12 week old C57Bl/6 mice were treated with administered with streptozotocin 
(50mg/kg, ip, once daily, 5 days) or hydrocortisone (70mg/kg, ip, once daily, 10 days) 
n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative 
energy intake, (D) cumulative fluid intake, (E) blood glucose and (F) final blood 
glucose.  
Comparisons were made against saline treated mice (*). Values were significant 
when p<0.05 *, p<0.01 ** and p<0.001 ***.
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Figure 3.10: Effects of streptozotocin or hydrocortisone on pancreatic islet area, beta cell area, alpha cell area, islet size distribution, 
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(A) Representative images of islets from saline, streptozotocin and hydrocortisone treated mice showing insulin (red), glucagon (green) and DAPI 
(blue). (B) Islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  (G) percentage alpha cells and (H) 
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Beta Cell Markers  
Representative images of islets from saline, streptozotocin and hydrocortisone treated mice stained for (A) insulin (red) and Pdx1 (green) or (B) 
insulin (red) and GLUT2 (green). (C) Percentage insulin positive cells expressing Pdx1 and (D) GLUT2 fluorescence intensity.  Determined by 
histological analysis of insulin/Pdx1 and insulin/GLUT2 double immunofluorescence staining.  









































































Figure 3.12: Effects of high fat feeding alone or in combination with exendin-4 on pancreatic islet area, beta cell area, alpha cell area, islet 
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(A) Representative images of islets from lean saline, high fat fed and high fat fed + exendin-4 treated mice showing insulin (red), glucagon (green) 
and DAPI (blue). (B) Islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  (G) percentage alpha 










































































































































































































































Figure 3.13: Effects of GIP or liraglutide treatment on pancreatic islet area, beta cell area, alpha cell area, islet size distribution, percentage 
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(A) Representative images of islets from C57Bl/6 wild-type saline, Db/db C57Bl/6 saline, Db/db + GIP and Db/db + liraglutide treated mice 
showing insulin (red), glucagon (green) and DAPI (blue). (B) Islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) 
percentage beta cells, (G) percentage alpha cells and (H) islet architecture. Values are mean ± SEM. Comparisons are versus saline, significant 

























































































































































































































































Effect of GLP-1 mimetic (liraglutide) and DPPIV 
inhibitor (sitagliptin) on islet morphology and 




4.1 Summary  
The effects of GLP-1 mimetic, liraglutide, and DPPIV inhibitor, sitagliptin, on beta cell 
transdifferentiation were explored in streptozotocin, hydrocortisone and high fat fed 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice. All diabetic models exhibited disturbances in 
glucose homeostasis and islet stress with induced beta-to-alpha cell 
transdifferentiation with streptozotocin eliciting this to a greatest extent. Beta cell 
transdifferentiation was reduced by 12 days treatment with twice daily 25nmol/kg 
liraglutide or once daily 50mg/kg sitagliptin in streptozotocin induced diabetes. Both 
agents suppressed hyperglycaemia, restored circulating and pancreatic insulin levels 
whilst keeping plasma and pancreatic glucagon levels suppressed. Within the 
pancreas liraglutide was proficient in stimulating beta cell proliferation. In high fat 
fed mice these treatments were unable to affect beta cell transdifferentiation. 
However, both incretin therapies increased pancreatic insulin content, suppressed 
plasma glucagon and beta cell apoptosis. In hydrocortisone treated mice these agents 
were able to prevent transdifferentiation to alpha cells but were unable to maintain 
beta cell maturity, with the number of insulin deficient beta cells still raised. In these 
mice only liraglutide was able to restore pancreatic insulin and glucagon contents 
whist suppressing both beta cell apoptosis and alpha cell proliferation. These data 
suggests that Ins1cre/+;Rosa26-eYFP C57Bl/6 mice display beta cell 
transdifferentiation in multiple animal models of diabetes. Treatment with the GLP-
1 receptor agonist, liraglutide, and the DPPIV inhibitor, sitagliptin, was sufficient to 
limit beta cell transdifferentiation. This shows that incretin therapies are capable of 
preventing beta-to-alpha transdifferentiation offering a potential new mechanism of 




4.2 Introduction  
4.2.1 Liraglutide  
GLP-1 receptor agonists, such as liraglutide, are a widely used drug class for the 
treatment of type-2 diabetes. GLP-1 is endogenously produced and secreted from the 
intestinal enteroendocrine L cells in response to feeding. GLP-1 receptors are 
expressed throughout the body with their activation resulting in a wide variety of 
responses, many of which beneficial for the treatment of type-2 diabetes and obesity. 
Within the endocrine pancreas GLP-1 acts on beta cells to potentiate glucose-
dependant insulin secretion, increase insulin biosynthesis, promote beta cell 
proliferation and reduce beta cell apoptosis, whilst on alpha cells it acts to inhibit 
glucagon secretion. The latter process is thought to be mediated through indirect 
paracrine stimulation of somatostatin secretion (Gromada et al, 1998; Nauck et al, 
1992). Within the gut GLP-1 acts to delay gastric emptying and through this and 
actions within the CNS inhibits feeding (Mest et al, 2005; Arthen and Schmidtz, 2004; 
Song et al, 2017; Nauck et al, 1997; Flint et al, 1998). Other central actions of GLP-1 
receptor activation include improved memory and cognition which may be useful for 
elucidating new treatments for cognitive disorders such as Alzheimer’s and dementia 
(Porter et al, 2013; Porter et al, 2010). Liraglutide in particular is GLP-1 mimetic 
stabilised due to the fatty acid incorporated into its structure prolonging its half-life 
against DPPIV degradation and delaying renal excretion.  
In streptozotocin induced diabetic mice and rats, liraglutide has been shown to 
reduce streptozotocin induced changes in blood glucose, plasma insulin and oxidative 




other GLP-1 based therapeutics have been shown to preserve beta cell mass in 
streptozotocin diabetes by reducing beta cell apoptosis and stimulating beta cell 
proliferation (Brubaker and Drucker, 2004; Vilsboll, 2009).  In high fat fed mice 
liraglutide has been shown to cause a number of metabolic changes that aid to 
alleviate their diabetic condition. These range from reducing body weight without 
affecting food intake, reducing blood glucose and plasma insulin whilst increasing 
pancreatic insulin content and reducing pancreatic glucagon content, ultimately 
improving insulin resistance (Wang et al, 2015; Millar et al, 2017; O’Harte et al, 2018). 
This was associated with reduction of beta cell mass in both high fat fed and standard 
chow fed mice, whilst not discernibly impacting alpha cell mass (Mondragon et al, 
2014; Millar et al, 2017). The effect of GLP-1 receptor agonists have yet to be 
published in hydrocortisone treated mice.  
 
4.2.2 Sitagliptin  
DPPIV is a serine threonine protease enzyme responsible for the cleavage and 
inactivation of many gut derived hormones. Its actions on GLP-1 and GIP cause 
cessation of the incretin effect. As a result pharmacological inhibitors of this enzyme, 
such as sitagliptin, increase the half-life of circulating GLP-1 and GIP to enhance 
glucose-stimulated insulin secretion and reduce postprandial elevations in glucagon 
to treat type-2 diabetes (Mest et al, 2005). Whether this is all attributable to elevated 
GLP-1 and GIP levels remains uncertain given that DPPIV inhibitors also prolong the 




Current literature states sitagliptin in streptozotocin induced diabetic mice protects 
against hyperglycaemia, improves glucose stimulated insulin secretion, and increases 
plasma insulin whilst lowering plasma glucagon (Ansarullah et al, 2013; Takeda et al, 
2012). Additionally, sitagliptin therapy has been shown to alleviate the reduction in 
insulin content whilst suppressing the elevation of glucagon content found in 
streptozotocin treated mice (Takeda et al, 2012). On an islet level, sitagliptin therapy 
increased beta cell mass and limited streptozotocin induced increase in alpha cell 
mass. DPP4 inhibition was also demonstrated to increase beta cell proliferation 
(Ansaraullah et al, 2013), reduce alpha cell proliferation and reduce apoptosis of beta 
and alpha cells in streptozotocin treated mice (Cho et al, 2011; Takeda et al, 2012). 
Quite elegantly these authors have shown that sitagliptin’s actions are more 
profound when the drug is administered in conjunction with streptozotocin 
compared with started treatment post streptozotocin insult. In high fat fed mice 
sitagliptin treatment has been shown to reduce body weight, non-fasting blood 
glucose, whilst elevating plasma insulin and GLP-1 levels (Cox et al, 2017; Gault et al, 
2015). Similar to GLP-1 mimetics, sitagliptin has also been shown to improve 
cognitive function in high fat fed mice (Gault et al, 2015).  Interesting Cox et al, (2017) 
have noted that depending on the duration of treatment sitagliptin has varied effects 
on beta cell proliferation, with short term (2 weeks) treatment increasing beta cell 
proliferation whilst long term (10 weeks treatment) reduced proliferation of beta 
cells. Similar to liraglutide, no data has yet been published on sitagliptin therapy in 




 The present studies utilised transgenic Ins1cre/+;Rosa26-eYFP C57Bl/6 mice that 
constitutively express a fluorescent marker (eYFP) within their beta cells allowing for 
lineage tracing studies (Thorens et al, 2015). This permitted investigation of beta cell 
dedifferentiation and transdifferentiation within animal models of diabetes. Three 
models of diabetes were explored each of which recreate a particular hallmark of 
diabetes. These were: multiple low-dose streptotozocin (insulin deficiency), high fat 
fed (insulin resistance with declining beta cell function) and multiple dose 
hydrocortisone (insulin resistance). Following identification of beta cell 
transdifferentiation in these models the actions of liraglutide and sitagliptin have on 
beta cell maturity or transdifferentiation were explored.  
 
4.3 Materials and Methods  
Materials and methods have been briefly summarised below. Full explanations of 
each method can be found within chapter 2. 
 
4.3.1 Animals 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice were bred in house at the Biomedical and 
Behavioural Research Unit (BBRU) at Ulster University, Coleraine. The original 
background of these mice have been characterised by Thorens et al, 2015. Mice were 
kept individually housed in a temperature controlled room (22±2°C) on a regular 12 
hour light/dark cycle. Mice had access to standard chow (Trou Nutrition, Norwich, 




University Animal Ethics Review Committee and conducted in accordance to the UK 
Animals (Scientific Procedures) Act 1986. 
Diabetes was induced in 12 week old male mice through administration of different 
chemicals as specified. For streptozotocin studies, mice were given 5 days 
consecutive intraperitoneal injections of 50mg/kg streptozotocin, freshly dissolved in 
citrate buffer, with diabetic symptoms presenting within the following 5 days. For 
hydrocortisone studies, mice were given 10 days consecutive intraperitoneal 
injections of 70mg/kg hydrocortisone, dissolved in saline (0.9% NaCl). In both of these 
models twice daily intraperitoneal administration of 25nmol/kg liraglutide and once 
daily oral administration of 50mg/kg sitagliptin was started two days prior to 
administration of streptozotocin/hydrocortisone and this dosing was continued until 
the end of the study at day 10. 
For high-fat feeding studies mice were kept on a high fat diet (45% fat) from weaning 
(4 weeks old) with experiments conducted at 15 weeks old when the now obese mice 
were similarly dosed with twice daily 25nmol/kg liraglutide or once daily 50mg/kg 
sitagliptin for 12 days. For all conducted studies mice were 8 per treatment group 
with body weight, blood glucose, calorie and fluid consumption monitored regularly. 
Dosing regimen was selected based on previously established literature (Moffet et al, 
2014; Gault et al, 2015). Prior to the end of the study, a glucose tolerance test was 
conducted whereby overnight fasted mice were subjected to an 18.8mMol/kg 
glucose load with blood glucose assessed regularly for the following hour. Timelines 




of body weight, non-fasting blood glucose, calorie and fluid consumption were 
assessed regularly.  
 
4.3.2 Biochemical Analysis  
Snap frozen pancreatic tissues, taken at the end of each study, were homogenised in 
acid ethanol (ethanol (75% (v/v) ethanol, 5% (v/v) distilled water and 1.5% (v/v) 12N 
HCl) and protein extracted in a pH neutral TRIS buffer. Protein content was 
determined using Bradford reagent (Sigma-Aldrich, Dorset, UK). Plasma and 
pancreatic insulin content was determined by an in-house insulin radioimmunoassay. 
Plasma and pancreatic glucagon content were determined by ELISA (glucagon 




Upon termination of studies, pancreatic tissue was extracted and fixed in 4% PFA for 
48 hours at 4°C. Tissues were processed and embedded in paraffin wax blocks using 
an automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany) 
and 5µm sections were cut on a microtome (Shandon finesse 325, Thermo scientific, 
UK). For immunohistochemistry, slides were dewaxed by immersion in xylene and 
rehydrated through a series of ethanol solutions (100-50%). Heat mediated antigen 
retrieval was then carried out at 95°C in citrate buffer (pH6) for 20 minutes. Sections 




following primary antibodies as appropriate:  mouse monoclonal anti-insulin 
antibody (ab6995, 1:1000; Abcam), guinea-pig anti-glucagon antibody (PCA2/4, 
1:200; raised in-house), rabbit anti-Ki67 antibody (ab15580, 1:200; Abcam) and rabbit 
anti-Pdx1 antibody (ab47267, 1:200; Abcam). Following this, slides were incubated 
for 45 minutes at 37°C with secondary antibodies: Alexa Fluor488 goat anti-guinea 
pig IgG — 1:400, Alexa Fluor 594 goat anti-mouse IgG — 1:400, Alexa Fluor 488 goat 
anti-rabbit IgG — 1:400, Alexa Fluor 594 goat anti-rabbit IgG — 1:400 or Alexa Fluor 
488 donkey anti-goat IgG — 1:400. Sections were then incubated a final time with 
DAPI for 15 minutes at 37°C. Slides were then mounted and ready for imaging using 
a fluorescent microscope (Olympus system microscope, model BX51) fitted with DAPI 
(350nm) FITC (488nm) and TRITC (594nm) filters and a DP70 camera adapter system. 
To assess apoptosis a TUNEL assay was carried out following manufacturer’s 
guidelines (In situ cell death kit, Fluorescein, Roche Diagnostics, UK). 
 
4.3.4 Image Analysis  
Cell^F imaging software (Olympus Soft Imaging Solutions, GmbH) was used to analyse 
the following islet parameters: islet area, beta cell area, alpha cell area (expressed at 
µm2), percentage beta cells and percentage alpha cells. Islets were deemed small 
(<10,000 µm2), medium (10,000-25,000 µm2) or large (>25,000 µm2) to determine 
islet size distribution. The number of islets per mm2 pancreas and proportion of islets 
with central alpha cells were judged in a blinded fashion. For transdifferentiation 
analysis beta cells expressing GFP with no insulin were termed “insulin-ve, GFP+ve 




glucagon were termed “glucagon+ve, GFP+ve cells”, an indication of beta-to-alpha cell 
transdifferentiated cells. To quantify apoptosis beta and alpha cells co-expressing 
TUNEL alongside insulin and glucagon respectively were counted. Similarly for 
proliferation Ki-67 and insulin/glucagon positive cells were totalled. Beta cell Pdx1 
expression was quantified using ImageJ software, counting the total number of 
insulin positive beta cells within an islet and expressing the number of those 
expressing Pdx1 as a percentage of that total. All cell counts were determined in a 
blinded manner with >60 islets analysed per treatment group.  
 
4.3.5 Statistics  
All results were generated and analysed using GraphPad PRISM (version 5), with data 
presented as mean ± SEM. Comparative analyses between groups were carried out 
using Student’s unpaired t-test, one-way ANOVA with a Bonferroni post-hoc test or a 
two-way repeated measures ANOVA with a Bonferroni post-hoc test where 
appropriate. Results were deemed significant once p<0.05.  
 
4.4 Results  
4.4.1 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on body weight, energy intake and fluid intake  
All mice displayed a decline in body weight which was not significant between groups 




streptozotocin showed a significant decline in percentage body weight change (-7.6 
± 0.3 vs -0.7 ± 0.8%; p<0.001, Figure 4.1B) with mice treated with sitagliptin showing 
a further reduction (-9.0 ± 0.6%; p<0.05, Figure 4.1B) relative to the diabetic animals. 
Streptozotocin treated mice displayed reduced cumulative calorie consumption from 
day 4 of the study onwards compared to saline-treated animals. Diabetic mice 
treated with liraglutide or sitagliptin showed a further reduction (p<0.05 and p<0.05, 
Figure 4.1C) in calorie consumption which was significantly lower than mice given 
solely streptozotocin from days 8 and 6 onwards respectively. Cumulative fluid intake 
was only raised (p<0.01) in streptozotocin treated animals after day 9 of the study. A 
stark contrast to mice that also received liraglutide and sitagliptin that showed raised 
fluid consumption (p<0.001 and p<0.001) from days 2 and 4 respectively (Figure 
4.1D).  
 
4.4.2 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon content  
Following 5 daily doses mice treated with streptozotocin alone showed an increase 
(p<0.001) in non-fasting glucose concentrations from day 7 onwards peaking to 26.3 
± 1.4 vs 7.7mM by day 10 (Figure 4.2A). Treatment with liraglutide and sitagliptin 
resulted in a delayed, subdued increase in non-fasted glucose levels peaking only to 
14.8 ± 1.8mM and 21.0 ± 0.5mM respectively; significantly lower (p<0.001) than the 
non-treated diabetic animals yet still higher (p<0.001) than normoglycaemic saline 




0.4 vs 9.2 ± 1.1ng/ml; p<0.001 and 29.1 ± 1.9 vs 42.6 ± 2.1ng/mg protein; p<0.001, 
Figure 4.2C-D) within streptozotocin treated diabetic animals respectively. Mice 
receiving liraglutide or sitagliptin were able to preserve circulating (10.5 ± 1.5ng/ml; 
p<0.001 and 8.4 ± 0.8ng/ml; p<0.01 respectively, Figure 4.2C) and pancreatic (43.3 ± 
3.1ng/mg protein; p<0.001 and 39.3 ± 4.3ng/mg protein; P<0.05, Figure 4.2D) insulin 
levels compared to the diabetic animals, to levels equivalent to the non-diabetic 
mice. Circulating glucagon levels were substantially higher in streptozotocin treated 
mice (0.08 ± 0.009 vs 0.02 ± 0.001ng/ml; p<0.001, Figure 4.2E). Plasma glucagon from 
liraglutide and sitagliptin treated mice were still raised compared to the non-diabetic 
animals however liraglutide treatment showed a reduction compared to the diabetic 
animals (0.04 ± 0.003ng/ml, p<0.01, Figure 4.2E). Likewise pancreatic glucagon 
content was raised in streptozotocin treated animals (18.7 ± 1.2 vs 7.8 ± 1.2ng/mg 
protein, p<0.01, Figure 4.2F) whist both the GLP-1 mimetic and DPPIV inhibitor 
capable of reducing these levels (8.5 ± 0.6ng/mg protein, p<0.001 and 11.8 ± 
0.9ng/mg protein, p<0.01, respectively, Figure 4.2F). Liraglutide in particular was able 
to restore pancreatic glucagon content to levels comparable to non-diabetic mice.  
 
4.4.3 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on islet parameters  
Representative images of islets from saline, streptozotocin, liraglutide plus 
streptozotocin an sitagliptin plus streptozotocin treated mice display insulin (red), 
glucagon (green) and nuclei (blue) (Figure 4.3A). Streptozotocin treated mice 




beta cell area (3309 ± 287.5 vs 7546 ± 814.0µm2; p<0.01, Figure 4.3C) and increased 
alpha cell area (2635 ± 271.8 vs 1589 ± 156.2µm2; p<0.001, Figure 4.3D). Treatment 
with liraglutide or sitagliptin showed similar, albeit subdued, changes in islet 
morphology. Islet area in liraglutide and sitagliptin treated groups was improved 
comparative to streptozotocin treated mice (7279 ± 625.8; p<0.001 and 6934 ± 
815.3µm2; p<0.05 respectively) due to conservation of beta cell area and elevations 
in alpha cell area (Figure 4.3B-D). Streptozotocin treated mice showed an ablation of 
large islets with medium sized islets predominating (31.7 ± 1.7 vs 19.3 ± 1.5%; p<0.01, 
Figure 4.3E). Percentage beta cells was significantly reduced (58.9 ± 1.8 vs 79.4 ± 
0.9%; p<0.001, Figure 4.3F) in all groups that received streptozotocin with the 
sitagliptin treated mice showing a further reduction (51.8 ± 1.7%; p<0.01, Figure 4.3F) 
comparative to the streptozotocin only animals. Reciprocal changes were also 
observed in percentage alpha cells which increased (43.1 ± 2.1 vs 20.4 ± 0.9%; 
p<0.001, Figure 4.3G) in all streptozotocin treated groups (49.1 ± 1.8%; p<0.01, Figure 
4.3G). Streptozotocin treatment severely disrupted islet architecture, quantified by 
the percentage of islets showing centrally located alpha cells (70.0 ± 4.4 vs 20.0 ± 
4.0%, p<0.001, Figure 4.3H). Liraglutide and sitagliptin therapies were able to 
substantially protect normal murine islet architecture, with the former able to do this 
to a much greater extent (liraglutide 33.0 ± 4.0%, p<0.001 and sitagliptin 56.0 ± 2.7%, 






4.4.4 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on beta-to-alpha cell transdifferentiation  
Beta-to-alpha cell transdifferentiation was determined by populations of insulin 
negative, GFP positive cells and glucagon positive, GFP positive cells with 
representative images shown in Figure 4.4A and Figure 4.4B respectively.  
Streptozotocin treated mice display a greater number of islets showing insulin 
negative, GFP positive cells (5.6 ± 0.7 vs 0.4 ± 0.1%, p<0.001, Figure 4.4C) and 
glucagon positive, GFP positive cells (5.7 ± 0.6 vs 1.4 ± 0.3%, p<0.001, Figure 4.4D). 
Mice given liraglutide in conjunction with streptozotocin had a reduced number of 
insulin negative, GFP positive cells (5.6 ± 0.7%; p<0.001, Figure 4.4C) and glucagon 
positive, GFP positive cells (3.6 ± 0.7%, p<0.05, Figure 4.4D) in comparison to the 
streptozotocin only treated animals. Similarly mice treated with sitagliptin exhibited 
islets with reduced insulin negative, GFP positive cells (3.3 ± 0.4%, p<0.01, Figure 
4.4C) and glucagon positive, GFP positive (3.6 ± 0.6%, p<0.05, Figure 4.4D) compared 
to the streptozotocin treated mice. 
 
4.4.5 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on beta cell and alpha cell apoptosis 
Beta cell and alpha cell apoptosis was assessed by populations of islets expressing 
TUNEL positive cells and insulin positive (Figure 4.5A) or glucagon positive cells 
(Figure 4.5B) respectively. Non-diabetic animals displayed low levels of beta cell 




p<0.001). Liraglutide (6.7 ± 1.1%, p<0.05) and sitagliptin (6.4 ± 0.9%, p<0.001, Figure 
4.5C) limited this death of beta cells. Similarly the number of alpha cells undergoing 
apoptosis was also increased by streptozotocin (4.6 ± 0.9 vs 1.7 ± 0.3%, p<0.001, 
Figure 4.5D). Treatment with sitagliptin had no effect on this raised apoptotic level 
however liraglutide treatment was able to elicit a reduction in alpha cell apoptosis 
(2.5 ± 0.6%, p<0.05, Figure 4.5D).  
 
4.4.6 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on beta cell and alpha cell proliferation  
Immunohistochemistry of insulin and ki-67 was used to assess beta cell proliferation 
(Figure 4.6A). Streptozotocin alone and in combination with sitagliptin had no impact 
on beta cell proliferation. Treatment with the GLP-1 receptor agonist, liraglutide, 
however produced a substantial elevation in beta cell proliferation (9.0 ± 1.2 vs 3.9 ± 
0.8%, p<0.001, Figure 4.6C). Alpha cell proliferation was evaluated by quantifying 
glucagon positive, ki-67 positive cells (Figure 4.6B). Non-diabetic animals exhibited 
low levels of glucagon proliferation (3.3 ± 0.6%) in contrast with the increase found 
in diabetic streptozotocin treated mice (8.2 ± 1.1%, p<0.001, Figure 4.6D). Mice 
treated with liraglutide showed no profound change in alpha cell proliferation, whilst 







4.4.7 Effects of streptozotocin alone or in combination with liraglutide or sitagliptin 
treatment on beta cell Pdx1 expression  
Expression of the mature beta cell marker Pdx1 was quantified by the number of Pdx1 
positive, insulin positive cells as represented in Figure 4.7A. Non-diabetic mice 
showed substantial expression of Pdx1 within beta cells (65.7 ± 1.3%) differing greatly 
from streptozotocin treated mice that depleted beta cell Pdx1 expression (53.3 ± 
1.0%, p<0.0001). Treatment with either liraglutide or sitagliptin was sufficient to 
restore Pdx1 expression (62.2 ± 1.1%, p<0.0001 and 60.2 ± 1.7%, p<0.0001 
respectively, Figure 4.7B). 
 
4.4.8 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on body weight, energy intake and fluid intake 
All mice kept on a high fat diet showed a significant increase in body weight (39.8 ± 
1.3 vs 25.7 ± 0.2g, p<0.001, Figure 4.8A) compared to lean mice at all time points. 
Between the first and last time points high fat fed mice treated with liraglutide had 
lost significant percentage of body weight (-13.3 ± 0.7%vs 0.7 ± 1.3%, p<0.001 Figure 
4.8B). High fat fed mice treated with sitagliptin maintained their percentage body 
weight comparative to the lean fed mice. As expected cumulative energy intake was 
increased in high fat fed mice throughout the study (887.2 ± 78.0 vs 538.8 ± 13.3kJ, 
p<0.001, Figure 4.8C). Mice treated with liraglutide exhibited less energy intake than 
high fat fed mice however this did not meet significance (Figure 4.8C). Similarly 




vs 92.4 ± 4.2ml, p<0.001, Figure 4.8D). However unlike energy intake, fluid 
consumption was significantly reduced in high fat fed mice given liraglutide and 
sitagliptin (154.5 ± 2.0ml, p<0.001 and 154.7 ± 12.4ml, <0.001 respectively, Figure 
4.8D).  
  
4.4.9 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on blood glucose, plasma insulin/glucagon, pancreatic 
insulin/glucagon and glucose tolerance test  
Over the study period mice between all treatment groups exhibited no substantial 
change in non-fasting blood glucose levels (Figure 4.9A).  However final blood glucose 
reading was notably reduced in liraglutide and sitagliptin treated mice compared to 
high fat fed alone (7.5 ± 0.2mM, P<0.01 and 7.6 ± 0.2mM, p<0.01 respectively vs 8.7 
± 0.3mM, Figure 4.9B). Plasma insulin was increased in all mice kept on high fat diet 
(13.7 ± 2.6 vs 6.9 ± 0.3ng/ml, p<0.05, Figure 4.9C) with no discernible difference 
between liraglutide and sitagliptin groups. Despite this increase, pancreatic insulin 
content was raised in liraglutide and sitagliptin treated groups (54.6 ± 3.0ng/mg 
protein, p<0.001 and 51.5 ± 2.6ng/mg protein, p<0.001 vs high fat fed alone 35.1 ± 
1.7ng/mg protein, Figure 4.9D). Similar to plasma insulin, circulating glucagon levels 
were only raised in high fat fed saline treated mice (0.05 ± 0.003 vs 0.02 ± 0.002ng/ml, 
p<0.001, Figure 4.9E). This was reduced in mice treated with liraglutide (0.03 ± 
0.002ng/ml, p<0.01) and sitagliptin (0.02 ± 0.003ng/ml, p<0.01) with the latter being 
equivalent to the lean mice. Contrasting findings were found with only high fat fed 




1.2ng/mg protein, P<0.05, Figure 4.9F). An intraperitoneal glucose tolerance test was 
conducted at the end of the study. All high fat fed mice displayed raised blood glucose 
levels at 30 minute and 60 minute time points. Only sitagliptin treated mice were able 
to significantly lower blood glucose at 60 minutes compared to the high fat fed saline 
mice (20.8 ± 0.6 vs 23.8 ± 1.2mM, p<0.05, Figure 4.9G). Despite this, when analysed 
by area under the curve only liraglutide treatment was able to reduce AUC compared 
to the high fat saline animals (1110 ± 42.0 vs 1266 ± 38.2, p<0.05, Figure 4.9H).  
 
4.4.10 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on islet parameters 
Representative images of islets from lean saline, high fat fed saline, high fat fed plus 
liraglutide and high fat fed plus sitagliptin treated mice displaying insulin (red), 
glucagon (green) and nuclei (blue) (Figure 4.10A). High fat fed mice pancreatic tissue 
contained much larger islets showing increases in islet area (19360 ± 1567 vs 7617 ± 
721.1µm2, P<0.001, Figure 4.10B), beta cell area (16590 ± 1347 vs 5926 ± 567.8µm2, 
p<0.001, Figure 4.10C) and alpha cell area (2778 ± 258.0 vs 1690 ± 185.2µm2, 
p<0.001, Figure 4.10D). Most prominently sitagliptin was able to elicit significant 
reductions in islet area (13400 ± 1274µm2, p<0.05, Figure 4.10B), beta cell area 
(11230 ± 1108µm2, p<0.01, Figure 4.10C) and alpha cell area (1950 ± 177.5, p<0.05, 
Figure 4.10D). Liraglutide however was only able to notably reduce beta cell area 
(11600 ± 1332µm2, p<0.05, Figure 4.10C).  Islet size distribution was markedly altered 
with all high fat fed groups displaying reductions in small islets (33.8 ± 2.1 vs 70.5 ± 




large sized islets (40.1 ± 2.5 vs 19.1 ± 1.2%, p<0.001 and 27.9 ± 2.7 vs 10.8 ± 1.4%, 
p<0.01 respectively, Figure 4.10E). Of note sitagliptin therapy was able to restore 
normal size distribution by increasing the proportion of smaller islets (51.2 ± 3.0%, 
p<0.001, Figure 4.10E) whilst reducing larger islets (11.3 ± 1.5%, p<0.001, Figure 
4.10E) to proportions comparable to lean mice. Twice daily liraglutide therapy was 
only able to raise the proportion of smaller islets (48.6 ± 1.6% p<0.001, Figure 4.10E) 
found within the pancreas compared to high fat fed mice. In line with these changes 
percentage beta cells was also increased in high fat fed mice (85.3 ± 0.6 vs 80.5 ± 08%, 
p<0.001. Figure 4.10F). Both treated groups produced a significant reduction in 
percentage beta cells (liraglutide 80.9 ± 1.0%, p<0.001 and sitagliptin 83.3 ± 0.8%, 
p<0.05, Figure 4.10F) however only liraglutide was able to reduce this to levels 
comparable to lean mice. Conversely percentage alpha cells was significantly reduced 
in high fat fed mice (14.7 ± 0.6 vs 19.9 ± 0.8%, p<0.001, Figure 4.10G) with liraglutide 
only able to return this to levels equivalent to lean mice (19.6 ± 1.1%, Figure 4.10G). 
Islet architecture became severely dysregulated with high fat feeding resulting in 
islets containing centrally located alpha cells (41.3 ± 3.9 vs 20.0 ± 4.0%, p<0.01, Figure 
4.10H). Liraglutide and sitagliptin treatments were able to preserve normal islet 
architecture however only the former was statistically significant (24.2 ± 2.3%, 







4.4.11 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on beta-to-alpha cell transdifferentiation 
Representative images of beta cell transdifferentiation, assessed by 
immunohistochemical staining of insulin with GFP and glucagon with GFP are 
presented in Figure 4.11 A and B respectively. There was a moderate increase in the 
percentage of islets displaying insulin negative, GFP positive cells in high fat fed mice 
(6.9 ± 0.7 vs 0.4 ± -0.1%, p<0.001, Figure 4.11C) which was reduced by both liraglutide 
(3.2 ± 0.4%, p<0.001, Figure 4.11C)  sitagliptin treatments (4.2 ± 0.6%, p<0.01, Figure 
4.11C). Likewise, glucagon positive, GFP positive cells increased in high fat fed mice 
(6.7 ± 0.6 vs 1.4 ± 0.3%, p<0.001, Figure 4.11D) although in this case only liraglutide 
elicited a reduction in this parameter (3.7 ± 0.4%, p<0.001, Figure 4.11D).  
 
4.4.12 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on beta and alpha cell apoptosis  
Representative histology images of beta cell apoptosis and alpha cell apoptosis are 
displayed in Figure 4.12A and B respectively. High fat feeding resulted in an increase 
in both beta cell (4.9 ± 0.7 vs 2.7 ± 0.6%, p<0.05, Figure 4.12C) and alpha cell apoptosis 
(4.8 ± 1.1 vs 1.7 ± 0.3%, p<0.01, Figure 4.12D). Both liraglutide and sitagliptin were 
able to elicit reductions in beta cell apoptosis (liraglutide 2.9 ± 0.6%, p<0.05 and 





4.4.13 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on beta and alpha cell proliferation 
Representative images displaying the effect of high fat feeding with liraglutide and 
sitagliptin on beta cell proliferation and alpha cell proliferation are displayed in Figure 
4.13A and 4.13B respectively. High fat feeding caused a significant increase in the 
number of beta cells and alpha cells undergoing proliferation (beta cells 5.9 ± 1.1 vs 
2.2 ± 0.5%, p<0.01, Figure 4.13C and alpha cells 5.7 ± 0.9 vs 3.3 ± 0.6%, p<0.01, Figure 
4.13D). Liraglutide had no further impact on beta cell or alpha proliferation, both with 
levels equivalent to the high fat fed saline group. Sitagliptin however was able to 
bring about a reduction in alpha cell proliferation (2.6 ± 0.6%, p<0.05, Figure 4.13D).  
 
4.4.14 Effects of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on beta cell Pdx1 expression 
Typical images of islets stained for insulin and Pdx1 from high fat fed mice treated 
with liraglutide or sitagliptin are presented in Figure 4.14A. High fat feeding caused a 
notable reduction in insulin positive cells expressing Pdx1 (49.6 ± 1.3 vs 65.7 ± 1.3%, 
p<0.001, Figure 4.14B). Although not able to restore Pdx1 expression to levels similar 
to lean mice, high fat fed mice treated with liraglutide showed a higher number of 
insulin positive cells expressing Pdx1 (54.2 ± 1.4%, p<0.05, Figure 4.14B), whilst 





4.4.15 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on body weight, energy intake and fluid intake  
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice were giving daily doses of hydrocortisone alone 
or with liraglutide or sitagliptin over the course of 10 days. Body weight was not 
significantly altered however percentage body weight change was notably reduced 
by treatment with hydrocortisone (-6.5 ± 1.0 vs -0.4 ± 0.8%, p<0.001, Figure 4.15B), 
with liraglutide and sitagliptin treated groups showing similar reductions. Cumulative 
energy intake was only raised in the hydrocortisone treated mice during the final two 
days of the study (day 10, 512.3 ± 16.0 vs 473.2 ± 17.8kJ, p<0.05, Figure 4.15C). Mice 
given liraglutide or sitagliptin showed an initial reduction in energy consumption at 
day 4, whilst consistent reductions became apparent from day 7 until the end of the 
study (day 10 liraglutide 431.3 ± 12.0kJ, p<0.001 and day 10 sitagliptin 436.3 ± 10.0, 
p<0.001, Figure 3.15C).  Fluid intake was notable raised in hydrocortisone alone, 
liraglutide and sitagliptin treated mice from days 7, 3 and 6 respectively. Both 
hydrocortisone alone and with liraglutide increased fluid consumption to similar 
levels, in great contrast to mice given sitagliptin that showed a dramatic increase in 
fluid consumption (day 10 sitagliptin 149.8 ± 12.5 vs day 10 hydrocortisone alone 






4.4.16 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon  
Mice dosed solely with hydrocortisone were able to maintain non-fasting plasma 
glucose levels equivalent to saline treated mice, however mice treated with 
liraglutide or sitagliptin showed a reduction in blood glucose levels within 3 days of 
starting treatment until the end of the study (day 10 liraglutide 5.6 ± 0.5, p<0.001 and 
day 10 sitagliptin 6.6 ± 0.3mM, Figure 4.16A/B). Plasma insulin was raised by 
hydrocortisone treatment (9.9 ± 1.1 vs 6.4 ± 0.3ng/ml, p<0.01, Figure 4.16C) and rose 
further with sitagliptin treatment (15.0 ± 0.6ng/ml, p<0.05, Figure 4.16C). Similarly 
pancreatic insulin content increased in hydrocortisone treated mice (77.6 ± 7.7 vs 
42.6 ± 2.1ng/mg protein, P<0.01, Figure 4.16D) with sitagliptin treated mice 
displaying equivalent increases. Liraglutide treatment however produced a reduction 
in pancreatic insulin content (50.7 ± 2.5ng/mg protein, p<0.01, Figure 4.16D). 
Circulating glucagon levels were elevated in hydrocortisone mice (0.03 ± 0.002 vs 0.02 
± 0.001ng/ml, p<0.05, Figure 4.16E). Liraglutide and sitagliptin therapies were able to 
lower plasma glucagon levels however only the latter treatment was significant (0.02 
± 0.001ng/ml, p<0.05, Figure 4.16E). Liraglutide treatment was able to elicit a 
reduction in pancreatic glucagon content relative to the hydrocortisone alone treated 






4.4.17 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on islet parameters 
Typical images of islets from mice treated with hydrocortisone alone or with 
liraglutide or sitagliptin are presented in Figure 4.17A. Islet area was increased by 
treatment with hydrocortisone (10790 ± 907.4 vs 7617 ± 721.1µm2, p<0.01, Figure 
4.17B) with notable increases in beta cell area accounting for this expansion (9499 ± 
805.2 vs 5926 ± 567.8µm2, p<0.001, Figure 4.17C). Hydrocortisone treated mice given 
liraglutide exhibited similar morphological changes. Sitagliptin treated mice however 
were found to have an expansion in alpha cell area (1838 ± 154.1 vs 1430 ± 141.2µm2, 
p<0.05, Figure 4.17D) in addition to increased beta cell area. Islet size distribution 
was largely unchanged by hydrocortisone or these treatments with the only 
remarkable change being an increase in medium sized islets (31.5 ± 4.5 vs 17.1 ± 2.6%, 
p<0.05, Figure 4.17E) found in sitagliptin treated mice comparative to those just 
dosed with hydrocortisone. Percentage beta cells, a guide to whether islets have 
increased in size proportionally, was raised by hydrocortisone treatment (89.2 ± 0.4 
vs 79.4 ± 0.9%, p<0.001, Figure 4.17F). Liraglutide and sitagliptin however was able 
to reduce percentage beta cells (liraglutide 86.0 ± 1.7%, p<0.01 and sitagliptin 84.2 ± 
0.8%, p<0.001, Figure 4.17F) compared to hydrocortisone alone treated mice. 
Percentage alpha cells (Figure 4.17G) and islet architecture (Figure 4.17H) was 






4.4.18 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on beta-to-alpha cell transdifferentiation  
Beta to alpha cell transdifferentiation was determined by immunohistochemistry 
staining for insulin with GFP and glucagon with GFP, with representative images 
displayed in Figure 4.18A and 4.18B respectively. Islets expressing insulin scarce, GFP 
positive cells were raised by hydrocortisone treatment (5.8 ± 0.8 vs 0.4 ± 0.1%, 
p<0.001, Figure 4.18C) with liraglutide and sitagliptin treated mice showing similar 
increases. In parallel with this, glucagon rich, GFP positive cells were also raised by 
hydrocortisone (6.1 ± 0.9 vs 1.4 ± 0.3%, p<0.001, Figure 4.18D). Liraglutide reduced 
the number of glucagon positive, GFP positive cells (4.0 ± 0.4%, p<0.05, Figure 4.18D).  
 
4.4.19 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on beta and alpha cell apoptosis  
Immunohistochemistry for TUNEL in combination with insulin or glucagon was 
conducted to determine beta and alpha cell apoptosis respectively, with 
representative images presented in Figure 4.19A and 4.19B respectively. 
Hydrocortisone treatment produced an increase in both beta cell (8.9 ± 1.0 vs 2.7 ± 
0.6%, p<0.001, Figure 4.19C) and alpha cell (11.5 ± 1.4 vs 1.7 ± 0.4%, p<0.001, Figure 
4.19D) apoptosis. Liraglutide was able to prevent this beta cell (1.1 ± 0.4%, p<0.001, 
Figure 4.19C) and alpha cell (4.1 ± 0.7%, p<0.001, Figure 4.1D) death. Sitagliptin 
however was only able to elicit reductions in beta cell apoptosis (5.4 ± 1.1%, p<0.05, 




4.4.20 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on beta and alpha cell proliferation  
Immunohistochemical staining for Ki-67 in conjunction with insulin or glucagon was 
carried out to quantify beta cell (Figure 4.20A) and alpha cell (Figure 4.20B) 
proliferation respectively. Beta cell proliferation was substantially elevated by 
hydrocortisone treatment (13.2 ± 1.6 vs 2.2 ± 0.5%, p<0.001, Figure 4.20C). Alpha cell 
proliferation was largely unremarkable between treatment groups with 
hydrocortisone.  
 
4.4.21 Effects of hydrocortisone alone or in combination with liraglutide or 
sitagliptin treatment on beta cell Pdx1 expression 
Representative images of islets stained for insulin (red) and Pdx1 (green) are 
displayed in Figure 4.21A and used to assess Pdx1 expression, an indication of beta 
cell maturity. Hydrocortisone treatment resulted in a reduction in the percentage of 
insulin positive cells also expression Pdx1 (57.3 ± 1.0 vs 65.7 ± 1.3%, p<0.001, Figure 
4.21B). Likewise, therapy with sitagliptin showed a similar reduction in beta cells 
expressing Pdx1. Liraglutide however was able to significantly preserve Pdx1 
expression within beta cells (63.6 ± 1.1%, p<0.001, Figure 4.21B) to levels equivalent 






4.5 Discussion  
These studies have utilised genetically modified Ins1cre/+;Rosa26-eYFP mice to identify 
beta cell transdifferentiation within three well defined animal models of diabetes. 
Multiple-low dose streptozotocin instilled significant beta cell plasticity and beta-to-
alpha cell transdifferentiation. Up to 6% of beta cells from these mice were no longer 
producing insulin, with 6% of now co-expressing glucagon. Corresponding increases 
in both beta cell apoptosis and alpha cell proliferation were also observed in 
streptozotocin treated mice. Collectively, these three mechanisms account for the 
reduction in beta cell mass and elevation in alpha cell mass seen in streptozotocin-
induced diabetes.  
High fat fed diabetic mice showed significant beta-to-alpha cell transdifferentiation. 
In this insulin resistant diabetes model, beta cell mass is expanded by hyperplasia and 
increased beta cell proliferation. Persistent insulin resistance induced beta cell stress 
still induces notable beta cell apoptosis and contributed to beta cell dedifferentiation 
and transdifferentiation.  This beta-to-alpha transdifferentiation combined with 
increased alpha cell proliferation outweighed alpha cell apoptosis to bring about an 
increase in alpha cell mass.   
Similarly hydrocortisone induced insulin resistant mice exhibited beta-to-alpha cell 
transdifferentiation. Beta cell proliferation occurred to overcome this steroid induced 
insulin resistance however the increased functional demand on beta cells led to their 
apoptosis. Loss of beta cell identity and subsequent beta-to-alpha cell 





Previously beta cell transdifferentiation has been demonstrated in genetic animal 
models by insertion or knocking out specific alpha and beta cell transcription factors 
respectively (Collombat et al, 2009; Hu et al, 2011; Talchai et al, 2012). The present 
studies however confirm that a similar level of beta cell plasticity can be induced by 
pharmacological treatment of streptozotocin or hydrocortisone and by high fat 
feeding. This opens further speculation whether this transdifferentiation process is 
common to diabetes pathogenesis regardless of the stressor used to induce disease 
and whether this is preserved up the phylogenetic tree within humans. Observations 
in type-2 diabetic patients have noticed low levels of beta cell apoptosis (Butler et al, 
2007). Given that hyperglucagonemia is present in these patients, it is plausible that 
beta-to-alpha cell transdifferentiation could be occurring. It also raises the question 
if current anti-diabetic agents can limit this transdifferentiation and if this alleviates 
diabetic symptoms and pathologies in these animals. 
 
GLP-1 receptor agonists, liraglutide, and DPPIV inhibitors, sitagliptin, are two widely 
used drug classes prescribed for the treatment of type-2 diabetes. In streptozotocin 
treated mice both of these agents were able to limit the number of islets displaying 
transdifferentiated beta cells and maintain beta cell maturity by upholding Pdx1 
expression (Gao et al, 2014). Collectively this shows that in streptozotocin-induced 
diabetes, liraglutide and sitagliptin maintain beta cell maturity which helped to limit 
beta-to-alpha cell transdifferentiation. This suggests that in this model increasing GIP 




and further supports that increasing circulating GLP-1 levels is sufficient to protect 
against transdifferentiation. 
In high fat fed mice only liraglutide was capable of reducing the number of beta cell 
transdifferentiating towards alpha cells. Interestingly liraglutide also maintained 
Pdx1 expression further implying that maintaining beta cell maturity is key to 
preventing transdifferentiation (Gao et al, 2014). Sitagliptin treatment here 
maintained the number of beta cells expressing insulin, without reducing beta cell 
glucagon expression, suggesting there is a degree of double hormone expression 
whilst beta cells transdifferentiate. In hydrocortisone treated mice, an insulin 
resistance model of diabetes, liraglutide notably reduced the number islets showing 
glucagon expressing beta cells. Given that islets showing insulin null beta cells were 
raised within this group, this suggests that liraglutide was able to prevent beta-to-
alpha cell transdifferentiation however beta cell maturity was lost despite retaining 
Pdx1 expression. Similarly sitagliptin treatment in these mice only appeared to 
exacerbate beta-to-alpha transdifferentiation. 
In addition to this change these models display other well characterised traits of 
diabetes. As is widely documented administration of streptozotocin leads to 
development of a diabetic phenotype displaying hyperglycaemia, polydipsia and 
immune infiltration within islets. When conducted in genetically modified 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice the result is no different with mice consistently 
displaying diabetic changes. In terms of metabolic parameters blood glucose is 
significantly elevated showing impaired glycaemic control (Vasu et al, 2015). This is 




in circulating plasma and pancreatic glucagon content. High fat fed Ins1cre/+;Rosa26-
eYFP mice display insulin resistance, confirmed by glucose tolerance test, 
hyperinsulinemia and hyperglucagonemia and reduced pancreatic glucagon. This fits 
in line with other studies utilising this model and in type-2 diabetics showcasing 
hyperinsulinemia and hyperglucagonemia as insulin resistance develops. 
Hydrocortisone treated Ins1cre/+;Rosa26-eYFP mice displayed evidence of insulin 
resistance shown by hyperinsulinemia and hyperglucagonemia, in line with similar 
studies conducted in WT C57Bl/6 mice (Vasu et al, 2015; Khan et al, 2016).  
Within these transgenic mice liraglutide and sitagliptin improved metabolism as 
expected in line with the current literature. Liraglutide treatment in particular was 
able to exert consistent reductions in percentage body weight change in all three 
diabetic mice models. This is consistent with clinical and preclinical data. In humans 
this has been shown to be effective in healthy individuals (Bays et al, 2017; Manigault 
and Thurston, 2016), type-2 diabetic patients and obese individuals (Santilli et al, 
2017). Similarly GLP-1 and analogues such as liraglutide has been shown to act 
centrally to reduce appetite and calorie consumption (Flint et al, 1998). Although the 
central actions of liraglutide have not been directly examined in these present studies 
it can be confirmed here that liraglutide consistently reduced calorie consumption in 
both lean and high-fat fed mice. In this streptozotocin model liraglutide and 
sitagliptin were able to restore plasma and pancreatic insulin content but could not 
however do this with glucagon to levels comparable with non-diabetic mice. As a 
result of this, non-fasting blood glucose was lowered by treatment with liraglutide 




diabetic mice. In diet-induced diabetes, incretin therapies improved insulin resistance 
by increased pancreatic insulin content, reduced circulating glucagon levels and 
improved glucose tolerance. In hydrocortisone mice incretin based therapies 
produced elevations in both circulating insulin and glucagon levels and pancreatic 
insulin content were present. In these mice, liraglutide was able to reduce pancreatic 
insulin content implying these mice required less insulin to meet metabolic demand, 
thus improving insulin resistance. 
 
In light of these results a number of questions can be raised. Firstly, what triggers this 
transdifferentiation in these models? Given that streptozotocin induced diabetes 
elicited more beta cells transdifferentiating than the other tested models it could be 
plausible that prolonged hyperglycaemia can trigger this transfer. This opens up new 
lines of thought in which are these anti-diabetic agents acting directly to prevent 
transdifferentiation or whether this occurs due to a secondary effect from 
suppressing hyperglycaemia. Further studies in streptozotocin mice using insulin or 
SGLT2 inhibitors to maintain normoglycaemia may shed light on this and are explored 
in later chapters. Additionally ex vivo studies utilising isolated islets from 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice can be conducted. By controlling the glucose 
environment the islets are in the direct or indirect effect of the anti-diabetic agents 
on transdifferentiation can be elucidated. Finally, why does a fixed dose of liraglutide 
and sitagliptin produce differing effects in these models of diabetes? Differences in 
hyperglycaemic vs insulin resistant beta cell stress within these models may shed light 




The presented studies highlight the beneficial actions of incretin therapies, liraglutide 
and sitagliptin, on improving diabetic symptoms in streptozotocin, diet-induced and 
hydrocortisone mouse models of diabetes. Taking this further, lineage tracing studies 
utilising Ins1cre/+;Rosa26-eYFP C57Bl/6 mice have shown these treatments to prevent 
















Figure 4.1: Effect of streptozotocin alone or in combination with liraglutide or sitagliptin on body weight, cumulative energy intake and 











12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with liraglutide or sitagliptin for two days prior to and in conjunction with 
administration of streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative 
energy intake and (D) cumulative fluid intake. Comparisons were made against saline (*) or against streptozotocin treated (Δ). Values were 
significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ. 
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Figure 4.2: Effect of streptozotocin alone or in combination with liraglutide or 
sitagliptin on blood glucose, plasma insulin, pancreatic insulin content, plasma 











12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with liraglutide or 
sitagliptin for two days prior to and in conjunction with administration of 
streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. Terminal blood was taken 
to assess plasma insulin and glucagon. (A) Blood glucose, (B) final blood glucose, (C) 
plasma insulin, (D) pancreatic insulin content, (E) plasma glucagon and (F) pancreatic 
glucagon content. Comparisons were made against saline (*) or against 
streptozotocin treated (Δ). Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ 
and p<0.001 ***/ΔΔΔ.  
Blood Glucose











































































































































































































































Figure 4.3: Effects of streptozotocin alone or in combination with liraglutide or sitagliptin on pancreatic islet area, beta cell area, alpha cell 











Insulin / Glucagon / DAPI 
 
 
* Legend overleaf 

















(A) Representative images of islets from saline, STZ, STZ plus liraglutide and STZ plus sitagliptin treated mice showing insulin (red), glucagon 
(green) and DAPI (blue). (B) Islet area (µm2), (C) beta cell area (µm2), (D) alpha cell area (µm2), (E) islet size distribution, (F) percentage beta cells 
(%), (G) percentage alpha cells (%) and (H) islet architecture. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, streptozotocin, 
streptozotocin plus liraglutide and streptozotocin plus sitagliptin stained for (A) 
insulin and GFP or (B) glucagon and GFP. Beta cell transdifferentiation determined by 
populations of insulin negative, GFP positive cells (C) and glucagon positive, GFP 
positive cells (D) using double immunofluorescence staining showing 
insulin/glucagon (red) and GFP (green). Values are mean ± SEM (n=8 mice/group). 
Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when 
*/Δp<0.05, **/ΔΔp<0.01 and ***/ΔΔΔp<0.001. 
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Representative images of islets from mice treated with saline, streptozotocin, 
streptozotocin plus liraglutide and streptozotocin plus sitagliptin stained for (A) 
insulin and TUNEL or (B) glucagon and TUNEL. Beta cell apoptosis and alpha cell 
apoptosis determined by populations of insulin positive, TUNEL positive (C) and 
glucagon positive, TUNEL positive (D) cells respectively by double 
immunofluorescence staining. Values are mean ± SEM (n=8 mice/group). 
Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when 
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Representative images of islets from mice treated with saline, streptozotocin, 
streptozotocin plus liraglutide and streptozotocin plus sitagliptin stained for (A) 
insulin and ki-67 or (B) glucagon and ki-67. Beta cell and alpha cell proliferation 
determined by populations of (C) insulin positive, ki-67 positive cell and (D) glucagon 
positive,  ki-67 positive cells respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin, streptozotocin plus liraglutide and streptozotocin plus sitagliptin 
on Pdx1 expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 
(green) and DAPI (blue).  
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 














































Figure 4.8: Effect of high fat feeding alone or in combination with liraglutide or sitagliptin on body weight, cumulative energy intake and 









15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months prior were treatment with liraglutide or sitagliptin by daily ip 
injections, n=6-8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative energy intake and (D) cumulative fluid intake. 
Comparisons were made against lean saline (*) or against high fat fed (Δ). Values mean ± SEM, significant when p<0.05 */Δ, p<0.01 **/ΔΔ and 
p<0.001 ***/ΔΔΔ. 
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Figure 4.9: Effect of high fat feeding alone or in combination with liraglutide or 
sitagliptin on blood glucose, plasma insulin, pancreatic insulin content, plasma 


















15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months 
prior to liraglutide or sitagliptin by daily ip injections, n=6-8 mice/group. (A) Blood 
glucose, (B) final blood glucose, (C) plasma insulin, (D) pancreatic insulin, (E) plasma 
glucagon, (F) pancreatic glucagon, (G) ip glucose tolerance test and (H) AUC. 
Comparisons were made against lean saline (*) or against high fat fed (Δ). Values 
mean ± SEM, significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ. 
Blood Glucose
































































































































































































































































































Figure 4.10: Effects of high fat feeding alone or in combination with liraglutide or sitagliptin on pancreatic islet area, beta cell area, alpha cell 
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Representative images of islets from (A) lean saline, HFF saline, HFF plus liraglutide and HFF plus sitagliptin mice showing insulin (red), glucagon 
(green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells, (G) percentage 
alpha cells and (H) islet architecture. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus high fat fed (Δ), 
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Representative images of islets from lean saline, high fat fed saline, high fat fed plus 
liraglutide and high fat fed plus sitagliptin treated mice stained for (A) insulin and GFP 
or (B) glucagon and GFP. Beta cell transdifferentiation determined by populations of 
insulin negative, GFP positive cells (C) and glucagon positive,  GFP positive cells (D) 
using double immunofluorescence staining show insulin/glucagon (red), GFP (green). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus lean saline control (*) 
or versus high fat fed saline (Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and 
***/ΔΔΔp<0.001.
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Representative images of islets from lean saline, high fat fed saline, high fat fed plus 
liraglutide and high fat fed plus sitagliptin stained for (A) insulin and TUNEL or (B) 
glucagon and TUNEL. Beta cell apoptosis and alpha cell apoptosis were quantified by 
populations of insulin positive, TUNEL positive (C) and glucagon positive, TUNEL 
positive cells (D) respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets lean saline, high fat fed saline, high fat fed plus 
liraglutide and high fat fed plus sitagliptin stained for (A) insulin and ki-67 or (B) 
glucagon and ki-67. Beta cell and alpha cell proliferation determined by populations 
of (C) insulin positive, ki-67 positive cells or (D) glucagon positive,  ki-67 positive cells 
respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, high fat fed saline, high fat fed plus liraglutide and high fat fed plus sitagliptin 
on Pdx1 expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 
(green) and DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus high fat fed (Δ), significant when */Δp<0.05, 














































Figure 4.15: Effect of hydrocortisone alone or in combination with liraglutide or sitagliptin on body weight, cumulative energy intake and 









12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with liraglutide or sitagliptin for two days prior to and in conjunction with 
administration of hydrocortisone (70mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative 
energy intake and (D) cumulative fluid intake. Comparisons were made against saline (*) or against hydrocortisone treated (Δ). Values were 
significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ. 
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Figure 4.16: Effect of hydrocortisone alone or in combination with liraglutide or 
sitagliptin on blood glucose, plasma insulin, pancreatic insulin content, plasma 











12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with liraglutide or 
sitagliptin for two days prior to and in conjunction with administration of 
hydrocortisone (70mg/kg, ip, once daily), n=8 mice/group. Terminal blood was taken 
to assess plasma insulin and glucagon. (A) Blood glucose, (B) final blood glucose, (C) 
plasma insulin and (D) pancreatic insulin content. Comparisons were made against 
saline (*) or against hydrocortisone treated (Δ). Values were significant when p<0.05 
*/Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Blood Glucose










































































































































































































































Figure 4.17: Effects of hydrocortisone alone or in combination with liraglutide or sitagliptin on pancreatic islet area, beta cell area, alpha cell 


























(A) Representative images of islets from saline, hydrocortisone, hydrocortisone plus liraglutide and hydrocortisone plus sitagliptin treated mice 
showing insulin (red), glucagon (green) and DAPI (blue). (B) islet area (µm2), (C) beta cell area (µm2), (D) alpha cell area (µm2), (E) islet size 
distribution, (F) percentage beta cells,  (G) percentage alpha cells and (H) islet architecture. Values are mean ± SEM(n=8 mice/group). Comparisons 
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Representative images of islets from mice treated with saline, hydrocortisone, 
hydrocortisone plus liraglutide and hydrocortisone plus sitagliptin stained for (A) 
insulin and GFP or (B) glucagon and GFP. Beta cell transdifferentiation determined by 
populations of insulin negative, GFP positive cells (C) and glucagon positive,  GFP 
positive cells (D) using double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, hydrocortisone, 
hydrocortisone plus liraglutide and hydrocortisone plus sitagliptin stained for (A) 
insulin and TUNEL or (B) glucagon and TUNEL. Beta cell apoptosis and alpha cell 
apoptosis determined by populations of (C) insulin positive, TUNEL positive and (D) 
glucagon positive,  TUNEL positive cells respectively by double immunofluorescence 
staining. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline 
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Representative images of islets from mice treated with saline, hydrocortisone, 
hydrocortisone plus liraglutide and hydrocortisone plus sitagliptin stained for (A) 
insulin and ki-67 or (B) glucagon and ki-67. Beta cell and alpha cell proliferation 
determined by populations of (C) insulin positive, ki-67 positive cells and (D) glucagon 
positive,  ki-67 positive cells respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, hydrocortisone, hydrocortisone plus liraglutide and hydrocortisone plus 
sitagliptin on Pdx1 expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), 
Pdx1 (green) and DAPI (blue). Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), 















































Effects of SGLT2 inhibition and insulin on islet 






5.1 Summary  
In streptozotocin Ins1cre/+;Rosa26-eYFP C57Bl/6 treated mice, daily administration of 
1mg/kg dapagliflozin for 10 days did not suppress hyperglycaemia despite a mild 
increase in plasma insulin. Circulating and pancreatic glucagon levels were notably 
reduced. Within the islet, alpha cell mass expansion was noted with dapagliflozin. 
This was attributed to notable reduction in alpha cell apoptosis given dapagliflozin 
had no impact on beta cells transdifferentiation or alpha cell proliferation. A 5mg/kg 
daily dose of dapagliflozin, for the same period, had similar effects in streptozotocin 
treated mice albeit also eliciting a glucose lowering effect. In high fat fed mice 
dapagliflozin expanded both beta cell mass due to increased beta cell proliferation, 
mildly prevented beta-to-alpha cell transdifferentiation, associated with improved 
beta cell Pdx1 expression, and alpha cell mass due to inhibition of alpha cell 
apoptosis. Dapagliflozin worsened islet mass expansion observed in insulin resistant 
hydrocortisone treated mice. SGLT2 inhibition in this model had no effect on beta 
cell transdifferentiation however reduced apoptosis of both beta and alpha cells. 
Insulin countered streptozotocin induced hyperglycaemia, improving circulating and 
pancreatic insulin and glucagon levels. Histologically insulin also protected against 
streptozotocin-induced changes in islet morphology and it greatly reduced beta-to-
alpha cell transdifferentiation, restoring beta cell Pdx1 expression. These studies 
suggest that alpha cell expansion seen with SGLT2 inhibitors is not caused by beta-
to-alpha cell transdifferentiation but is largely an effect of reduced alpha cell 
apoptosis. Furthermore in streptozotocin diabetes restoring normoglycaemia is 
highly beneficial in preventing beta-to-alpha cell transdifferentiation, implying that 
hyperglycaemia may be an important trigger in this process.   
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5.2 Introduction  
 
5.2.1 Dapagliflozin  
Dapagliflozin belongs to the sodium glucose co-transporter 2 (SGLT2) inhibitor drug 
class. Inhibition of this transporter prevents reabsorption of glucose within the 
proximal renal tubules, where 90% of glucose reabsorption occurs, thus increasing 
excretion and ultimately lowering plasma glucose (Wright, 2001; Kanai et al, 1994; 
Rossetti et al, 1987). Patients with type-2 diabetes display increased expression of 
SGLT2 with exaggerated renal glucose reabsorption (Vestri et al, 2001; Freitas et al, 
2008). In a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes, dapagliflozin has 
been shown to produce a sustainable reduction in blood glucose and limit the decline 
in beta cell mass that occurs in these rats (Macdonald et al, 2010). These authors did 
not publish data regarding the effect on alpha cell mass however others have 
reported substantial gains in alpha cell mass with increases in alpha cell glucagon 
secretion and plasma glucagon levels following dapagliflozin treatment (Millar et al, 
2017; Millar et al, 2016; Bonner et al, 2015; Merovci et al, 2014; Zambrowicz et al, 
2013). Data also suggests that SGLT2 regulates islet function based on the finding of 
SGLT2 expression on islet alpha cells (Chen et al, 2012).  
How dapagliflozin causes this expansion in alpha cells has yet to be fully determined 
with beta-to-alpha cell transdifferentiation a potential mechanism. This Chapter aims 
to explore this aspect by investigating dapagliflozin effects in streptozotocin, high fat 
fed and hydrocortisone models of diabetes. In Ins1cre/+;Rosa26-eYFP C57Bl/6 mice 
were used to track beta cell transdifferentiation as noted in the previous Chapter. 
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5.2.2 Insulin  
Insulin is a 51 amino acid hormone secreted from beta cells. First synthesised as 
preproinsulin, of 110 amino acids, this protein undergoes cleavage to form proinsulin 
within the endoplasmic reticulum before being packaged within secretory granules 
by the golgi apparatus (Orci et al, 1986). Within these granules enzymatic cleavage 
liberates mature insulin protein from the linking C-peptide (Goodge et al, 2000). 
Glucose is a key stimulant promoting insulin secretion however interactions between 
amino acids, fatty acids, neurotransmitters and hormones are all involved in 
regulating insulin release (Rorsman et al, 2013; Ashcroft et al, 1994). Once secreted 
the hormone acts on the insulin receptor, expressed on skeletal muscle and adipose 
tissue, to increase GLUT4 mediated glucose uptake necessary for energy and 
triglyceride storage respectively. Additionally this anabolic hormone promotes 
protein synthesis whilst inhibiting protein degradation leading to weight gain 
(Watson and Pessin, 2001).  
Insulin replacement therapy is the primary treatment for type-1 diabetes and makes 
up late-stage treatment for type-2 diabetes when beta cell function has declined to 
the point where insulin resistance cannot be overcome by pharmacotherapies. In the 
present studies insulin will be utilised to examine the effect of glycaemia on beta-to-
alpha cell transdifferentiation. Administration of streptozotocin and the resulting 
hyperglycaemia alters islet morphology dramatically increasing levels of beta-to-
alpha cell transdifferentiation. To explore the contribution hyperglycaemia makes to 
transdifferentiation normogylcaemia will be maintained in streptozotocin treated 
mice via administration of insulin. This approach should also provide an insight as to 
whether other anti-diabetic agents are beneficial through their specific mechanisms 
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of action or whether they limit beta cell transdifferentiation is secondary to their 
glucose lowering ability.  
 
5.3 Methods  
Materials and methods have been briefly summarised below. Full explanations of 
each method can be found within chapter 2.  
 
5.3.1 Animals  
Diabetes was induced in 12 week old male Ins1cre/+;Rosa26-eYFP C57Bl/6 mice by 5 
daily dosing of streptozotocin (50mg/kg body weight). Within the following 5 days 
mice would present with diabetic symptoms. For hydrocortisone studies mice were 
dosed by intraperitoneal injections of 70mg/kg body weight hydrocortisone for 10 
consecutive days. In both studies mice were dosed by once daily oral administration 
of 1mg/kg dapagliflozin or 5mg/kg dapagliflozin (where specified), commencing two 
days prior to streptozotocin/hydrocortisone dosing and continued until the end of 
the study. For the insulin treatment group streptozotocin-treated mice were dosed 
with 1 unit of bovine insulin every 8 hours commencing when hyperglycaemia 
(>15mM) presented. Similarly for diet-induced diabetes studies, high-fat fed mice 
were dosed with 1mg/kg dapagliflozin by daily oral gavage for 10 days. At the end of 
this 10 days dosing high-fat fed mice were fasted for a glucose tolerance test using 
18.8mmol/kg body weight glucose. For all conducted studies mice were 8 per 
treatment group with body weight, calorie and fluid consumption recorded at regular 
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intervals. The dosing regimen was chosen based upon previous work (Millar et al 
2017; Millar et al, 2016; Green et al, 2016). At the end of each study, pancreatic tissue 
was excised and cut longitudinally with one half taken for immunohistochemistry and 
the other for hormone content. A timeline of conducted studies is presented in Figure 
5.0.  Data for saline, streptozotocin, high-fat fed and hydrocortisone controls are 
reused from Chapter 4.  
 
5.3.2 Biochemical Analysis  
For hormone content analyses protein was extracted from snap frozen pancreatic 
tissue following  homogenisation in acid ethanol (ethanol (75% (v/v) ethanol, 5% (v/v) 
distilled water and 1.5% (v/v) 12N HCl). Total protein content was determined by 
Bradford assay. An in-house radioimmunoassay was used to quantify plasma and 
pancreatic insulin, whilst glucagon levels were assessed by ELISA.  
 
5.3.3 Immunohistochemistry  
Longitudinally cut pancreatic tissue was fixed in 4% PFA for 48 hours at 4°C before 
dehydration and processing within an automated tissue processor. Processed 
pancreatic tissue was embedded in wax blocks and sectioned at 5µm thickness. For 
immunohistochemistry slides were first immersed in xylene to remove wax and then 
rehydrated through a series of ethanol washes (100-50%). Antigen retrieval was then 
performed using acidic citrate buffer (pH 6) at 95°C for 20 minutes, followed by 20 
minutes at room temperature to cool. Slides were then blocked in a 4% BSA solution 
before incubation with primary antibodies. Primary antibodies used were as follows: 
mouse monoclonal anti-insulin antibody (ab6995, 1:1000; Abcam), guinea-pig anti-
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glucagon antibody (PCA2/4, 1:200; raised in-house), rabbit anti-Ki67 antibody 
(ab15580, 1:200; Abcam) and rabbit anti-Pdx1 antibody (ab47267, 1:200; Abcam). 
After overnight incubation slides were washed in PBS before incubation with 
fluorescently-linked secondary antibodies used as appropriate: Alexa Fluor488 goat 
anti-guinea pig IgG — 1:400, Alexa Fluor 594 goat anti-mouse IgG — 1:400, Alexa 
Fluor 488 goat anti-rabbit IgG — 1:400, Alexa Fluor 594 goat anti-rabbit IgG — 1:400 
or Alexa Fluor 488 donkey anti-goat IgG — 1:400. After a further wash in PBS to 
remove excess antibody before 15 minute incubation with DAPI to stain nuclei. Slides 
were mounting with cover slips ready for imaging on a fluorescent microscope 
(Olympus system microscope, model BX51) fitted with DAPI (350nm) FITC (488nm) 
and TRITC (594nm) filters and a DP70 camera adapter system. To assess apoptosis a 
TUNEL assay was carried out following manufacturer’s guidelines (In situ cell death 
kit, Fluorescein, Roche Diagnostics, UK). 
 
5.3.4 Image Analysis  
Cell^F imaging software (Olympus Soft Imaging Solutions, GmbH) was used to 
analyse the following islet parameters: islet area, beta cell area, alpha cell area 
(expressed at µm2), percentage beta cells and percentage alpha cells. Islets were 
deemed small (<10,000 µm2), medium (10,000-25,000 µm2) or large (>25,000 µm2) 
to determine islet size distribution. The number of islets per mm2 pancreas and 
proportion of islets with central alpha cells were judged in a blinded fashion. For 
transdifferentiation analysis beta cells expressing GFP with no insulin were termed 
“insulin-ve, GFP+ve cells” whilst those expressing GFP with glucagon were termed 
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“glucagon+ve, GFP+ve cells.” To quantify apoptosis beta and alpha cells co-expressing 
TUNEL alongside insulin and glucagon respectively were counted. Similarly for 
proliferation Ki-67 and insulin/glucagon positive cells were totalled. Beta cell Pdx1 
expression was quantified using ImageJ software, counting the total number of 
insulin positive beta cells within an islet and expressing the number of those 
expressing Pdx1 as a percentage of that total. All cell counts were determined in a 
blinded manner with >60 islets analysed per treatment group.  
 
5.3.5 Statistics  
All results were generated and analysed using GraphPad PRISM (version 5), with data 
presented as mean ± SEM. Comparative analyses between groups were carried out 
using Student’s unpaired t-test, one-way ANOVA with a Bonferroni post-hoc test or 
a two-way repeated measures ANOVA with a Bonferroni post-hoc test where 
appropriate. Results were deemed significant once p<0.05.  
 
5.4 Results  
5.4.1 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on body weight, energy intake and fluid intake  
Mice treated with dapagliflozin presented with body weight loss from day 5 onwards 
(Figure 5.1A), peaking to 17.1 ± 2.8%, p<0.001 percentage weight loss (Figure 5.1B). 
Similarly, cumulative energy consumption was reduced in dapagliflozin treated mice 
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(338.7 ± 25.4 vs 445.5 ± 9.0kJ, p<0.01, Figure 5.1C), whereas cumulative fluid 
consumption was raised (109.7 ± 8.2 vs 94.8 ± 3.2ml, p<0.05, Figure 5.1D). 
 
5.4.2 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon content  
1mg/kg dapagliflozin treatment had no effect on non-fasting blood glucose 
compared to streptozotocin treatment alone (26.3 ± 1.9 vs 26.3 ± 1.4mM, Figure 
5.2A-B). Despite this, dapagliflozin was able to elicit increases in plasma insulin (7.2 
± 0.5 ± 5.2 ± 0.4ng/ml, p<0.05, Figure 5.2C) and reductions in plasma glucagon (0.03 
± 0.001 vs 0.08 ± 0.009ng/ml, p<0.001, Figure 5.2E) and pancreatic glucagon content 
(7.3 ± 0.4 vs 18.7 ± 1.2ng/mg protein, p<0.001, Figure 5.2F).  
 
5.4.3 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on islet parameters 
Representative images of islets stained for insulin (red) and glucagon (green) from 
mice treated with dapagliflozin (Figure 5.3A). Dapagliflozin treatment exacerbated 
streptozotocin-induced loss of beta cell area (1732 ± 238.4 vs 3309 ± 287.5µm2, 
p<0.001, Figure 5.3C), whilst alpha cell area remained raised (2897 ± 342.0µm2, 
Figure 5.3D). Streptozotocin-induced alterations to percentage beta cells (39.9 ± 2.1 
vs 58.9 ± 1.8%, p<0.001, Figure 5.3F) and percentage alpha cells (60.1 ± 2.1 vs 43.1 ± 
2.1%, p<0.001, Figure 5.3G) were worsened by dapagliflozin treatment. Alpha cell 
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distribution was marginally improved with dapagliflozin treatment (50.0 ± 3.0 vs 70.0 
± 4.4%, p<0.001, Figure 5.3H) but was still impaired compared to non-diabetic mice 
(20.0 ± 4.0%). 
 
5.4.4 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on beta-to-alpha cell transdifferentiation  
Representative images of islets stained for (Figure 5.4A) insulin (red) and GFP (green) 
or (Figure 5.4B) glucagon (red) and GFP (green) from mice treated with dapagliflozin. 
SGLT2 inhibition had no impact on streptozotocin-induced beta-to-alpha cell 
transdifferentiation determined by insulin negative, GFP positive cells (6.4 ± 1.0 vs 
5.6 ± 0.7%, NS, Figure 5.4C) and glucagon positive, GFP positive cells (4.6 ± 0.6 vs 5.7 
± 0.7%, NS, Figure 5.4D). 
 
5.4.5 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on beta and alpha cell apoptosis 
Islets stained for insulin (red) and TUNEL (green) or glucagon (red) and TUNEL (green) 
are displayed Figure 5.5A and B respectively. Dapagliflozin had no impact on 
streptozotocin induced beta cell apoptosis (6.5 ± 1.3 vs 10.9 ± 1.9%, NS, Figure 5.5C) 





5.4.6 Effects of streptozotocin alone or in combination with dapagliflozin treatment 
on beta and alpha cell proliferation 
Islets stained for insulin (green) and ki-67 (red) or glucagon (green) and ki-67 (red) 
are presented in Figure 5.6A and B respectively. Dapagliflozin increased beta cell 
proliferation (4.8 ± 1.5 vs 2.2 ± 0.5% saline, p<0.05, Figure 5.6C) and reduced alpha 
cell proliferation (3.7 ± 1.6 vs 8.2 ± 1.1%, p<0.05, Figure 5.6D). 
 
5.4.7 Effects of streptozotocin alone or in combination with low dose dapagliflozin 
treatment on beta cell Pdx-1 expression 
Representative images of islets stained for insulin (red) and Pdx-1 (green) are found 
in Figure 5.7A. 1mg/kg body weight dapagliflozin treatment had no effect on 
streptozotocin-induced reductions in beta cell Pdx-1 expression (50.6 ± 1.7 vs 53.3 ± 
1.0%, NS, Figure 5.7B).  
 
5.4.8 Effects of high fat feeding alone or in combination with low dose dapagliflozin 
treatment on body weight, percentage body weight change, energy and fluid intake 
Dapagliflozin treatment reduced percentage body weight (-13.8 ± 0.9 vs 0.7 ± 1.3%, 
p<0.001, Figure 5.8B) but had no notable effect on energy consumption (Figure 5.8C). 
Fluid consumption was markedly reduced from day 4 of the study onwards (145.0 ± 




5.4.9 Effects of high fat feeding alone or in combination with low dose dapagliflozin 
treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon content 
Although variable, dapagliflozin elicited a subtle reduction in non-fasting blood 
glucose (7.5 ± 0.4 vs 8.7 ± 0.3mM, p<0.05, Figure 5.9A-B). Dapagliflozin treatment 
was able to raise pancreatic insulin content (43.8 ± 3.4 vs 35.1 ± 1.7ng/mg protein, 
p<0.05, Figure 5.9D) whilst reducing plasma glucagon (0.03 ± 0.002 vs 0.05 ± 
0.003ng/ml, p<0.05, Figure 5.9E). During a glucose tolerance test, dapagliflozin 
significantly reduced blood glucose at 60 minutes (17.6 ± 1.1 vs 23.8 ± 1.2mM, 
p<0.001, Figure 5.9F) and elicited a reduction in AUC (1066 ± 31.6 vs 1266 ± 38.9, 
p<0.01, Figure 5.9G).  
 
5.4.10 Effects of high fat feeding alone or in combination with low dose 
dapagliflozin treatment on islet parameters 
Figure 5.10A displays representative images of islets stained for insulin (red) and 
glucagon (green) from mice treated with dapagliflozin. Of note, alpha cell area was 
markedly increased (3705 ± 392.4 vs 2778 ± 258.0µm2, p<0.05, Figure 5.10D) whilst 
percentage beta cells was reduced (79.7 ± 1.0 vs 85.3 ± 0.6%, p<0.001, Figure 5.10F) 





5.4.11 Effects of high fat feeding alone or in combination with low dose 
dapagliflozin treatment on beta-to-alpha cell transdifferentiation 
Representative images of islets stained for (Figure 5.11A) insulin (red) and GFP 
(green) or (Figure 5.11B) glucagon (red) and GFP (green) from high fat fed mice 
treated with dapagliflozin. Dapagliflozin treatment reduced the number insulin 
deficient, GFP positive cells (4.5 ± 0.6 vs 6.9% ± 0.8, p<0.05, Figure 5.11C) whilst 
having no impact on glucagon positive, GFP positive cells.  
 
5.4.12 Effects of high fat feeding alone or in combination with low dose 
dapagliflozin treatment on beta and alpha cell apoptosis 
Representative images of islets stained for insulin or glucagon (red) with TUNEL 
(green) are displayed in Figure 5.12A and B respectively. Dapagliflozin had no effect 
on beta cell apoptosis (Figure 5.12C) or alpha cell apoptosis (Figure 5.12D).  
 
5.4.13 Effects of high fat feeding alone or in combination with low dose 
dapagliflozin treatment on beta and alpha cell proliferation 
Islets stained for ki-67 (red) alongside insulin or glucagon (green) are displayed in 
Figure 5.13A and B respectively. In high fat fed mice dapagliflozin elevated beta cell 
proliferation (9.4 ± 1.0 vs 5.9 ± 1.1%, p<0.05, Figure 5.13C), whilst having no effect 




5.4.14 Effects of high fat feeding alone or in combination with low dose 
dapagliflozin treatment on beta cell Pdx-1 expression 
Representative images of islets from high fat fed dapagliflozin treated mice stained 
for insulin (red) and Pdx-1 (green) are displayed in Figure 5.14A. Treatment with 
SGLT2 inhibitor improved beta cell Pdx-1 expression (53.4 ± 1.0 vs 49.6 ± 1.3%, 
p<0.05, Figure 5.14B), albeit not to levels equivalent to lean mice (65.7 ± 1.3%).  
 
5.4.15 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on body weight, energy and fluid intake 
Mice treated with hydrocortisone reduced body weight with dapagliflozin treatment 
not impacting this change (-8.3 ± 0.6 vs -6.5 ± 1.0%, NS, Figure 5.15B). Of note, 
dapagliflozin treated mice displayed a reduction in cumulative energy consumption 
(440.4 ± 13.7 vs 509.0 ± 15.2kJ, p<0.001, Figure 5.15C) and cumulative fluid intake 
(90.8 ± 9.2 vs 110.4 ± 5.6ml, p<0.05, Figure 5.15D). 
 
 
5.4.16 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon content 
Although quite variable dapagliflozin had no profound impact on non-fasting blood 
glucose levels (Figure 5.16A-B). Similarly both plasma insulin and glucagon were 
found raised in these mice to similar levels to mice dosed solely with hydrocortisone. 
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Only pancreatic insulin content was reduced by dapagliflozin treatment (45.1 ± 6.0 
vs 77.6 ± 7.7ng/mg protein, p<0.01, Figure 5.16D).  
 
5.4.17 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on islet parameters 
Representative images of islets stained for insulin (red) and glucagon (green) are 
displayed in Figure 5.17A. In hydrocortisone treated mice, dapagliflozin markedly 
increased islet area (17840 ± 2016µm2 vs 10790 ± 907.4µm2, p<0.001, Figure 5.17B) 
beta cell area (16930 ± 2215 vs 9499 ± 805.2µm2, p<0.001, Figure 5.17C) and alpha 
cell area (2477 ± 327.7 vs 1430 ± 141.2, p<0.001, Figure 5.17D). Islet size distribution 
was markedly altered by dapagliflozin treatment with reductions in small sized islets 
(39.0 ± 9.2 vs 75.5 ± 3.6%, p<0.05, Figure 5.17E) in line with an increase in medium 
sized islets (39.2 ± 5.2 vs 17.1 ± 2.6%, p<0.01, Figure 5.17E). 
  
5.4.18 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on beta-to-alpha cell transdifferentiation 
GFP staining was carried out to determine transdifferentiation coupled with insulin 
or glucagon as shown in Figure 5.18A and B respectively. In hydrocortisone treated 
mice dapagliflozin failed to elicit any discernible changes in insulin negative, GFP 




5.4.19 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on beta and alpha cell apoptosis 
TUNEL immunohistochemistry was used alongside insulin or glucagon to determine 
beta and alpha cell apoptosis shown in Figures 5.19A and B respectively. Dapagliflozin 
treatment protected both beta cells (2.6 ± 0.5 vs 8.9 ± 1.0%, p<0.001, Figure 5.19C) 
and alpha cells (4.8 ± 0.7 vs 11.6 ± 1.5%, p<0.001, Figure 5.19D) against 
hydrocortisone-induced apoptosis. 
  
5.4.20 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on beta and alpha cell proliferation 
Representative images of ki-67 staining carried out in conjunction with insulin or 
glucagon are presented in Figures 5.20A and B respectively. Beta cell proliferation 
was markedly reduced by dapagliflozin (6.7 ± 1.1 vs 13.2 ± 1.6%, p<0.001, Figure 
5.20C) whilst alpha cell proliferation was only slightly lowered when compared to 
saline animals (1.9 ± 0.4 vs 3.4 ± 0.6%, p<0.05, Figure 5.20D). 
 
5.4.21 Effects of hydrocortisone alone or in combination with low dose 
dapagliflozin treatment on beta cell Pdx-1 expression 
Islets stained for insulin (red) and Pdx-1 (green) are presented in Figure 5.21A. 
Dapagliflozin had no discernible impact on beta cell Pdx-1 expression (57.9 ± 1.2 vs 




5.4.22 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on body weight, percentage body weight change, energy 
and fluid intake 
High dose dapagliflozin [5mg/kg body weight] caused a reduction in percentage 
weight change in streptozotocin treated animals (-13.0 ± 1.1 vs -7.6 ± 0.3%, p<0.001, 
Figure 5.22B). This dose had no effect on energy consumption however it increased 
fluid consumption (109.2 ± 5.7 vs 94.8 ± 3.1ml, p<0.05, Figure 5.22D). 
 
5.4.23 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on blood glucose, plasma insulin/glucagon and pancreatic 
insulin/glucagon content 
Treatment with dapagliflozin protected against streptozotocin-induced 
hyperglycaemia (18.8 ± 0.9 vs 26.3 ± 1.4mM, p<0.01, Figure 5.23A-B). Streptozotocin 
reduced plasma insulin with dapagliflozin having not further effect. Pancreatic insulin 
content however was dramatically increased by dapagliflozin treatment (53.9 ± 1.3 
vs 29.1 ± 2.0, p<0.001, Figure 5.23D). Glucagon levels both within plasma (0.03 ± 
0.001 vs 0.08 ± 0.009ng/ml, p<0.001, Figure 5.23E) and pancreas (12.7 ± 1.0 vs 18.7 
± 1.2ng/mg protein, p<0.05, Figure 5.23F) were substantially reduced with a high 





5.4.24 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on islet parameters 
Representative images of islets stained for insulin (red) and glucagon (green) are 
displayed in Figure 5.24A. High dose dapagliflozin exacerbated streptozotocin-
induced beta cell loss (2088 ± 203.3 vs 3309 ± 287.5µm2, p<0.001, Figure 5.24C). Islet 
size distribution was altered with an increase in the number of small islets (90.6 ± 1.5 
vs 68.3 ± 1.7%, p<0.001, Figure 5.24E) and a reciprocal reduction in the number of 
medium sized islets (8.1 ± 1.9 vs 31.7 ± 1.7%, p<0.001, Figure 24E).  Similarly high 
dose dapagliflozin exacerbated streptozotocin- induced reductions and gains in 
percentage beta cells (42.1 ± 1.5 vs 58.9 ± 1.8%, p<0.001, Figure 5.24F) and 
percentage alpha cells (58.0 ± 1.5 vs 43.1 ± 2.1%, p<0.001, Figure 5.24G) respectively. 
Islet architecture was improved by dapagliflozin treatment (52.2 ± 3.2 vs 70.0 ± 4.4%, 
p<0.01, Figure 5.24H) however was still notably impaired compared to non-diabetic 
mice.  
 
5.4.25 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on beta-to-alpha cell transdifferentiation 
Representative images of islets stained for GFP (green) in conjunction with insulin or 
glucagon (red) are presented in Figure 5.25A and B respectively. A 5mg/kg dose of 
dapagliflozin elicited a reduction in insulin negative, GFP positive cells (3.7 ± 0.6 vs 




5.4.26 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on beta and alpha cell apoptosis 
Characteristic images of TUNEL (green) staining alongside insulin or glucagon (red) 
are shown in Figure 5.26A and B respectively. Dapagliflozin had no discernible effect 
on streptozotocin-induced beta cell apoptosis, however it exacerbated alpha cell 
apoptosis (7.9 ± 0.9 vs 4.7 ± 1.0%, p<0.05, Figure 5.26D).  
 
5.4.27 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on beta and alpha cell proliferation 
Ki-67 (red) staining was carried out in conjunction with insulin or glucagon (green) as 
shown in Figures 5.27A and B respectively. A high dose of dapagliflozin notably 
elevated beta cell proliferation (7.1 ± 1.0 vs 4.0 ± 0.9%, p<0.05, Figure 5.27C) whilst 
having no impact on proliferation of alpha cells. 
 
5.4.28 Effects of streptozotocin alone or in combination with high dose 
dapagliflozin treatment on beta cell Pdx-1 expression 
Representative images of islets stained for insulin (red) and Pdx-1 (green) are 
presented in Figure 5.28A. 5mg/kg dose dapagliflozin improved beta cell Pdx-1 
expression (66.4 ± 0.9 vs 53.3 ± 1.0%, p<0.001, Figure 5.28B) to levels comparable to 




5.4.29 Effects of streptozotocin alone or with insulin treatment on body weight, 
energy and fluid intake 
Administration of insulin protected against streptozotocin-induced weight loss (-3.7 
± 0.5 vs -7.6 ± 0.3%, p<0.001, Figure 5.29B) whilst increasing cumulative energy 
intake (516.9 ± 25.1 vs 445.5 ± 9.0kJ, p<0.01, Figure 5.29C) and reducing water 
consumption (64.4 ± 3.7 vs 94.8 ± 3.2ml, p<0.001, Figure 5.29D).  
 
5.4.30 Effects of streptozotocin alone or with insulin treatment on blood glucose, 
plasma insulin/glucagon and pancreatic insulin/glucagon content 
Predictably administration of insulin reduced streptozotocin-induced 
hyperglycaemia (13.6 ± 1.2 vs 26.3 ± 1.4mM, p<0.001, Figure 5.30A-B). Similarly, 
bovine insulin administration restored normal plasma insulin (8.3 ± 0.4 vs 5.2 ± 
0.4ng/ml, p<0.001, Figure 5.30C), pancreatic insulin levels (41.3 ± 4.5 vs 29.1 ± 2.0 
ng/mg protein, p<0.01, Figure 5.30D) as well as plasma glucagon (0.04 ± 0.004 vs 0.08 
± 0.009ng/ml, p<0.01, Figure 5.30E) and pancreatic glucagon content (7.6 ± 2.3 vs 
18.7 ± 1.2 ng/mg protein, p<0.05, Figure 5.30F). 
  
5.4.31 Effects of streptozotocin alone or with insulin treatment on islet parameters 
Representative images of islets showing insulin (red) and glucagon (green) 
immunohistochemistry are presented in Figure 5.31A). Islet area was improved by 
insulin treatment (6733 ± 823.7 vs 4407 ± 393.3µm2, p<0.05, Figure 5.31B) despite 
changes in beta cell area and alpha cell area failing to reach significance. Insulin 
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therapy profoundly raised percentage beta cells (65.7 ± 1.7 vs 58.9 ± 1.8%, p<0.01, 
Figure 5.31F) with a reciprocal reduction in percentage alpha cells (34.3 ± 1.7 vs 43.1 
± 2.1, p<0.01, Figure 5.31G). Likewise islet architecture was improved by insulin 
therapy (31.0 ± 4.0 vs 70.0 ± 4.4%, p0.001, Figure 5.31H). 
 
5.4.32 Effects of streptozotocin alone or with insulin treatment on beta-to-alpha 
cell transdifferentiation 
Immunohistochemistry of GFP (green) with insulin or glucagon (red) is presented in 
Figure 5.32A and B respectively. Administration of insulin resulted in a marked 
reduction in the number insulin negative, GFP positive cells (1.2 ± 0.4 vs 5.6 ± 0.7%, 
p<0.001, Figure 5.32C) and glucagon positive, GFP positive cells (2.8 ± 0.5 vs 5.7 ± 
0.7%, p<0.01, Figure 5.32D).  
 
5.4.33 Effects of streptozotocin alone or with insulin treatment on beta and alpha 
cell apoptosis 
Immunohistochemistry images for TUNEL (green) in conjunction with insulin or 
glucagon (red) are presented in Figure 5.33A and B respectively. Insulin therapy 
caused a reduction in beta cell apoptosis (5.8 ± 1.0 vs 10.9 ± 1.9%, p<0.05, Figure 





5.4.34 Effects of streptozotocin alone or with insulin treatment on beta and alpha 
cell proliferation 
Representative images of islets stained for ki-67 (red) alongside insulin or glucagon 
(green) are presented in Figure 5.34A and B respectively. Insulin treatment caused a 
notable reduction in alpha cell proliferation (2.8 ± 0.6 vs 8.2 ± 1.1%, p<0.001, Figure 
5.34D) whilst having no significant effect on beta cell proliferation.  
 
5.4.35 Effects of streptozotocin alone or with insulin treatment on beta cell Pdx-1 
expression 
Immunohistochemistry for insulin (red) and Pdx-1 (green) was carried out and 
presented in Figure 5.35A. Streptozotocin-treated mice given insulin showed 
improved beta cell Pdx-1 expression (68.3 ± 2.4 vs 53.3 ± 1.0%, p<0.001, Figure 5.35B) 
to levels comparable to non-diabetic mice.  
 
5.5 Discussion  
As noted in the previous Chapter, beta-to-alpha cell transdifferentiation is observed 
in diet-induced diabetes, multiple dose hydrocortisone and multiple low-dose 
streptozotocin models, the greatest extent found in the latter model. The presented 
studies have explored the effect of dapagliflozin, a SGLT2 inhibitor, on islet 
morphology and this beta-to-alpha cell transdifferentiation process. Based upon 
previous studies showing favourable anti-diabetic effects, a 1mg/kg oral dose was 
selected for the use within these studies (Millar et al, 2016; Millar et al, 2017). This 
dose of dapagliflozin in streptozotocin-treated Ins1cre/+;Rosa26-eYFP C57Bl/6 mice 
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had no effect on reducing the number of islets showing transdifferentiated beta cells, 
with reduced beta cell Pdx-1 expression helping to confirm loss of beta cell maturity.   
Alpha cell apoptosis however was reduced by dapagliflozin treatment. This suggests 
that the increase in alpha cell area noted in these mice was due to reduced alpha cell 
apoptosis. Alpha cell proliferation does not contribute to this increased alpha cell 
area given that it was not observed within these mice. 
Unexpectedly this 1mg/kg dose of dapagliflozin did not produce the expected glucose 
lowering effect. This suggests that the observed islet changes were not a 
consequence of improved diabetes control, but a direct action of SGLT2 inhibition. 
To prove this further, a higher dose of 5mg/kg dapagliflozin was selected and 
administered to streptozotocin-diabetic Ins1cre/+;Rosa26-eYFP C57Bl/6 mice. This 
dose showed a more profound glucose-lowering effect, as widely stated within the 
literature, however it was insufficient to restore normoglycaemia (Macdonald et al, 
2010). Within the pancreas, the islets showed similar changes compared to mice 
treated with a lower dose of dapagliflozin, with increased alpha cell mass largely 
attributable reduced apoptosis of alpha cells.  
In diet-induced high fat fed mice, the low dose of dapagliflozin had a slight effect on 
reducing the number of islets showing transdifferentiated beta cells. This was 
supported by improved beta cell maturity as denoted by improved beta cell Pdx-1 
expression. Despite this reduction in beta cell transdifferentiation, alpha cell mass 
was still raised in high fat fed dapagliflozin treated mice. Given that alpha cell 
apoptosis and proliferation was unchanged the cause of this increase in alpha cell 
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mass is still undetermined. Beta cell proliferation was upregulated and may 
contribute to marked the increase in large islets (>25,000µm2) observed.   
Dapagliflozin therapy had no impact on beta cell transdifferentiation levels in 
hydrocortisone-treated animals, with lowered Pdx-1 expression equivalent to 
hydrocortisone alone. Much like before, the increase in alpha cell mass seen in these 
mice was due to a reduction in alpha cell apoptosis. In this model, beta cell mass was 
also elevated with our data showing that this was due to a combination of increased 
beta cell proliferation and reduction in beta cell apoptosis. Beta cell mass was notably 
increased by dapagliflozin treatment, an effect largely attributable to beta cell 
hypertrophy and reduced beta cell apoptosis. Interestingly, in this model of diabetes, 
dapagliflozin elicited a reduction in beta cell proliferation compared with both 
streptozotocin and high fat fed models where proliferation increased. 
 
These results show that dapagliflozin had little impact regarding beta cell 
transdifferentiation, however it acted to lower alpha cell apoptosis. Despite the 
kidney being the primary target of SGLT2 inhibitors, evidence is growing regarding 
effects within the brain (Millar et al, 2017) and within the pancreas as shown here 
and by others (Chen et al, 2012; Bonner et al, 2015). Nonetheless use of SGLT2 
inhibitors should be promoted due to their ability to lower blood glucose 
independent of insulin, increase insulin sensitivity and promote weight loss (List et 
al, 2009; Han et al, 2008). Their ability to reduce glucose reabsorption complements 
the action of other anti-diabetic agents and has been shown when combined with 
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DPPIV inhibitors of GLP-1 receptor agonists (Scheen et al, 2016; Jabbour et al, 2014; 
Rosenstock et al, 2015; Millar et al, 2017).  
 
Streptozotocin elicits both a direct chemical insult on the pancreatic islet, likely due 
to DNA alkylation and insulitis, as well as an indirect insult due to prolonged 
hyperglycaemia (Srinivasan and Ramaro, 2007). Administration of insulin post 
streptozotocin insult to counteract hyperglycaemia should provide insight on 
whether beta cell transdifferentiation is impacted directly by anti-diabetic agents or 
whether this may be a secondary action due to their glucose lowering effect.  
Administration of 1 unit insulin every 8 hours was effective at reducing non-fasting 
hyperglycaemia however glucose was still elevated suggesting a stricter dosing 
regimen may be more beneficial. Nonetheless insulin therapy severely stunted 
streptozotocin-induced changes in islet morphology; reduced beta cell mass and 
increased alpha cell mass. Islet architecture was markedly improved with most islets 
showing regular peripheral distribution of alpha cells. By preventing prolonged 
elevations in blood glucose beta cell maturity as determined by Pdx-1 expression was 
restored with beta-to-alpha cell transdifferentiation markedly reduced to levels 
comparable to non-diabetic mice (Gao et al, 2014).  This supports the theory 
suggested by Cinti et al, 2014 whereby beta cells transdifferentiate to protect 
themselves from apoptosis and that when favourable metabolic conditions return 
(normoglycaemia for streptozotocin diabetes) readily revert back to mature beta 
cells.   
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This hyperglycaemic stress mediated transdifferentiation is supported by others that 
used pancreatectomy, or KATP-GOF mice to induce hyperglycaemia and induce beta 
cell dedifferentiation (Jonas et al, 1999; Wang et al, 2014). Similarly both these 
authors also observed that restoration of normoglycaemia, either by phlorizin or 
insulin, was sufficient to reverse this dedifferentiation (Jonas, et al, 1999; Wang et al, 
2014). Opposing findings have also been observed in db/db mice whereby insulin 
therapy was insufficient to reduce beta cell dedifferentiation (Ishida et al, 2017). In 
this instance reductions in alpha cell proliferation and beta cell transdifferentiation 
work synergistically to counteract reduced alpha cell apoptosis to limit the extent of 
alpha cell mass expansion. Likewise conservation of mature beta cells and potentially 
insulin-stimulated beta cell proliferation, albeit not significant, collectively limited 
beta cell loss observed in streptozotocin-induced diabetes. As expected 
administration of insulin protected against hyperglycaemia-induced metabolic 
changes in calorie consumption and fluid intake. Increasing circulating insulin 
exogenously appears to trigger a negative feedback on glucagon limiting both 
circulating levels and pancreatic production of this hormone. 
 
This Chapter has shed light on the source of the increased alpha cells noted in 
diabetic animal models and patients. Beta-to-alpha cell transdifferentiation in 
streptozotocin diabetes was substantially reduced by administration of insulin and 
restoration of normoglycaemia. This finding strongly suggests that removal of beta 
cell stressors, in this model hyperglycaemia, is sufficient for the restoration of 
transdifferentiated beta cells back to functional insulin producing cells. Whether this 
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Figure 5.1 Effects of streptozotocin alone or in combination with dapagliflozin on body weight, cumulative energy intake and cumulative 











12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with 1mg/kg dapagliflozin for two days prior to and in conjunction with administration 
of streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative energy intake 
and (D) cumulative fluid intake. Comparisons were made against saline (*) or against streptozotocin treated (Δ). Values were significant when 
p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.
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Figure 5.2: Effect of streptozotocin alone or in combination with dapagliflozin on 
blood glucose, plasma insulin, pancreatic insulin content, plasma glucagon and 











12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with 1mg/kg 
dapagliflozin for two days prior to and in conjunction with administration of 
streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. Terminal blood was taken 
to assess plasma insulin and glucagon. (A) Blood glucose, (B) final blood glucose, (C) 
plasma insulin, (D) pancreatic insulin content, (E) plasma glucagon and (F) pancreatic 
glucagon content.  
Comparisons were made against saline (*) or against streptozotocin treated (Δ). 
Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Blood Glucose


















































































































































































































Figure 5.3 Effects of streptozotocin alone or in combination dapagliflozin on pancreatic islet area, beta cell area, alpha cell area, islet size 
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Representative images of islets from saline, streptozotocin and streptozotocin plus 1mg/kg dapagliflozin treated mice showing insulin 
(red), glucagon (green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta 
cells,  (G) percentage alpha cells and (H) islet architecture. Values are mean ± SEM(n=8 mice/group). Comparisons versus saline control 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (1mg/kg) stained for (A) insulin and GFP or (B) 
glucagon and GFP. Beta cell transdifferentiation determined by populations of insulin 
negative, GFP positive cells (C) and glucagon positive, GFP positive cells (D) using 
double immunofluorescence staining showing insulin/glucagon (red) and GFP 
(green).  
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
versus streptozotocin (Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and ***p<0.001. 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (1mg/kg) stained for (A) insulin and TUNEL or (B) 
glucagon and TUNEL. Beta cell apoptosis and alpha cell apoptosis determined by 
populations of insulin positive, TUNEL positive (C) and glucagon positive, TUNEL 
positive (D) cells respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (1mg/kg) stained for (A) insulin and ki-67 or (B) 
glucagon and ki-67. Beta cell and alpha cell proliferation determined by populations 
of (C) insulin positive, ki-67 positive cell and (D) glucagon positive,  ki-67 positive cells 
respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin and streptozotocin plus dapagliflozin (1mg/kg) on Pdx1 
expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 (green) and 
DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 









































Figure 5.8: Effects of high fat feeding alone or in combination with dapagliflozin on body weight, cumulative energy intake and cumulative 










15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months prior were treatment with dapagliflozin (1mg/kg) by daily oral 
gavage, n=6-8 mice/group. (A) body weight, (B) percentage body weight change, (C) cumulative energy intake and (D) cumulative fluid intake. 
Comparisons were made against lean saline (*) or against high fat fed (Δ). Values mean ± SEM, significant when p<0.05 */Δ, p<0.01 **/ΔΔ and 
p<0.001 ***/ΔΔΔ. 
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Figure 5.9: Effects of high fat feeding alone or in combination with dapagliflozin on 
blood glucose, plasma insulin, pancreatic insulin content, plasma glucagon, 









15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months 
prior were treatment dapagliflozin (1mg/kg) by daily oral gavage, n=6-8 mice/group. 
(A) Blood glucose, (B) final blood glucose, (C) plasma insulin, (D) pancreatic insulin, 
(E) plasma glucagon, (F) pancreatic glucagon, G) ip glucose tolerance test and (F) AUC. 
Comparisons were made against lean saline (*) or against high fat fed (Δ). Values 
mean ± SEM, significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ. 
Blood Glucose













































































































































































































































































Figure 5.10: Effects of high fat feeding alone or in combination dapagliflozin on pancreatic islet area, beta cell area, alpha cell area, islet size 
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Representative images of islets from (A) lean saline, high fat fed saline and high fat fed plus dapagliflozin (1mg/kg) mice showing insulin (red), 
glucagon (green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells, (G) 
percentage alpha cells and (H) islet architecture. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus high 
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Representative images of islets from lean saline, high fat fed saline and high fat fed 
plus dapagliflozin (1mg/kg) treated mice stained for (A) insulin and GFP or (B) 
glucagon and GFP. Beta cell transdifferentiation determined by populations of insulin 
negative, GFP positive cells (C) and glucagon positive,  GFP positive cells (D) using 
double immunofluorescence staining show insulin/glucagon (red), GFP (green). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus lean saline control (*) 
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Representative images of islets from lean saline, high fat fed saline and high fat fed 
plus dapagliflozin (1mg/kg) stained for (A) insulin and TUNEL or (B) glucagon and 
TUNEL. Beta cell apoptosis and alpha cell apoptosis were quantified by populations 
of insulin positive, TUNEL positive (C) and glucagon positive, TUNEL positive cells (D) 
respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 












































































































Representative images of islets lean saline, high fat fed saline and high fat fed plus 
dapagliflozin (1mg/kg) stained for (A) insulin and ki-67 or (B) glucagon and ki-67. Beta 
cell and alpha cell proliferation determined by populations of (C) insulin positive, ki-
67 positive cells or (D) glucagon positive,  ki-67 positive cells respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, high fat fed saline and high fat fed plus dapagliflozin (1mg/kg) on Pdx1 
expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 (green) and 
DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus high fat fed (Δ), significant when */Δp<0.05, 
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Figure 5.15: Effects of hydrocortisone alone or in combination with dapagliflozin on body weight, cumulative energy intake and cumulative 








12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with dapagliflozin for two days prior to and in conjunction with administration of 
hydrocortisone (70mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative energy intake 
and (D) cumulative fluid intake. Comparisons were made against saline (*) or against hydrocortisone treated (Δ). Values were significant when 
p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Body Weight
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Figure 5.16: Effect of hydrocortisone alone or in combination with dapagliflozin on 
blood glucose, plasma insulin, pancreatic insulin content, plasma glucagon and 










12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with dapagliflozin for 
two days prior to and in conjunction with administration of hydrocortisone (70mg/kg, 
ip, once daily), n=8 mice/group. Terminal blood was taken to assess plasma insulin 
and glucagon. (A) Blood glucose, (B) final blood glucose, (C) plasma insulin, (D) 
pancreatic insulin content (E) plasma glucagon and (F) pancreatic glucagon content. 
Comparisons were made against saline (*) or against hydrocortisone treated (Δ). 
Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Blood Glucose















































































































































































































Figure 5.17 Effects of hydrocortisone alone or in combination dapagliflozin on pancreatic islet area, beta cell area, alpha cell area, islet size 
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(A) Representative images of islets from saline, hydrocortisone and hydrocortisone plus dapagliflozin treated mice showing insulin (red), glucagon 
(green) and DAPI (blue). (B) Islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  (G) percentage 
alpha cells and (H) islet architecture. Values are mean ± SEM(n=8 mice/group). Comparisons versus saline control (*) or versus hydrocortisone 
(Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and ***/ΔΔΔp<0.001. 
214 
 







































Representative images of islets from mice treated with saline, hydrocortisone and 
hydrocortisone plus dapagliflozin (1mg/kg) stained for (A) insulin and GFP or (B) 
glucagon and GFP. Beta cell transdifferentiation determined by populations of insulin 
negative, GFP positive cells (C) and glucagon positive, GFP positive cells (D) using 
double immunofluorescence staining showing insulin/glucagon (red) and GFP 
(green).  
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, hydrocortisone and 
hydrocortisone plus dapagliflozin (1mg/kg) stained for (A) insulin and TUNEL or (B) 
glucagon and TUNEL. Beta cell apoptosis and alpha cell apoptosis determined by 
populations of insulin positive, TUNEL positive (C) and glucagon positive, TUNEL 
positive (D) cells respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, hydrocortisone and 
hydrocortisone plus dapagliflozin (1mg/kg) stained for (A) insulin and ki-67 or (B) 
glucagon and ki-67. Beta cell and alpha cell proliferation determined by populations 
of (C) insulin positive, ki-67 positive cell and (D) glucagon positive,  ki-67 positive cells 
respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
Representative images of islets from mice treated with (A) saline, hydrocortisone alone and hydrocortisone plus dapagliflozin on Pdx1 expression. 
(B) Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 (green) and DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus hydrocortisone (Δ), significant when */Δp<0.05, 


















































12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with 5mg/kg dapagliflozin for two days prior to and in conjunction with administration 
of streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative energy intake 
and (D) cumulative fluid intake. Comparisons were made against saline (*) or against streptozotocin treated (Δ). Values were significant when 
p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ. 
Body Weight
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Figure 5.23 Effect of streptozotocin alone or in combination with dapagliflozin on 
blood glucose, plasma insulin, pancreatic insulin content, plasma glucagon and 
pancreatic glucagon content 
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12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with 5mg/kg 
dapagliflozin for two days prior to and in conjunction with administration of 
streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. Terminal blood was taken 
to assess plasma insulin and glucagon. Blood glucose, (B) final blood glucose, (C) 
plasma insulin, (D) pancreatic insulin content, (E) plasma glucagon and (F) pancreatic 
glucagon content. 
Comparisons were made against saline (*) or against streptozotocin treated (Δ). 
Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
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Figure 5.24: Effects of streptozotocin alone or in combination dapagliflozin on pancreatic islet area, beta cell area, alpha cell area, islet size 










Insulin / Glucagon / DAPI 
 
 
* Legend overleaf  
















(A) Representative images of islets from saline, streptozotocin and streptozotocin plus 5mg/kg dapagliflozin treated mice showing insulin 
(red), glucagon (green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  
(G) percentage alpha cells and (H) islet architecture. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (5mg/kg) stained for (A) insulin and GFP or (B) 
glucagon and GFP. Beta cell transdifferentiation determined by populations of insulin 
negative, GFP positive cells (C) and glucagon positive, GFP positive cells (D) using 
double immunofluorescence staining showing insulin/glucagon (red) and GFP 
(green).  
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
versus streptozotocin (Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and 
***/ΔΔΔp<0.001. 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (5mg/kg) stained for (A) insulin and TUNEL or (B) 
glucagon and TUNEL. Beta cell apoptosis and alpha cell apoptosis determined by 
populations of insulin positive, TUNEL positive (C) and glucagon positive, TUNEL 
positive (D) cells respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus dapagliflozin (5mg/kg) stained for (A) insulin and ki-67 or (B) 
glucagon and ki-67. Beta cell and alpha cell proliferation determined by populations 
of (C) insulin positive, ki-67 positive cell and (D) glucagon positive,  ki-67 positive cells 
respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin and streptozotocin plus dapagliflozin (5mg/kg) on Pdx1 
expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 (green) and 
DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 












































12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were administered streptozotocin (50mg/kg, ip, once daily) and treated with insulin (1unit every 
8 hours) when hyperglycaemia presented, n=8 mice/group. (A) Body weight, (B) percentage body weight change, (C) cumulative energy intake 
and (D) cumulative fluid intake. Comparisons were made against saline (*) or against streptozotocin treated (Δ). Values were significant when 
p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Body Weight
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Figure 5.30: Effects of streptozotocin alone or with insulin treatment on blood 












12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were administered streptozotocin 
(50mg/kg, ip, once daily) and treated with insulin (1unit every 8 hours) when 
hyperglycaemia presented, n=8 mice/group. Terminal blood was taken to assess 
plasma insulin and glucagon. (A) Blood glucose, (B) final blood glucose, (C) plasma 
insulin, (D) pancreatic insulin content, (E) plasma glucagon and (F) pancreatic 
glucagon content. 
Comparisons were made against saline (*) or against streptozotocin treated (Δ). 
Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
Blood Glucose


























































































































































































































Figure 5.31: Effects of streptozotocin alone or insulin treatment on pancreatic islet area, beta cell area, alpha cell area, islet size distribution, 
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(A) Representative images of islets from saline, streptozotocin and streptozotocin plus insulin treated mice showing insulin (red), glucagon (green) 
and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  (G) percentage alpha cells 
and (H) islet architecture. Values are mean ± SEM(n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus insulin stained for (A) insulin and GFP or (B) glucagon and GFP. 
Beta cell transdifferentiation determined by populations of insulin negative, GFP 
positive cells (C) and glucagon positive, GFP positive cells (D) using double 
immunofluorescence staining showing insulin/glucagon (red) and GFP (green).  
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus insulin stained for (A) insulin and TUNEL or (B) glucagon and 
TUNEL. Beta cell apoptosis and alpha cell apoptosis determined by populations of 
insulin positive, TUNEL positive (C) and glucagon positive, TUNEL positive (D) cells 
respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Representative images of islets from mice treated with saline, streptozotocin and 
streptozotocin plus insulin stained for (A) insulin and ki-67 or (B) glucagon and ki-67. 
Beta cell and alpha cell proliferation determined by populations of (C) insulin 
positive, ki-67 positive cell and (D) glucagon positive,  ki-67 positive cells respectively. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
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Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin and streptozotocin plus insulin on Pdx1 expression (B). 
Determined by histological analysis of insulin/Pdx1 double immunofluorescence staining showing insulin (red), Pdx1 (green) and DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 














































Effect of apelin and xenin on islet morphology 





6.1 Summary  
Apelin and xenin are both peptides that have been shown to improve insulin 
secretion and beta cell function, survival and proliferation. Chemically modified 
versions of these peptides extend their biological half-life making them potential 
novel anti-diabetic agents for the future. In the present study, 10 days once daily 
treatment with 25nmol/kg pGlu-apelin-(Glut-pal)-amide or xenin-25-GluPal 
effectively reducing beta-to-alpha cell transdifferentiation in both streptozotocin and 
high fat feeding induced diabetes. Both agents displayed improved metabolic 
parameters and improvements in islet function showcasing their potential as anti-
diabetic agents. Of note in streptozotocin-induced diabetes, both peptides were able 
to reduce circulating glucagon whilst elevating circulating insulin levels and 
increasing beta cell proliferation. Xenin in particular was as effective as liraglutide in 
suppressing streptozotocin induced hyperglycaemia whist conserving beta cell mass 
and limiting expansion of alpha cells. Similarly in diet-induced obese diabetic mice, 
both peptide agents were able to suppress circulating glucagon levels, improve 
glucose tolerance, limit islet beta and alpha cell expansion, and reduce beta cell 
apoptosis and alpha cell proliferation. Apelin in particular further suppressed alpha 
cell mass expansion by increasing alpha cell apoptosis. These studies outline the 
many beneficial properties both apelin and xenin based peptides elicit in diabetic 
animal models, including suppression of beta cell transdifferentiation.  
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6.2 Introduction  
 
6.2.1 Apelin  
Apelin was first discovered and isolated from adipose extracts. The 36 amino acid 
adipokine, either whole or truncated to apelin-13, binds to the APJ receptor 
expressed within the central nervous system and peripheral tissues to regulate 
angiogenesis, water homeostasis and energy homeostasis (Hu et al, 2016). The latter 
would implicate apelin’s involvement in metabolic disorders such as diabetes and 
obesity. Apelin knock-out mice display impaired metabolism exhibiting 
hyperglycaemia, reduced glucose tolerance and insulin insensitivity. These were all 
improved by exogenous administration of apelin, strongly linking this adipokine in 
regulation of insulin sensitivity (Yu et al, 2010). Apelin levels are notably raised in 
both obese rodents and humans implicating its involvement in metabolism (Dray et 
al, 2008; Boucher et al, 2005). Central actions of apelin within the hypothalamus have 
been attributed to the peptide’s ability to reduce appetite and food intake in mice 
(O’Harte et al, 2017) and rats (Sunter et al, 2003). 
Apelin is degraded by ACE2 (angiotensin converting enzyme-2) which cleaves 
phenylalanine from the C-terminus, permitted further enzymatic degradation and 
loss of bioactivity (Murza et al, 2014). Previous research investigating peptide 
modifications have found that acylation of apelin-13 analogues resulted in significant 
extension of half-life without altering insulin stimulating ability (O’Harte et al, 2017). 
These author’s concluded that beneficial effects of pGlu(Lys8GluPAL)apelin-13 amide 
in a diet-induced obese-diabetic mouse model were as effective as liraglutide in 
reducing blood glucose, normalising insulin levels, enhancing glucose tolerance and 
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insulin sensitivity (O’Harte et al, 2018). Notably apelin outperformed liraglutide in 
terms of reducing percentage body fat and improving bone mineral density (O’Harte 
et al, 2018). In akita mice apelin-13 has been shown to act within the pancreas to 
preserve islet mass and insulin content potentially by alleviating diabetes-induced 
endoplasmic reticulum (ER) stress (Chen et al, 2011).  
 
6.2.2 Xenin 
Xenin is a 25 amino acid peptide hormone secreted alongside GIP from the 
enteroendocrine K cells within the digestive tract (Anlauf et al, 2000; Feurle et al, 
1992). Its actions within the body range from potentiating GIP’s insulinotropic action, 
reducing gastric emptying, increasing gallbladder contractions and promoting 
breakdown of lipids and reducing lipogenesis (Martin et al, 2012; Wice et al, 2010). 
Xenin has been shown to suppress appetite, a feat attributed to its gastric effects as 
well as its central actions within the hypothalamus (Alexiou et al, 1998; Cooke et al, 
2009) once xenin crosses the blood-brain barrier. With rapid degradation within 30 
minutes, xenin has only been shown to potentiate glucose-stimulated insulin 
secretion when injected shortly before the glucose load is administered (Taylor et al, 
2010). As a result, peptide modifications involving the addition of fatty acids have 
been carried out to improve enzymatic stability and extend pharmacokinetic ability 
(Martin et al, 2012; Irwin et al, 2006). 
Xenin-25 has been shown to potentiate glucose-stimulated insulin release whilst 
promoting beta cell resistance against apoptosis both within pancreatic beta cell lines 
(BRIN-BD11) and isolated mouse islets (Taylor et al, 2010). Furthermore xenin-25 has 
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been demonstrated to potentiate the action of the incretin hormone GIP, making it 
a promising candidate for an anti-diabetic agent. In high fat fed mice modified xenin-
25 has been shown to improve glucose tolerance and significantly reduce alpha cell 
area whilst increasing beta cell area (Parthsarathy et al, 2016).  
 
Both of these non-classical peptides show great potential for consideration as next 
generation anti-diabetic therapies. They have been vigorously tested within diet-
induced models of obesity-diabetes however little has been done investigating their 
effect on beta cell transdifferentiation in this model or within streptozotocin-induced 
diabetes. The present Chapter aims to investigate this utilising transgenic 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice. 
 
6.3 Methods  
A brief summary of the methods implemented are outlined below. For full 
descriptions of methods and materials used please refer to Chapter 2.  
 
6.3.1 Animals  
12 week old male Ins1cre/+;Rosa26-eYFP C57Bl/6 mice had diabetes induced via 5 daily 
intraperitoneal injections of 50mg/kg streptozotocin, freshly dissolved in citrate 
buffer. Mice presented with clear diabetic symptoms within the following 5 days post 
dosing. Modified apelin (pGlu-apelin-(Glut-pal)-amide) or modified xenin-25 (xenin-
25-GluPal) were both administered at 25nmol/kg by once daily intraperitoneal 
injections for two days prior to administration of streptozotocin and this was 
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continued for each day until the end of the study at day 10. For high-fat fed studies, 
mice were kept on a 45% fat content high fat diet from the time of weaning at 4 
weeks old  for 11 weeks by which time mice were obese. Experiments were 
conducted with these high fat fed mice at 15 weeks of age. In line with the other 
models, mice were dosed with 25nmol/kg pGlu-apelin-(Glut-pal)-amide or 
25nmol/kg xenin-25-GluPal by daily intraperitoneal injections for 10 days. Prior to 
the end of the study, a glucose tolerance test was conducted on high-fat fed mice. 
Following an overnight fast, mice were subjected to an 18.8mMol/kg glucose load 
with blood glucose assessed regularly for the following hour. A timeline outlining 
these studies is displayed in Figure 6.0. For all studies, mice were 8 per treatment 
group, or 6 where stated. Body weight, blood glucose, calorie and fluid consumption 
were monitored as stated. Peptide modification, dose and dosing schedule was 
chosen based on established literature and previous studies carried out within the 
lab (Martin et al, 2012; Parthsarathy et al, 2017; Parthsararthy et al, 2018; O’Harte 
et al, 2018; O’Harte et al, 2017). Data for saline, streptozotocin, high-fat fed and 
hydrocortisone controls are reused from Chapter 4. 
All mice were kept individually housed during the time of experiments within holding 
rooms maintained at 22±2°C kept on a 12 hour light/dark cycle. Mice had free access 
to drinking water and standard chow or high fat chow, where appropriate. All 
breeding and studies were approved by Ulster University Animal Ethics Review 





6.3.2 Biochemical Analysis  
Longitudinally sectioned pancreatic tissue was snap frozen within liquid nitrogen at 
the end of each study and stored at -70°C before processing. Tissues were 
homogenised in acid ethanol and centrifuged at 3000rpm for 15 minutes at 4°C. The 
supernatant was transferred to fresh tube and TRIS buffer was added to extract 
protein. Protein homogenates were put though an in-house radioimmunoassay to 
determine insulin content, a Bradford assay to determine total protein content and 
an ELISA to determine glucagon levels. Non-fasting plasma insulin was also 
determined by radioimmunoassay whilst plasma glucagon was assessed by ELISA. 
Both Bradford and ELISA were performed in line with the manufacturer’s guidelines.  
 
6.3.3 Immunohistochemistry 
Longitudinally cut pancreatic tissue was collected from mice at the end of each study 
and fixed in 4% paraformaldehyde for 48 hours. Fixed tissues were then processed 
using a Leica automated tissue processor before embedding in wax blocks and 
sectioned into 5µm slices onto polysine coated slides. To begin 
immunohistochemistry slides were immersed in xylene to remove wax and 
rehydrated in a series of ethanol solutions (100 – 50%). Antigen retrieval was carried 
out in citrate buffer heated to 95°C, followed by blocking in a 4% BSA solution. Slides 
were incubated with primary antibodies overnight at 4°C, with the following 
antibodies used: mouse monoclonal anti-insulin antibody (ab6995, 1:1000; Abcam), 
guinea-pig anti-glucagon antibody (PCA2/4, 1:200; raised in-house), rabbit anti-Ki67 
antibody (ab15580, 1:200; Abcam) and rabbit anti-Pdx1 antibody (ab47267, 1:200; 
253 
 
Abcam). The next day slides were washed in PBS before incubating with secondary 
antibody at 37°C. The following secondary antibodies were used where appropriate: 
Alexa Fluor488 goat anti-guinea pig IgG — 1:400, Alexa Fluor 594 goat anti-mouse 
IgG — 1:400, Alexa Fluor 488 goat anti-rabbit IgG — 1:400, Alexa Fluor 594 goat anti-
rabbit IgG — 1:400 or Alexa Fluor 488 donkey anti-goat IgG — 1:400. To stain nuclei 
a final incubation was carried out at 37°C with 300nM DAPI. To assess apoptosis a 
TUNEL assay was carried out following manufacturer’s guidelines (In situ cell death 
kit, Fluorescein, Roche Diagnostics, UK). Stained slides were mounted and kept at 
4°C, covered from light until ready to image. Imaging was carried out using an 
Olympus fluorescent microscope fitted with DAPI (350nm) FITC (488nm) and TRITC 
(594nm) filters and a DP70 camera adapter system. 
 
6.3.4 Image Analysis  
Images were analysed by an experienced user on Cell^F imaging software to assess: 
islet area, beta cell area, alpha cell area (expressed at µm2), percentage beta cells 
and percentage alpha cells. For islet size distribution islets were defined as small, 
medium or large if they were <10,000µm2, 10,000-25,000µm2 or 25,000µm2 
respectively. Islet architecture was defined by the proportion of islets displaying 
central alpha cells. To define beta cell transdifferentiation insulin, GFP staining was 
assessed by quantifying the number of insulin negative, GFP positive staining cells, 
whilst glucagon, GFP staining was assessed by quantifying glucagon positive, GFP 
positive staining cells.  Beta cell and alpha cell apoptosis was quantified by counting 
the number of insulin positive or glucagon positive, TUNEL positive cells respectively. 
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Similarly this was done to analyse proliferation in beta and alpha cells using ki-67 co-
stained with insulin or glucagon respectively. ImageJ software was used to quantify 
beta cell Pdx1 expression, expressed as a percentage of the number of insulin 
positive cells expressing Pdx1. All counts were determined in a blinded manner with 
>60 islets analysed per treatment group. 
 
6.3.5 Statistics 
GraphPad PRISM v.5 software was used to generate and analyse all figures, with data 
presented as mean ± SEM. Comparative analysis between two groups was carried 
out using Student’s unpaired t-test. To compare multiple groups one-way ANOVA 
tests were conducted using a Bonferroni post-hoc test. Similarly to compare multiple 
groups over various time points a repeated measures two-way ANOVA test was 
conducted using a Bonferroni post-hoc test. Results were classed significant when 
p<0.05. 
 
6.4 Results  
6.4.1 Effect of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on body weight, energy intake and fluid 
intake 
Compared to the streptozotocin treated group, mice additionally given apelin and 
xenin showed reduced percentage body weight change (apelin -3.3 ± 1.0%, P<0.001 
and xenin -2.0 ± 0.9%, P<0.001 vs STZ -7.6 ± 0.6%, Figure 6.1B). Cumulative energy 
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intake was similarly reduced in apelin treated mice compared to streptozotocin alone 
(407.7 ± 7.6 vs 445.5 ± 9.0kJ, P<0.01, Figure 6.1C). Xenin treated mice however 
displayed energy consumption equivalent to streptozotocin treated mice. Peculiarly, 
cumulative fluid consumption was greatly increased by both apelin and xenin 
treatments from as early as day 4 of the study, ultimately peaking at the final day 
(day 10 apelin 140.6 ± 8.7ml, P<0.001 and day 10 xenin 148.8 ± 8.5ml vs day 10 STZ 
94.9 ± 3.4ml, P<0.001, Figure 6.1D).  
 
6.4.2 Effects of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on blood glucose, plasma insulin/glucagon and 
pancreatic insulin/glucagon content  
Both apelin and xenin treated groups of mice exhibited characteristic streptozotocin 
induced hyperglycaemia, albeit onset of this was delayed (Figure 6.2A). Xenin 
treatment in particular reduced final blood glucose comparative to streptozotocin 
(21.3 ± 1.5 vs 26.3 ± 1.4mM, P<0.05, Figure 6.2B). Plasma insulin was restored by 
both apelin (9.1 ± 1.0ng/ml) and xenin (7.6 ± 0.9ng/ml) treatments to levels 
comparable to non-diabetic mice (9.2 ± 1.1ng/ml, Figure 6.2C). Pancreatic insulin 
content was reduced by streptozotocin treatment, with apelin and xenin groups 
having no additional impact on this parameter (Figure 6.2D). Plasma glucagon was 
considerably reduced by both apelin and xenin compared to streptozotocin (apelin 
0.029 ± 0.003ngml, p<0.01 and xenin 0.025 ± 0.004ng/ml vs 0.080 ± 0.009ng/ml, 
p<0.001, Figure 6.2E) to levels equivalent to non-diabetic mice. Similar to pancreatic 
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insulin content, glucagon content was unchanged by apelin and xenin treatments 
compared to streptozotocin alone (Figure 6.2F).  
 
6.4.3 Effects of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on islet parameters  
Representative images of saline, streptozotocin, streptozotocin plus pGlu-apelin-
(Glut-pal)-amide and streptozotocin plus xenin-25-GluPal treated islets stained for 
insulin (red) and glucagon (green) with nuclei (blue) are shown in Figure 6.3A. 
Treatment with apelin resulted in a reduction in islet area (5344 ± 600.5µm2 vs 8893 
± 942.5µm2, p<0.01, Figure 6.3B) and beta cell area (3479 ± 413.2µm2 vs 7546 ± 
814.0µm2, p<0.01, Figure 6.3C) equivalent to that found in streptozotocin alone 
however alpha cell area was not raised (Figure 6.3D). Xenin however protected 
against streptozotocin induced changes increasing islet area (6870 ± 889.5 vs 4407 ± 
393.3µm, p<0.05, Figure 6.3B) and beta cell area (4875 ± 656.0 vs 3309 ± 287.5µm2, 
p<0.05, Figure 6.3C) whilst reducing alpha cell area (1776 ± 161.8 vs 2635 ± 271.8µm2, 
p<0.01, Figure 6.3D). Islet size distribution was similar between apelin and xenin 
groups with both treatments increasing the proportion of small and large-sized islets 
whilst reducing medium-sized islets (figure 6.3E). Similar to previous changes only 
xenin treatment was able to elicit increases in percentage beta cells (63.8 ± 1.5 vs 
58.9 ± 1.8%, p<0.05, Figure 6.3F) and reductions in percentage alpha cells (36.2 ± 1.5 
vs 43.1 ± 2.1%, p<0.01, Figure 6.3G). Islet architecture determined by the percentage 
of islets with central alpha cells was improved by apelin and xenin (apelin 42.7 ± 4.0%, 
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p<0.001 and xenin 45.5 ± 3.7% vs 70.0 ± 4.4%, p<0.001, Figure 6.3H) but still 
disrupted compared to non-diabetic islets (20.0 ± 4.0%, Figure 6.3H). 
 
6.4.4 Effects of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on beta-to-alpha cell transdifferentiation 
Representative images of islets stained for insulin (red) and GFP (green) or glucagon 
(red) and GFP (green) are shown in Figure 6.4A and B respectively. Both apelin and 
xenin were able to reduce both the number insulin negative, GFP positive cells (apelin 
1.6 ± 0.3%, p<0.001 and xenin 1.7 ± 0.4% vs STZ 5.6 ± 0.7%, p<0.001, Figure 6.4C) and 
those showing glucagon positive, GFP positive cells (apelin 2.8 ± 0.4%, p<0.001 and 
xenin 2.7 ± 0.5% vs STZ 5.7 ± 0.7%, p<0.001, Figure 6.4D).   
 
6.4.5 Effects of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on beta cell and alpha cell apoptosis 
Beta cell and alpha cell apoptosis were determined by insulin and glucagon plus 
TUNEL staining, with representative islets shown in Figure 6.5A and B respectively. 
Beta cell apoptosis was raised by treatment with streptozotocin with apelin and xenin 
preventing this (apelin 6.3 ± 1.2%, p<0.05 and xenin 3.8 ± 0.7%, p<0.001 vs STZ 10.9 
± 1.9%, Figure 6.5C). Similarly alpha cell apoptosis was found to be raised by 
streptozotocin, however treatment with xenin was able to reduce this (2.5 ± 0.6 vs 




6.4.6 Effect of streptozotocin alone or in combination with pGlu-apelin-(Glut-pal)-
amide or xenin-25-GluPal treatment on beta cell and alpha cell proliferation  
Representative images of islets stained for ki-67 with either insulin (Figure 6.6A) or 
glucagon (Figure 6.6B) were used to assess beta cell and alpha cell proliferation 
respectively. Both apelin and xenin were able to elicit substantial elevations in beta 
cell proliferation (apelin 9.1 ± 1.1%, p<0.01 and xenin 9.0 ± 1.4%, p<0.01 vs STZ 4.0 ± 
0.9%, Figure 6.6C), whilst alpha cell proliferation remained unchanged (Figure 6.6D).  
  
6.4.7 Effects of streptozotocin alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on beta cell Pdx1 expression 
Figure 6.7A displays representative images of islets stained for insulin (red) and Pdx-
1 (green) counterstained with dapi (blue). Apelin and xenin were able to significantly 
increase the percentage of beta cells expressing Pdx-1 against streptozotocin treated 
mice (apelin 63.0 ± 1.4%, p<0.001 and xenin 58.4 ± 1.7% vs 53.3 ± 1.0%, p<0.001, 
Figure 6.7B) with only the former restoring Pdx-1 expression to levels similar to non-
diabetic mice.  
 
6.4.8 Effect of high fat feeding alone or in combination with liraglutide or 
sitagliptin treatment on body weight, energy intake and fluid intake 
Neither peptide impacted body weight or cumulative energy intake. Cumulative fluid 
intake however was reduced in both treatment groups as early as day 5 of the study 
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until the final day (day 12 apelin 134.6 ± 6.3ml, p<0.001 and day 12 xenin 129.9 ± 
3.2ml vs day 12 high fat fed saline 215.9 ± 6.9ml, p<0.001, Figure 6.8D). 
 
6.4.9 Effects of high fat feeding alone or in combination with apelin or xenin 
treatment on blood glucose, plasma insulin/glucagon, pancreatic insulin/glucagon 
and glucose tolerance test  
Non-fasting blood glucose levels were largely unaltered throughout the study (Figure 
6.9A) however on the final day mice within the xenin group displayed a mild 
reduction in blood glucose (7.9 ± 0.2 vs 8.7 ± 0.3mM, p<0.05, figure 6.9B). Circulating 
insulin levels were unchanged by these peptide treatments (figure 6.9C) although 
pancreatic insulin content was found raised by apelin and xenin (apelin 65.9 ± 
8.8ng/ml, p<0.001 and xenin 73.8 ± 3.6 vs 54.6 ± 3.0ng/ml, p<0.001, Figure 6.9D). As 
seen previously, apelin and xenin also exerted a plasma glucagon lowering effect in 
high fat fed mice (apelin 0.022 ± 0.003ng/ml, p<0.001 and xenin 0.020 ± 0.007 vs 0.05 
± 0.003ng/ml, p<0.001, Figure 6.9E) despite having no effect on pancreatic glucagon 
content (Figure 6.F). At the end of the study an ip GTT was carried out with only xenin 
treated mice showing a reduction in blood glucose at 60 minutes (19.3 ± 1.1 vs 23.8 
± 1.2mM, p<0.05, Figure 6.9G), despite overall AUC being unchanged (Figure 6.9H).  
 
6.4.10 Effects of high fat feeding alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on islet parameters 
Representative images of islets from each treatment group are displayed in Figure 
6.10A. Treatment with modified apelin resulted in a significant reduction in islet area 
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(14160 ± 1480 vs 19360 ± 1567µm2, p<0.05, Figure 6.10B) due to reductions in both 
beta cell (12300 ± 1314 vs 16590 ± 1347µm2, p<0.05, Figure 6.10C) and alpha cell 
(1863 ± 196.6 vs 2778 ± 258.0µm2, p<0.05, Figure 6.10D) areas. Modified xenin 
elicited similar reductions in islet area, beta cell area and alpha cell area (14280 ± 
1257µm2, p<0.05, 12330 ± 1125µm2, p<0.05 and 1945 ± 156.7µm2, p<0.05, Figure 
6.10B-D respectively) within high fat fed mice. Similarly both apelin and xenin elicited 
a change in islet size, with smaller islets predominating (Figure 6.10E). Percentage 
beta and alpha cells were unaltered by these treatment groups (Figure 6.10F-G). 
Number of islets displaying irregular central alpha cells was reduced by apelin 
treatment only (29.2 ± 2.3 vs 41.3 ± 3.9%, p<0.05, Figure 6.10H).     
 
6.4.11 Effects of high fat feeding alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on beta-to-alpha cell transdifferentiation 
Representative images of islets stained for insulin with GFP and glucagon with GFP 
are presented in Figure 6.11A-B respectively. Modified apelin and xenin both 
markedly reduced the number of insulin deficient beta cells (apelin 2.9 ± 0.3%, 
p<0.001 and xenin 2.5 ± 0.3%, p<0.001, vs STZ 6.9 ± 0.8%, Figure 6.11C). Similarly 
these treatments were able to significantly reduce the number of glucagon positive 
beta cells (apelin 3.3 ± 0.5%, p<0.001 and xenin 2.1 ± 0.3%, p<0.001 vs STZ 6.7 ± 0.6%, 





6.4.12 Effects of high fat feeding alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on beta and alpha cell apoptosis 
Representative images of islets stained with TUNEL to determine in beta cell and 
alpha cell apoptosis are shown in Figure 6.12A and B respectively. Remarkably apelin 
and xenin treatments were both able to markedly reduce beta cell apoptosis to levels 
comparable to non-diabetic mice (apelin 2.2 ± 0.5%, p<0.01 and xenin 1.7% ± -0.4%, 
p<0.001 vs HFF 4.9 ± 0.7%, Figure 6.12C). alpha cell death was unaffected by either 
peptide treatment. 
  
6.4.13 Effects of high fat feeding alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on beta and alpha cell proliferation  
Representative images of islets stained for ki-67 used to determine beta cell and 
alpha cell proliferation are shown in Figure 6.13A-B respectively. In high fat fed mice 
apelin and xenin had no effect on beta cell proliferation compared to high fat feeding 
alone. In regards to alpha cell proliferation, both treatments elicited a substantial 
reduction (apelin 2.4 ± 0.5%, p<0.01 and xenin 2.5 ± 0.7%, p<0.05 vs HFF 5.7 ± 0.9%, 
Figure 6.13D). 
 
6.4.14 Effect of high fat feeding alone or in combination with pGlu-apelin-(Glut-
pal)-amide or xenin-25-GluPal treatment on beta cell Pdx1 expression 
Representative images showcasing beta cell Pdx1 expression from high fat fed apelin 
or xenin treated mice are shown in Figure 6.14A. Both treatments were able to 
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maintain Pdx1 expression within beta cells compared to high fat fed saline treated 
mice (apelin 54.2 ± 1.1%, p<0.01 and xenin 55.8 ± 1.1% vs 49.6 ± 1.3%, p<0.001, 
Figure 6.14B).  
 
6.5 Discussion  
Building upon the previous data investigating current anti-diabetic agents on beta 
cell transdifferentiation, the present study focuses on two relatively novel, non-
classical peptides, apelin and xenin. In these studies, both peptides were chemically 
modified to prolong their circulating half-life as described previously (Martin et al, 
2012; Parthsarathy et al, 2018). 
In streptozotocin-induced diabetes, both apelin and more profoundly xenin were 
able to reduce the number of islets showing beta-to-alpha cell transdifferentiation 
whilst maintaining beta cell maturity by Pdx-1 expression. This may be in part due to 
their ability to suppress streptozotocin-induced hyperglycaemia, allowing for a 
healthier metabolic environment in which beta cells were not forced to 
transdifferentiate (Cinti et al, 2015). Despite eliciting a reduction in alpha cell 
apoptosis, xenin was able to significantly prevent the streptozotocin-induced 
increase in alpha cell mass, whereas apelin therapy fell short of significance. Given 
that alpha cell proliferation was largely unchanged it can be deduced that the ability 
of xenin to prevent beta-to-alpha cell transdifferentiation is predominantly 
responsible for conserving beta cell mass and limiting alpha cell expansion. Unlike 
other tested anti-diabetic agents, apelin and xenin were able to stimulate beta cell 
proliferation in streptozotocin-treated mice.  Similarly both peptides were able to 
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restore circulating insulin and glucagon levels in these mice. Whether this effect 
would be similar in humans is undetermined, but such an effect would make these 
peptides a tempting treatment for diabetes.  
Quite consistently modified apelin and xenin were effective at preventing beta-to-
alpha cell transdifferentiation in diet-induced diabetes. Both peptides were effective 
at preventing diet-induced alpha cell proliferation. As a results of these two effects, 
alpha cell mass was largely reduced to levels comparable to lean non-diabetic mice. 
In particular, xenin also exerted this effect on alpha cell mass by increasing alpha cell 
apoptosis. Contrasting with streptozotocin diabetes, these agents had no effect on 
beta cell proliferation in high fat fed mice but they were highly effective at reducing 
beta cell apoptosis. In high-fat fed mice both agent suppressed circulating glucagon 
levels a feat similarly observed in streptozotocin diabetic mice. 
Consistent with previous studies, pGlu-apelin-(Glut-pal)-amide and xenin-25-GluPal 
performed as expected improving pancreatic insulin content, reducing plasma 
glucagon levels and enhancing glucose tolerance in high-fat fed mice. This apelin 
analogue performed well in streptozotocin-induced diabetic mice improving plasma 
insulin and reducing plasma glucagon. The study reported by O’Harte et al (2017), 
pGlu-apelin-(Glut-pal)-amide did not elicit a reduction in calorie consumption in high-
fat fed mice but it did decrease feeding in streptozotocin-treated mice. The lack of 
effect could be in part due to the short duration of the present studies. Xenin-25-
GluPal appeared to outperform apelin in streptozotocin-treated mice by reducing 
non-fasting blood glucose levels in addition to sharing the beneficial effects exerted 
by apelin. The efficacy of these peptides in glucose-lowering capability may have 
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matched that of liraglutide had they been dosed twice daily instead of a single daily 
dose.   
These studies outline the beneficial effects of apelin and xenin as potential anti-
diabetic therapies. In many respects, these novel peptide therapeutics have 





Figure 6.0: Timeline of Ins1cre/+;Rosa26-eYFP C57Bl/6 Studies  
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Figure 6.1: Effects of streptozotocin alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on body weight, 










12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with pGlu-Apelin-(Glut-pal)amide or xenin-25-GluPal for two days prior to and in 
conjunction with administration of streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. (A) Body weight, (B) percentage body weight change, 
(C) cumulative energy intake and (D) cumulative fluid intake. Comparisons were made against saline (*) or against streptozotocin treated (Δ). 
Values were significant when p<0.05 */Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.  
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Figure 6.2: Effects of streptozotocin alone or in combination with pGlu-apelin(Glut-
pal)-amide or xenin-25-GluPal on blood glucose, plasma insulin, pancreatic insulin 









12 week old InsCre;Rosa26-eYFP C57Bl/6 mice were treated with pGlu-Apelin-(Glut-
pal)amide or xenin-25-GluPal for two days prior to and in conjunction with 
administration of streptozotocin (50mg/kg, ip, once daily), n=8 mice/group. Terminal 
blood was taken to assess plasma insulin and glucagon. (A) Blood glucose, (B) final 
blood glucose, (C) plasma insulin, (D) pancreatic insulin content, (E) plasma glucagon 
and (F) pancreatic glucagon content. Comparisons were made against saline (*) or 
against streptozotocin treated (Δ). Values were significant when p<0.05 */Δ, p<0.01 
**/ΔΔ and p<0.001 ***/ΔΔΔ.  
Blood Glucose


































































































































































































































Figure 6.3: Effects of streptozotocin alone or in combination pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet area, beta cell 













* Legend overleaf   















Representative images of islets from (A) streptozotocin plus pGlu-Apelin-(Glut-pal)amide or xenin-25-GluPal treated mice showing insulin (red), 
glucagon (green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution, (F) percentage beta cells,  (G) 
percentage alpha cells and (H) islet architecture. Values are mean ± SEM(n=8 mice/group). Comparisons versus saline control (*) or versus 






























































































































































































































Figure 6.4: Effects of streptozotocin alone or in combination pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta-to-alpha 









* Legend overleaf 























Representative images of islets from saline, streptozotocin, streptozotocin plus pGlu-
apelin-(Glut-pal)--amide or streptozotocin plus xenin-25-GluPal showing (A) insulin 
(red), GFP (green) and (B) glucagon (red), GFP (green) staining. Beta cell 
transdifferentiation determined by populations of insulin negative, GFP positive cells 
(C) and glucagon positive,  GFP positive cells (D) using double immunofluorescence 
staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 
versus streptozotocin (Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and 
***/ΔΔΔp<0.001. 









































































Figure 6.5: Effects of streptozotocin alone or in combination pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta cell and 














* Legend overleaf 





















Representative images of islets from mice treated with saline, streptozotocin, 
streptozotocin plus pGlu-apelin-(Glut-pal)-amide or streptozotocin plus xenin-25-
GluPal stained for (A) insulin and TUNEL or (B) glucagon and TUNEL. Beta cell 
apoptosis and alpha cell apoptosis determined by populations of (C) insulin positive, 
TUNEL positive and (D) glucagon positive,  TUNEL positive cells respectively by double 
immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 










































































Figure 6.6: Effects of streptozotocin alone or in combination pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta cell and 







































Representative images of islets from mice treated with saline, streptozotocin, 
streptozotocin plus pGlu-apelin-(Glut-pal)-amide and streptozotocin plus xenin-25-
GluPal stained for (A) insulin and ki-67 or (B) glucagon and ki-67. Beta cell and alpha 
cell proliferation determined by populations of (C) insulin positive, ki-67 positive cells 
or (D) glucagon positive,  ki-67 positive cells respectively by double 
immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 






















































































* Legend overleaf 













Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin, streptozotocin plus pGlu-apelin-(Glut-pal)-amide and 
streptozotocin plus xenin-25-GluPal on Pdx1 expression (B). Determined by histological analysis of insulin/Pdx1 double immunofluorescence 
staining showing insulin (red), Pdx1 (green) and DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 





































Figure 6.8: Effects of high fat feeding alone or in combination pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on body weight, cumulative 









15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months prior were treatment with pGlu-apelin-(Glut-pal)-amide or 
xenin-25-GluPal by daily ip injections, n=6-8 mice/group. (A) body weight, (B) percentage body weight change, (C) cumulative energy intake and 
(D) cumulative fluid intake. Comparisons were made against lean saline (*) or against high fat fed (Δ). Values mean ± SEM, significant when p<0.05 
*/Δ, p<0.01 **/ΔΔ and p<0.001 ***/ΔΔΔ.
Body Weight
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Figure 6.9: Effects of high fat feeding alone or in combination with pGlu-
apelin(Glut-pal)-amide or xenin-25-GluPal on blood glucose, plasma insulin, 








15 week old InsCre;Rosa26-eYFP C57Bl/6 mice kept on a high fat diet for 2 months 
prior were treatment with pGlu-apelin-(Glut-pal)-amide or xenin-25-GluPal by daily 
ip injections, n=6-8 mice/group. Blood glucose, (B) final blood glucose, (C) plasma 
insulin, (D) pancreatic insulin, (E) plasma glucagon, (F) pancreatic glucagon, (G) ip 
glucose tolerance test and (H) AUC. Comparisons were made against lean saline (*) 
or against high fat fed (Δ). Values mean ± SEM, significant when p<0.05 */Δ, p<0.01 
**/ΔΔ and p<0.001 ***/ΔΔΔ
Blood Glucose






















































































































































































































































































Figure 6.10: Effects of high fat feeding alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet area, 













* Legend overleaf 















(A) Representative images of islets from high fat fed plus pGlu-apelin-(Glut-pal)-amide or xenin-25-GluPal mice showing insulin (red), glucagon 
(green) and DAPI (blue). (B) islet area, (C) beta cell area, (D) alpha cell area, (E) islet size distribution (F) percentage beta cells, (G) percentage 
alpha cells and (H) islet architecture. Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus high fat fed 






















































































































































































































































Figure 6.11: Effects of high fat feeding alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta-














* Legend overleaf 































Representative images of islets from lean saline, high fat fed saline, high fat fed plus 
pGlu-apelin-(Glut-pal)-amide and high fat fed plus xenin-25-GluPal treated mice 
stained for (A) insulin and GFP or (B) glucagon and GFP. Beta cell transdifferentiation 
determined by populations of (C) insulin negative, GFP positive cells and (D) glucagon 
positive GFP positive cells using double immunofluorescence staining. Values are 
mean ± SEM (n=8 mice/group). Comparisons versus lean saline control (*) or versus 
high fat fed saline (Δ), significant when */Δp<0.05, **/ΔΔp<0.01 and 
***/ΔΔΔp<0.001. 















































































Figure 6.12: Effects of high fat feeding alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta 



































Representative images of islets from lean saline, high fat fed saline, high fat fed plus 
pGlu-apelin-(Glut-pal)-amide and high fat fed plus xenin-25-GluPal treated mice 
stained for (A) insulin and TUNEL or (B) glucagon and TUNEL. Beta cell apoptosis and 
alpha cell apoptosis determined by populations of (C) insulin positive, TUNEL positive 
and (D) glucagon positive,  TUNEL positive cells respectively by double 
immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 









































































Figure 6.13: Effects of high fat feeding alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta 













* Legend overleaf 
Lean Saline  High-fat Fed Saline  High-fat Fed + Apelin High-fat Fed + Xenin 
























Representative images of islets lean saline, high fat fed saline, high fat fed plus pGlu-
apelin-(Glut-pal)-amide and high fat fed plus xenin-25-GluPal stained for (A) insulin 
and ki-67 or (B) glucagon and ki-67. Beta cell and alpha cell proliferation determined 
by populations of (C) insulin positive, ki-67 positive cells and (D) glucagon positive,  
ki-67 positive cells respectively by double immunofluorescence staining. 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or 






































































Figure 6.14: Effects of high fat feeding alone or in combination with pGlu-apelin(Glut-pal)-amide or xenin-25-GluPal on pancreatic islet beta 














* Legend overleaf  













Pdx1 Expression Analysis 
(A) Representative images of islets from mice treated with saline, streptozotocin, streptozotocin plus pGlu-apelin-(Glut-pal)-amide and 
streptozotocin plus xenin-25-GluPal on Pdx1 expression. (B) Determined by histological analysis of insulin/Pdx1 double immunofluorescence 
staining showing insulin (red), Pdx1 (green) and DAPI (blue). 
Values are mean ± SEM (n=8 mice/group). Comparisons versus saline control (*) or versus streptozotocin (Δ), significant when */Δp<0.05, 
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7.1 Diabetes and Obesity  
Diabetes is strongly associated with obesity with both of these disorders rapidly 
becoming major global epidemics of our lifetime. With the incidence currently 
estimated to increase to 693 million people within the next 25 years and the 
burgeoning economic costs of managing diabetes this will remain an issue for 
generations to come (Cho et al, 2018; Hex et al, 2012). Fully understanding the 
pathogenesis of diabetes remains key in the ultimate goal to effectively treat, 
manage and potentially arrest diabetes to a point where the disorder can do no harm. 
 
7.2 Islet cell transdifferentiation in the pathogenesis of diabetes  
7.2.1 Islet plasticity in the pathogenesis of diabetes  
Over the past decade, islet cell plasticity has been shown to be feasible by genetic 
manipulation of alpha/beta cell specific transcription factors to drive either beta-to-
alpha cell or alpha-to-beta cell transdifferentiation. Evidence of this plasticity and 
transdifferentiation has been reported using animal models and with human clinical 
biopsies. Work by others has shown that type-2 diabetes in mice is associated with 
loss of beta cell identity and resultant transdifferentiation (Talchai et al, 2012; Thorel 
et al, 2010; Chera et al, 2014; Ye et al, 2015; Wang et al, 2014). Studies in non-human 
primates have shown that their beta cells are similarly plastic and that they are able 
to dedifferentiate during high fat diet induced diabetes (Fiori et al, 2013). Given this 
growing breadth of evidence, it is plausible that similar physiology occurs in humans. 
In fact, studies have shown that human islets, from donors of various age and sex, 
can rapidly convert into glucagon producing alpha cells without genetic manipulation 
of transcription factors (Spiker et al, 2013).  Additionally, immunohistochemical 
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analysis of human organ donor material revealed that 31.9% of beta cells were 
dedifferentiated in type-2 diabetics compared with 8.7% in non-diabetics, with 84% 
of insulin positive cells showing reduced mature beta cell transcription factors 
(FOXO1, NKX6.1 and MAFA). These factors were also found in glucagon and 
somatostatin producing cells (Cinti et al, 2015). This strongly supports the view of 
beta cell dedifferentiation and potential beta-to-alpha transdifferentiation in type-2 
diabetes. These authors go on to suggest this mechanism acts to protect beta cells 
from death, preserving them for redifferentiation when suitable metabolic 
conditions arrive (Cinti et al, 2015). As such, identifying pharmacologic agents that 
prevent this change or enable redifferentiation of transdifferentiated beta cells 
provides a novel approach for beta cell restoration therapy.  
In addition to this endocrine plasticity, evidence of a neogenic niche within islets has 
recent been described (Huising et al, 2018). Located at the islet periphery where beta 
and alpha cells meet lies a population of immature beta cells which the authors 
speculate may be former beta cells that underwent beta-to-alpha cell 
transdifferentiation based on a stimulus arising from their specific 
microenvironment, ie signalling between alpha and beta cells within the islet 
periphery. Given the extensive paracrine signalling already known to occur within the 
islet this theory explaining what triggers beta cell transdifferentiation is plausible.  
Work described in this thesis attempts to identify transdifferentiation in vitro and in 
vivo by showing beta cell transdifferentiation within multiple low dose 
streptozotocin, high fat fed diet induced and multiple hydrocortisone mouse models 
of diabetes. Once characterised the next step was to identify anti-diabetic agents that 
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would prevent or reverse this transdifferentiation for beta cell restoration therapy 
(Figure 7.1).  
 
7.2.2 Cell lines to model beta cell transdifferentiation  
The use of cell lines offers a cost effective and large supply of highly proliferative, 
homogenous biological material that bypasses ethical concerns associated with use 
of animals (Kaur and Dufour, 2012; MacDonald et al, 1990). A good cell line maintains 
functional features similar to the primary type that it is derived from, however this 
can be hard to judge if the primary cell’s physiology is not fully understood. 
Generation of cell lines involve genetic manipulation may alter the native physiology 
of the cell, it’s functions and responses to stimuli (Kaur and Dufour, 2012).   Serial 
passage of cell lines can result in phenotypic variation over time to the point where 
they may not accurately represent primary cells. Because of these drawbacks, beta 
cell lines may not be best suited to study transdifferentiation. Despite this, the 
chance of finding an animal based alternative to studying beta cell dedifferentiation 
and transdifferentiation should still be sought after. For studying 
transdifferentiation, cell lines offer a unique advantage over animal models. In vivo 
models only allow assessment of transdifferentiation at limited time points, usually 
restricted to the start and end of treatments. In vitro cell based studies allow 
investigations at many more time points, under strictly controlled conditions, to 
examine the order of changes involved in beta cell transdifferentiation. Studies 
adopting this approach have demonstrated that loss of mature beta cell markers 
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precedes the ectopic expression of progenitor and alpha cell markers (Diedisheim et 
al, 2018). 
The present research explored three widely used beta cell lines, exposing them to 
different stress conditions in an attempt to find an environment that promotes beta 
cell dedifferentiation or transdifferentiation. INS-1 and MIN6 cells proved most 
useful for modelling beta cell transdifferentiation. Both of these cell lines displayed 
consistent changes in insulin and glucagon expression when exposed to lipotoxic or 
cytokine mediated toxicity. These culture conditions in particular consistently 
resulted in an increase in cells co-expressing insulin and glucagon.  Present findings 
are backed up by others that have utilised INS-1 and MIN6 cells to investigate beta 
cell dedifferentiation (Chen et al, 2018). Similarly these authors have cultured cells in 
glucotoxic conditions  (22.2mM and 33.3mM glucose) or with angiotensin-2 and in 
both cell lines noted reduction in expression of mature beta cell genes (insulin and 
Pdx1) and increases in progenitor genes (Ngn3 and Oct4) (Chen et al, 2018).  
To provide relevance to human disease, studies have been done utilising EndoC-βH1, 
a human beta cell line to study beta cell plasticity (Diedisheim et al, 2018). These 
authors found fibroblast growth factor 2 (FGF2) induced beta cell dedifferentiation 
in these cells determined by reduced expression of beta cell markers (INS, MAFB and 
GCK) and ectopic expression of progenitor markers (MYC, HES1, SOX9 and NGN3). 
Interestingly, this dedifferentiation was reversed upon removal of FGF2 and 
Importantly primary human islets cultured in FGF2 supplemented media showed 
similar signs of beta cell dedifferentiation showcasing this process is plausible in 
humans and could potentially occur in diabetes (Diedisheim et al, 2018).  
295 
 
7.2.3 Multiple low dose streptozotocin as a model for transdifferentiation  
Streptozotocin is a selective beta cell toxin that induces diabetes through beta cell 
demise. When given through a multiple low dose (50mg/kg body weight) protocol 
streptozotocin induces insulitis in addition to its direct toxicity on beta cells to 
ultimately reduce islet function and number (Gleichman, 1998; Bonnevie-Nielsen et 
al, 1981; Like and Rossini, 1976). The present lineage tracing experiments, utilising 
Ins1cre/+;Rosa26-eYFP C57Bl/6 mice, showcase extensive beta-to-alpha 
transdifferentiation associated with loss of beta cell markers (Pdx1) in this model of 
diabetes. Furthermore this current work aids to characterise this animal model 
showcasing its worsening hyperglycaemia, reductions in plasma and pancreatic 
insulin levels and concomitant increases in circulating and pancreatic glucagon levels. 
Within the pancreas, islet area is severely compromised due to loss of beta cell mass 
despite expansion of alpha cell mass, with this finding matched by others (Vasu et al, 
2015; O’Brien et al, 1996). Lineage tracing and analysis of apoptosis and proliferation 
has determined that this alpha cell expansion is a combination of beta-to-alpha cell 
transdifferentiation and alpha cell proliferation outweighing alpha cell apoptosis. 
This transdifferentiation in combination with increased beta cell apoptosis accounts 
for the dramatic loss of beta cell mass observed in these mice. This marked increase 
in beta-to-alpha cell transdifferentiation makes this a suitable model for investigating 
transdifferentiation, despite the initial diabetogenic insult differing from the 





7.2.4 Diet induced high fat feeding as a model for transdifferentiation  
High fat diet induced obesity is strongly associated with development of a diabetic 
phenotype, highly comparable to the characteristics seen in human type-2 diabetes, 
and as such is used commonly as model of type-2 diabetes (King et al, 2012). This 
model has been used in rodents (mice and rats) as well as non-human primates to 
recreate diabetes. Indeed, high fat fed non-human primates have been shown to 
have dedifferentiated beta cells (Fiori et al, 2013) implicating this process in humans 
and this model as a relevant way to study and explore beta cell transdifferentiation. 
This thesis investigated high fat-fed NIH Swiss mouse islets and noted significant 
expansions in beta and alpha cell masses (Vasu et al, 2017). This was associated with 
an increase in cells co-expressing insulin and glucagon, highly suggestive of beta-to-
alpha cell transdifferentiation. High fat fed Ins1cre/+;Rosa26-eYFP C57Bl/6 mice put on 
high fat diet for 8 weeks exhibited substantial weight gain although they did not 
exhibit overt hyperglycaemia or elevated pancreatic insulin content unlike other 
strains of mice such as NIH Swiss (Gault et al, 2007; Moffett et al, 2015; Vasu et al, 
2017).   These transgenic mice however did show elevations in circulating insulin and 
glucagon levels with reduced pancreatic glucagon content, the former likely a 
reflection of insulin resistance. This was confirmed during a glucose tolerance test 
when these high fat fed mice retained their hyperglycaemia after 60 minutes of 
receiving a glucose load. The islets of these mice were adapted to their insulin 
resistant environment as shown by an expanded beta cell and alpha cell mass 
collectively increasing islet area. Beta cell proliferation and hypertrophy was found 
to account for this increase. However prolonged insulin resistance causes beta cell 
stress resulting in beta cell apoptosis and loss of beta cell identity (Pdx1) leading to 
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beta-to-alpha cell transdifferentiation. This combined with increased alpha cell 
proliferation accounts for the expansion of alpha cell mass seen in these mice.  These 
findings confirm validity for the use of these transgenic mice and high fat feeding as 
a model for examining beta cell transdifferentiation.  
 
7.2.5 Multiple hydrocortisone as a model for transdifferentiation  
To instil insulin resistance, hydrocortisone can be dosed to mice to model the 
pathology of type-2 diabetes (Bailey and Flatt, 1982; Swali et al, 2008). In line with 
previous studies using WT C57Bl/6 mice, Ins1cre/+;Rosa26-eYFP C57Bl/6 mice dosed 
with hydrocortisone maintained non-fasting glucose levels. However they showed 
increased circulating and pancreatic insulin levels, likely reflective of their insulin 
resistance (Vasu et al, 2015). The present studies examined this model further 
showing plasma glucagon is also elevated in these mice. Beta cell proliferation has 
previously been shown to be the cause of the expanded beta cell mass observed in 
these mice, with the present studies supporting this view (Vasu et al, 2015). Unlike 
past studies these transgenic mice did not exhibit a noteworthy increase in alpha cell 
mass (Vasu et al, 2015; Khan et al, 2016). This is likely due to the increase in alpha 
cell apoptosis outweighing beta-to-alpha cell transdifferentiation. Given that these 
mice do not exhibit substantial expansions in alpha cell mass with most alpha cells 
succumbing to death, this model may not be as well suited for exploring 





7.2.6 Other animal models of transdifferentiation  
Research conducted by Latreille at Imperial College London has focused on stress 
induced dysfunctional microRNAs (miRNA) as the underlying cause of diseases. These 
authors identified a specific mRNA, miR-7, in beta cells which when overexpressed in 
transgenic mice resulted in diabetes with impaired insulin secretion and beta cell 
dedifferentiation. The latter was defined by reductions in beta cell markers (Pdx1, 
Nkx6.1, Mafa and Neurod1) and activation of pre-endocrine marker Sox9 (Latreille et 
al, 2014).  Interestingly alpha cell and somatostatin markers were upregulated 
offering the potential to study beta-to-alpha cell transdifferentiation (Mak and 
Latreille, 2018).  Similarly in obesity induced diabetes, db/db mice and humans with 
type-2 diabetes, miR-7 was found to be dysregulated. These authors suggest that 
inhibition of miR-7 resulted in therapeutic benefit against diabetes restoring 
functional beta cell mass by reversal of beta cell dedifferentiation and improving beta 
cell function (Mak and Latreille, 2018).  
Db/db mice are commonly used as an animal model of diabetes and obesity. 
Functional mutation in the leptin receptor impairs leptin signalling resulting in 
hyperphagia, obesity, beta cell dysfunction and diabetes. These mice have been 
shown to exhibit reductions in beta cell specific markers associated with increased 
progenitor markers and as such are used by many to examine beta cell 
dedifferentiation. Activation of RAS signalling, by angiotensin-2, has been shown to 
potentiate beta cell dedifferentiation in these mice and induces the 
transdifferentiation of beta cells into alpha cells (Chen et al, 2018).  Treatment with 
an ACE inhibitor was shown to reverse this dedifferentiation and potentially prevent 
or reverse this beta-to-alpha cell transdifferentiation (Chen et al, 2018). The present 
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thesis examined islet morphology in db/db mice and similarly noted signs of beta-to-
alpha cell transdifferentiation shown by an increase in alpha cell mass and bi-
hormonal cells expressing both insulin and glucagon. The drawback however is that 
lineage tracing is not possible making it impossible to fully determine 
dedifferentiation and transdifferentiation. This could be potentially overcome 
though selective cross breeding with our transgenic Ins1cre/+;Rosa26-eYFP mice to 
generate offspring with the recessive db/db gene with specific YFP tagging of their 
beta cells. Beta cell dedifferentiation and transdifferentiation could then more 
accurately be quantified in db/db diabetes.  
 
7.3 Effect of anti-diabetic agents on beta cell transdifferentiation  
7.3.1 Effect of incretins on transdifferentiation  
Incretin peptides GLP-1 and GIP have already been shown beneficial against diabetes 
improve islet function in a plethora of ways. These include but are not limited to 
potentiating glucose-stimulated insulin secretion, suppression of glucagon secretion 
and promotion of satiety (Mest et al, 2005; Arthen and Schmidtz, 2004; Song et al, 
2017; Nauck et al, 1997; Flint et al, 1998). Until recently studies examining the effect 
of incretins on beta cell transdifferentiation has been limited. This thesis has explored 
the possibility that using clinically prescribed GLP-1 receptor agonist, liraglutide, and 
a DPPIV inhibitor, sitagliptin, affect this process. Table 7.1 summarises the studies 
found in this thesis. In streptozotocin induced diabetic mice, both agents were able 
to reduce beta-to-alpha cell transdifferentiation. Given that these drugs only 
modestly reduced hyperglycaemia at the doses employed, it is likely that this benefit 
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in restoring beta cell identity is a direct effect of increasing incretins rather than 
secondary to alleviating glucotoxic stress. This is of particular importance as 
alleviation of hyperglycaemia shown elsewhere in this thesis using insulin and by 
others has been found to prevent beta-to-alpha cell transdifferentiation and reverse 
beta cell dedifferentiation respectively (Wang et al, 2014). Similarly, the 
improvement in beta cell transdifferentiation caused by these agents may be due to 
the reduction in energy intake, given that calorie restriction has been noted to reduce 
beta cell dedifferentiation (Sheng et al, 2015).  Liraglutide and sitagliptin increase 
circulating and pancreatic insulin concomitant with reduction in glucagon levels. This 
supports the idea that these agents may be involved in the prevention or inhibition 
beta-to-alpha cell transdifferentiation. These effects on glycaemia, circulating and 
pancreatic hormones are consistent with previous research (Ansarullah et al, 2013; 
Takeda et al, 2012; Wang et al, 2015; Millar et al, 2017; O’Harte et al, 2018). In high 
fat fed diabetes, both liraglutide and sitagliptin were able to reduce beta-to-alpha 
cell transdifferentiation. This reduction, along with increased alpha cell apoptosis 
likely accounts for the reduced alpha cell mass seen in sitagliptin treated mice. 
Liraglutide treated high fat fed mice did not show a reduction in alpha cell mass likely 
due to increases in alpha cell proliferation countering apoptosis and 
transdifferentiation.   Increasing circulating incretin levels failed to improve beta cell 
transdifferentiation in hydrocortisone treated mice. In db/db mice however, 
liraglutide reduced alpha cell mass possibly due to prevention of beta-to-alpha cell 
transdifferentiation, although without lineage tracing this cannot be confirmed.  GIP 
antagonism had no notable impact on islet morphology in db/db mice (Pathak et al, 
2015). Very recent studies have shown that GLP-1 therapy can increase beta cell mass 
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through stimulation of alpha-to-beta cell transdifferentiation which potentially 
contributes to the changes in beta cell mass seen within this thesis (Lee et al, 2018). 
 
7.3.2 SGLT2 inhibition on transdifferentiation and alpha cell hyperplasia 
The selective SGLT2 inhibitor dapagliflozin is used to reduce glycaemia by increasing 
renal excretion of glucose. This insulin independent approach to reducing glycaemia 
offers potential for combination therapy with traditional anti-diabetic agents that 
potentiate beta cell function. Table 7.2 summarises the effects of dapagliflozin in 
diabetic models tested within this thesis.  Unexpectedly SGLT2 inhibitors were found 
to increase islet alpha cell mass as noted in these present studies and by others 
(Millar et al, 2017; Millar et al, 2016; Bonner et al, 2015; Merovci et al, 2014; 
Zambrowicz et al, 2013). The present study aimed to explore the causes of this alpha 
cell expansion theorising that beta-to-alpha cell transdifferentiation could be 
culpable. However when tested, dapagliflozin did not exacerbate beta-to-alpha cell 
transdifferentiation in streptozotocin diabetes, despite testing at high and low doses 
of dapagliflozin, or in hydrocortisone diabetes. In fact dapagliflozin produced a 
modest reduction in beta-to-alpha cell transdifferentiation in high fat fed diabetes. 
Literature has similarly shown SGLT inhibition not to reverse beta cell 
dedifferentiation, with these authors suggesting that alpha cell mass expands to 
compensate against lowering glycaemia (Ishida et al, 2017).  This effectively rules out 
worsening of beta-to-alpha cell transdifferentiation as the cause of alpha cell mass 
expansion however these studies consistently showed SGLT2 inhibition to reduce 




7.3.3 Effect of apelin and xenin on transdifferentiation 
Apelin is an adipokine that has recently been shown to be involved in glucose 
metabolism, potentiating glucose stimulated insulin release (O’Harte et al, 2017). 
Apelin knockout mice are hyperglycaemic with reduced glucose tolerance and insulin 
sensitivity, all of which were remedied by exogenous apelin dosing (Yu et al, 2010). 
Xenin is a gut derived peptide that has similarly been shown to augment glucose 
stimulated insulin release (Taylor et al, 2010). Chemical modifications of both of 
these peptides (pGlu-apelin-(Glut-pal)-amide and xenin-25-GluPal) improved their 
biological half-life making them suitable drug candidates for the treatment of 
diabetes. The present study helps characterise their function in three animal models 
of diabetes and to assess whether they can impact beta cell transdifferentiation, with 
results summarised in Table 7.3. In streptozotocin diabetes, apelin and xenin were as 
effective as incretin based therapies at preventing beta-to-alpha cell 
transdifferentiation, whilst also increasing beta cell proliferation. Similarly in high fat 
fed diabetes both novel peptides reduced beta cell transdifferentiation and increased 
beta cell resistance to apoptosis. These studies add to growing evidence highlighting 
the beneficial effects of apelin and xenin in the hope they will result in clinical trials 
to provide an efficacious, safe and economical approach to treat diabetes.  
 
7.4 Scope for future work  
Future work should aim to elucidate the mechanisms GLP-1 receptor agonists and 
DPPIV inhibitors prevent beta-to-alpha cell transdifferentiation. Fully understanding 
the mechanisms of this transdifferentiation process will provide opportunities to 
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develop targeted novel treatments for the restoration of beta cell mass. This could 
potentially be done through the use of Ins1cre/+;Rosa26-eYFP C57Bl/6 mouse islets ex 
vivo where the surrounding metabolic environment can be strictly controlled. Other 
widely used anti-diabetic agents including sulfonylureas, meglitinides and 
thiazoldinediones may also be able to impact beta cell transdifferentiation. The latter 
in particular has been used in db/db mice to reduce beta cell secretory workload 
however this was insufficient to restore dedifferentiated beta cells (Ishida et al, 
2017). Although not a pharmacologic agent the benefit of calorie restriction on 
improving beta cell responses in diabetes has been widely shown. Calorie restricted 
db/db mice exhibit reduced levels of beta cell dedifferentiation (Sheng et al, 2015). 
Thus, it would be interesting to explore the combination of dietary restriction with 
anti-diabetic drugs. Whether maintaining functional beta cell mass solely through 
prevention or reversal of beta cell transdifferentiation is sufficient to treat diabetes 
remains to be answered. Fully understanding the molecular triggers and pathways 
that lead to beta cell transdifferentiation will allow further investigation into this. The 
remit of this thesis has focused on beta-to-alpha cell transdifferentiation, however 
there is a possibility that stressed beta cells may transdifferentiate to somatostatin 
secreting delta cells. Further immunohistochemistry would reveal this, however 
preliminary staining with GFP and somatostatin shows no co-expression in 
streptozotocin treated mice, suggesting little to no beta-to-delta transdifferentiation 






7.5 Concluding remarks  
This thesis has highlighted the relevance of beta cell plasticity in the pathogenesis of 
diabetes with emphasis on beta-to-alpha cell transdifferentiation. This has been 
demonstrated by lineage tracing of beta cells in multiple low dose streptozotocin, 
high fat fed and multiple hydrocortisone models of diabetes. This transdifferentiation 
process likely accounts for the increase in alpha cell mass and hyperglucagonemia 
seen in type-2 diabetics. Reversion of these transdifferentiated cells back to 
functional beta cells offers a novel approach for beta cell restoration therapy. 
Incretin based therapies, apelin and xenin maintained beta cell identity by preventing 
beta-to-alpha cell transdifferentiation showing proof of concept. These promising 
findings will hopefully lead to further investigations into the mechanisms involved in 
transdifferentiation in the hope to develop specific agents capable of restoring beta 












Table 7.1: Effects elicited by liraglutide or sitagliptin in streptozotocin, high fat fed 
and hydrocortisone diabetes 
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Δ vs STZ/HFF/HC – Δp<0.05, ΔΔp<0.01, ΔΔΔ p<0.001 
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Table 7.2: Effects elicited by dapagliflozin or insulin in streptozotocin, high fat fed 
and hydrocortisone diabetes 
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Δ vs STZ/HFF/HC – Δp<0.05, ΔΔp<0.01, ΔΔΔ p<0.001 
LD – low dose dapa 1mg/kg, HD – high dose dapa 5mg/kg 
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Table 7.3: Effects elicited by pGlu-apelin-(Glut-pal)-amide or xenin-25-GluPal in 
streptozotocin, high fat fed and hydrocortisone diabetes 
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Figure 7.1: Characterisation and prevention of beta-to-alpha cell 










Beta-to-alpha cell transdifferentiation can occur directly (straight arrows) or 
indirectly (curved arrows) via an initial dedifferentiation of beta cell markers before 
upregulation of alpha cell markers. This transdifferentiation has been shown to occur 
in multiple low-dose streptozotocin, high fat fed and hydrocortisone mouse models 
of diabetes. Beta-to-alpha cell transdifferentiation can be prevented or reversed 
(grey cross) by incretin therapies, liraglutide and sitagliptin, and non-classical 




Figure 7.2: No evidence of beta-to-delta transdifferentiation in STZ-treated Ins1cre+/-;Rosa26-eYFP C57Bl/6 mice  
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Representative images of islets from streptozotocin treated mice stained for somatostatin (red), GFP (green) and nuclei (blue). Populations of 
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